{
  "7 Toxicological information": {
    "7.1 Toxicokinetics, metabolism and distribution": {
      "7.1.1 Basic toxicokinetics": {
        "001 | Key | Experimental study": {
          "document_id": "5ecc83a4-13a5-40ce-96bb-9480bdbe8ab7_d18b246e-13d7-423f-a045-5da4c757759e",
          "markdown_content": "#### Basic toxicokinetics\n\nJump to\n\nHide empty fields\n\n### Administrative data\n\nConfidentiality\n\n[Not publishable]\n\nJustification\n\n[Not publishable]\n\nUse restricted to selected regulatory programmes\n\n[Not publishable]\n\nEndpoint\n\nbasic toxicokinetics in vivo\n\nType of information\n\nexperimental study\n\nAdequacy of study\n\nkey study\n\nRobust study summary\n\n[Not publishable]\n\nUsed for classification\n\n[Not publishable]\n\nUsed for SDS\n\n[Not publishable]\n\nStudy period: start date\n\n[Empty]\n\nEnd date\n\n[Empty]\n\nRemark\n\n[Empty]\n\nReliability\n\n4 (not assignable)\n\nRationale for reliability incl. deficiencies\n\nsecondary literature\n\nData waiving\n\n[Empty]\n\nJustification for data waiving\n\n[Empty]\n\nJustification for type of information\n\n[Empty]\n\n### Attached justification\n\n### Cross-reference\n\n### Data source\n\nReference\n\n* [Pharmacotoxicological aspects of levosulpiride.](0bba3384-7bf4-4c6d-983d-78a29e387ee6_d18b246e-13d7-423f-a045-5da4c757759e)\n\nData access\n\n[Not publishable]\n\nData protection claimed\n\n[Not publishable]\n\n### Materials and methods\n\nObjective of study\n\n[Empty]\n\n### Test guideline\n\nPrinciples of method if other than guideline\n\n[Empty]\n\nGLP compliance\n\n[Empty]\n\n### Test material\n\nTest material information\n\n[Empty]\n\nAdditional test material information\n\n[Empty]\n\nSpecific details on test material used for the study\n\n[Empty]\n\nSpecific details on test material used for the study (confidential)\n\n[Not publishable]\n\nRadiolabelling\n\n[Empty]\n\n### Radiolabelled test material\n\n### Test animals\n\nSpecies\n\n[Empty]\n\nStrain\n\n[Empty]\n\nDetails on species / strain selection\n\n[Empty]\n\n### Administration / exposure\n\nRoute of administration\n\n[Empty]\n\nVehicle\n\n[Empty]\n\nDetails on exposure\n\n[Empty]\n\nDuration and frequency of treatment / exposure\n\n[Empty]\n\n### Doses / concentrations\n\nControl animals\n\n[Empty]\n\nPositive control reference chemical\n\n[Empty]\n\nDetails on study design\n\n[Empty]\n\nDetails on dosing and sampling\n\n[Empty]\n\nStatistics\n\n[Empty]\n\n### Model and software\n\nModel name and version\n\n[Empty]\n\nSoftware name and version\n\n[Empty]\n\nRemarks\n\n[Not publishable]\n\n### Any other information on materials and methods incl. tables\n\n[Not publishable]\n\n### Results and discussion\n\nPreliminary studies\n\n[Empty]\n\n### Main ADME results\n\n### Toxicokinetic / pharmacokinetic studies\n\nDetails on absorption\n\n[Empty]\n\nDetails on distribution in tissues\n\n[Empty]\n\n### Transfer into organs\n\nDetails on excretion\n\n[Empty]\n\n### Toxicokinetic parameters\n\n### Metabolite characterisation studies\n\nMetabolites identified\n\n[Empty]\n\nDetails on metabolites\n\n[Empty]\n\n### Distribution of metabolites in matrices\n\n### Appendix: Metabolites and their parents in treatment groups\n\n### Metabolites in treatment groups\n\n### Enzymatic activity\n\nEnzymatic activity measured\n\n[Empty]\n\n### Bioaccessibility (or Bioavailability)\n\nBioaccessibility (or Bioavailability) testing results\n\n[Empty]\n\n### Additional information about applicability domain and reliability of (Q)SAR predictions\n\nFit with the applicability domain\n\n[Empty]\n\nJustification for the fit with the applicability domain\n\n[Empty]\n\nFit with the space defined by the training set of the model\n\n[Empty]\n\nMechanistic and metabolic considerations\n\n[Empty]\n\n### Similar substances with experimental data\n\nPerformance of the model for similar substances\n\n[Empty]\n\nConclusions on applicability domain and reliability\n\n[Empty]\n\nUncertainty\n\n[Empty]\n\n### Any other information on results incl. tables\n\nIn rats treated with sulpiride 200 mg/kg by oral route the pharmacokinetic parameters were the following: Cmax 6.8Âµg/ml; tmax 3 h; t1/2 1.4 h; bioavailability 15%. The low bioavailability of sulpiride following oral administration (about 15%) is due not to the metabolism in the liver, but to a reduced absorption by the gastrointestinal tract. Many metabolites were obtained from rats and dogs orally treated with sulpiride. Particularly, in rats, metabolites represented 56% of the administered drug (60 mg/kg) and 38% of them were conjugates. In the dog, the metabolites represented 15% of the administered sulpiride (50 mg/kg), of which 4% were conjugates. However, none of the metabolites documented in these species was found in human urine. In the Rhesus monkeys treated with sulpiride at 10 mg/kg by oral or intravenous route, in both the urine and the bile were documented the following fractions of the administered dose: 60-80% sulpiride, 10-30% 5-oxopyrrolidine sulpiride and 3-8% unidentified metabolite. After intramuscular administration (50 mg) to healthy volunteers, the bioavailability of L-sulpiride is practically complete (about 99%), whereas the oral bioavailability of the same dosage is about 30%. The half-lives are 6.2, 8.3 and 9.7 h respectively, for the intravenous, intramuscular and oral administration (50 mg), with a total clearance of about 260 ml/min. Sulpiride is not bound to plasma proteins to any large extent. In dog plasma 16% of the sulpiride is bound over a concentration range of 1 to 50Âµg/ml. In human plasma 14% is bound over the same concentration range. Thus, the protein binding is constant and independent of sulpiride concentrations in dog plasma and human plasma. The results of a comparative pharmacokinetic study after single oral administration of D-, L- and racemic sulpiride demonstrated that the pharmacokinetic profiles are largely identical. Also, the urinary excretion is similar for racemic and L-sulpiride and accounts for about 65-70% of the dose after intravenous administration, totally as unchanged drug. The mean renal clearance is in the range 260-310 ml/min after intravenous administration of the two drugs (L- and racemic-sulpiride) and suggests a tubular secretion of sulpiride since clearance exceeded glomerular filtration rate. This conclusion is also supported by data on metabolism of sulpiride.\n\n### Overall remarks, attachments\n\nOverall remarks\n\n[Not publishable]\n\n### Attachments\n\n### Applicant's summary and conclusion\n\nConclusions\n\n[Empty]\n\nExecutive summary\n\nIn rats treated with sulpiride 200 mg/kg by oral route the pharmacokinetic parameters were the following: Cmax 6.8 Âµg/ml; tmax 3 h; t1/2 1.4 h; bioavailability 15%. The low bioavailability of sulpiride following oral administration (about 15%) is due not to the metabolism in the liver, but to a reduced absorption by the gastrointestinal tract. Many metabolites were obtained from rats and dogs orally treated with sulpiride. Particularly, in rats, metabolites represented 56% of the administered drug (60 mg/kg) and 38% of them were conjugates. In the dog, the metabolites represented 15% of the administered sulpiride (50 mg/kg), of which 4% were conjugates. However, none of the metabolites documented in these species was found in human urine. In the Rhesus monkeys treated with sulpiride at 10 mg/kg by oral or intravenous route, in both the urine and the bile were documented the following fractions of the administered dose: 60-80% sulpiride, 10-30% 5-oxopyrrolidine sulpiride and 3-8% unidentified metabolite. After intramuscular administration (50 mg) to healthy volunteers, the bioavailability of L-sulpiride is practically complete (about 99%), whereas the oral bioavailability of the same dosage is about 30%. The half-lives are 6.2, 8.3 and 9.7 h respectively, for the intravenous, intramuscular and oral administration (50 mg), with a total clearance of about 260 ml/min. Sulpiride is not bound to plasma proteins to any large extent. In dog plasma 16% of the sulpiride is bound over a concentration range of 1 to 50 Âµg/ml. In human plasma 14% is bound over the same concentration range. Thus, the protein binding is constant and independent of sulpiride concentrations in dog plasma and human plasma. The results of a comparative pharmacokinetic study after single oral administration of D-, L- and racemic sulpiride demonstrated that the pharmacokinetic profiles are largely identical. Also, the urinary excretion is similar for racemic and L-sulpiride and accounts for about 65-70% of the dose after intravenous administration, totally as unchanged drug. The mean renal clearance is in the range 260-310 ml/min after intravenous administration of the two drugs (L- and racemic-sulpiride) and suggests a tubular secretion of sulpiride since clearance exceeded glomerular filtration rate. This conclusion is also supported by data on metabolism of sulpiride.\n\nBack to top",
          "content_length": 8362,
          "status": "success"
        }
      },
      "7.1.2 Dermal absorption": {}
    },
    "7.2 Acute Toxicity": {
      "7.2.1 Acute toxicity: oral": {
        "001 | Other | Experimental study": {
          "document_id": "203ca9b0-557b-44b2-950e-4cf2e0fcb254_d18b246e-13d7-423f-a045-5da4c757759e",
          "markdown_content": "#### Acute toxicity: oral\n\nJump to\n\nHide empty fields\n\n### Administrative data\n\nConfidentiality\n\n[Not publishable]\n\nJustification\n\n[Not publishable]\n\nUse restricted to selected regulatory programmes\n\n[Not publishable]\n\nEndpoint\n\nacute toxicity: oral\n\nType of information\n\nexperimental study\n\nAdequacy of study\n\nother information\n\nRobust study summary\n\n[Not publishable]\n\nUsed for classification\n\n[Not publishable]\n\nUsed for SDS\n\n[Not publishable]\n\nStudy period: start date\n\n[Empty]\n\nEnd date\n\n[Empty]\n\nRemark\n\n[Empty]\n\nReliability\n\n4 (not assignable)\n\nRationale for reliability incl. deficiencies\n\nsecondary literature\n\nData waiving\n\n[Empty]\n\nJustification for data waiving\n\n[Empty]\n\nJustification for type of information\n\n[Empty]\n\n### Attached justification\n\n### Cross-reference\n\n### Data source\n\nReference\n\n* [Sulpiride [USAN:INN:BAN:JAN]](0ceeeb3b-c053-4339-95c5-f18f831aceff_d18b246e-13d7-423f-a045-5da4c757759e)\n\nData access\n\n[Not publishable]\n\nData protection claimed\n\n[Not publishable]\n\n### Materials and methods\n\n### Test guideline\n\nPrinciples of method if other than guideline\n\n[Empty]\n\nGLP compliance\n\nnot specified\n\nTest type\n\nother:\nnot specified.\n\nLimit test\n\n[Empty]\n\n### Test material\n\nTest material information\n\n[Test material information](58f5f39d-02e9-43fd-bfb1-bb2cde8000ff_d18b246e-13d7-423f-a045-5da4c757759e)\n\nAdditional test material information\n\n[Empty]\n\nSpecific details on test material used for the study\n\nSulpiride and sulpiride HCl are expected to be similar for this endpoint.\n\nSpecific details on test material used for the study (confidential)\n\n[Not publishable]\n\n### Test animals\n\nSpecies\n\nrabbit\n\nStrain\n\nnot specified\n\nSex\n\nnot specified\n\nDetails on test animals or test system and environmental conditions\n\n[Empty]\n\n### Administration / exposure\n\nRoute of administration\n\noral: unspecified\n\nVehicle\n\nnot specified\n\nDetails on oral exposure\n\n[Empty]\n\nDoses\n\n[Empty]\n\nNo. of animals per sex per dose\n\n[Empty]\n\nControl animals\n\n[Empty]\n\nDetails on study design\n\n[Empty]\n\nStatistics\n\n[Empty]\n\nHigh dose level used\n\n[Empty]\n\nJustification for deviation from the high dose level\n\n[Not publishable]\n\n### Model and software\n\nModel name and version\n\n[Empty]\n\nSoftware name and version\n\n[Empty]\n\nRemarks\n\n[Not publishable]\n\n### Any other information on materials and methods incl. tables\n\n[Not publishable]\n\n### Results and discussion\n\nPreliminary study\n\n[Empty]\n\n### Effect levels\n\n### #1 - Effect levels\n\nKey result\n\nSex\n\nnot specified\n\nDose descriptor\n\nLD50\n\nEffect level\n\n4,000 \n\n\n \n\nmg/kg bw\n\nBased on\n\n[Empty]\n\n95% CL\n\n[Empty]\n\nRemarks on result\n\n[Empty]\n\nMortality\n\n[Empty]\n\nClinical signs\n\n* other:\n  Gastrointestinal: hypermotility, diarrhea.\n  Lungs, thorax, or respiration: respiratory depression.\n  Behavioral: somnolence (general depressed activity).\n\nBody weight\n\n[Empty]\n\nGross pathology\n\n[Empty]\n\nOther findings\n\n[Empty]\n\n### Additional information about applicability domain and reliability of (Q)SAR predictions\n\nFit with the applicability domain\n\n[Empty]\n\nJustification for the fit with the applicability domain\n\n[Empty]\n\nFit with the space defined by the training set of the model\n\n[Empty]\n\nMechanistic and metabolic considerations\n\n[Empty]\n\n### Similar substances with experimental data\n\nPerformance of the model for similar substances\n\n[Empty]\n\nConclusions on applicability domain and reliability\n\n[Empty]\n\nUncertainty\n\n[Empty]\n\n### Any other information on results incl. tables\n\n[Empty]\n\n### Overall remarks, attachments\n\nOverall remarks\n\n[Not publishable]\n\n### Attachments\n\n### Applicant's summary and conclusion\n\nInterpretation of results\n\nGHS criteria not met\n\nConclusions\n\nThe substance has a LD50 (rabbit) of 4000 mg/kg bw.\n\nExecutive summary\n\n[Empty]\n\nBack to top",
          "content_length": 3718,
          "status": "success"
        },
        "002 | Other | Experimental study": {
          "document_id": "88e385fe-827d-4929-9a49-baa625a26f09_d18b246e-13d7-423f-a045-5da4c757759e",
          "markdown_content": "#### Acute toxicity: oral\n\nJump to\n\nHide empty fields\n\n### Administrative data\n\nConfidentiality\n\n[Not publishable]\n\nJustification\n\n[Not publishable]\n\nUse restricted to selected regulatory programmes\n\n[Not publishable]\n\nEndpoint\n\nacute toxicity: oral\n\nType of information\n\nexperimental study\n\nAdequacy of study\n\nother information\n\nRobust study summary\n\n[Not publishable]\n\nUsed for classification\n\n[Not publishable]\n\nUsed for SDS\n\n[Not publishable]\n\nStudy period: start date\n\n[Empty]\n\nEnd date\n\n[Empty]\n\nRemark\n\n[Empty]\n\nReliability\n\n4 (not assignable)\n\nRationale for reliability incl. deficiencies\n\nsecondary literature\n\nData waiving\n\n[Empty]\n\nJustification for data waiving\n\n[Empty]\n\nJustification for type of information\n\n[Empty]\n\n### Attached justification\n\n### Cross-reference\n\n### Data source\n\nReference\n\n* [Sulpiride [USAN:INN:BAN:JAN]](0ceeeb3b-c053-4339-95c5-f18f831aceff_d18b246e-13d7-423f-a045-5da4c757759e)\n\nData access\n\n[Not publishable]\n\nData protection claimed\n\n[Not publishable]\n\n### Materials and methods\n\n### Test guideline\n\n### #1 - Test guideline\n\nQualifier\n\n[Empty]\n\nGuideline\n\nother:\nnot specified\n\nVersion / remarks\n\n[Empty]\n\nDeviations\n\n[Empty]\n\nPrinciples of method if other than guideline\n\n[Empty]\n\nGLP compliance\n\nnot specified\n\nTest type\n\nother:\nnot specified.\n\nLimit test\n\n[Empty]\n\n### Test material\n\nTest material information\n\n[Test material information](58f5f39d-02e9-43fd-bfb1-bb2cde8000ff_d18b246e-13d7-423f-a045-5da4c757759e)\n\nAdditional test material information\n\n[Empty]\n\nSpecific details on test material used for the study\n\nSulpiride and sulpiride HCl are expected to be similar for this endpoint.\n\nSpecific details on test material used for the study (confidential)\n\n[Not publishable]\n\n### Test animals\n\nSpecies\n\nmouse\n\nStrain\n\nnot specified\n\nSex\n\nnot specified\n\nDetails on test animals or test system and environmental conditions\n\n[Empty]\n\n### Administration / exposure\n\nRoute of administration\n\noral: unspecified\n\nVehicle\n\nnot specified\n\nDetails on oral exposure\n\n[Empty]\n\nDoses\n\n[Empty]\n\nNo. of animals per sex per dose\n\n[Empty]\n\nControl animals\n\n[Empty]\n\nDetails on study design\n\n[Empty]\n\nStatistics\n\n[Empty]\n\nHigh dose level used\n\n[Empty]\n\nJustification for deviation from the high dose level\n\n[Not publishable]\n\n### Model and software\n\nModel name and version\n\n[Empty]\n\nSoftware name and version\n\n[Empty]\n\nRemarks\n\n[Not publishable]\n\n### Any other information on materials and methods incl. tables\n\n[Not publishable]\n\n### Results and discussion\n\nPreliminary study\n\n[Empty]\n\n### Effect levels\n\n### #1 - Effect levels\n\nKey result\n\nSex\n\nnot specified\n\nDose descriptor\n\nLD50\n\nEffect level\n\n1,700 \n\n\n \n\nmg/kg bw\n\nBased on\n\n[Empty]\n\n95% CL\n\n[Empty]\n\nRemarks on result\n\n[Empty]\n\nMortality\n\n[Empty]\n\nClinical signs\n\n* other:\n  not specified.\n\nBody weight\n\n[Empty]\n\nGross pathology\n\n[Empty]\n\nOther findings\n\n[Empty]\n\n### Additional information about applicability domain and reliability of (Q)SAR predictions\n\nFit with the applicability domain\n\n[Empty]\n\nJustification for the fit with the applicability domain\n\n[Empty]\n\nFit with the space defined by the training set of the model\n\n[Empty]\n\nMechanistic and metabolic considerations\n\n[Empty]\n\n### Similar substances with experimental data\n\nPerformance of the model for similar substances\n\n[Empty]\n\nConclusions on applicability domain and reliability\n\n[Empty]\n\nUncertainty\n\n[Empty]\n\n### Any other information on results incl. tables\n\n[Empty]\n\n### Overall remarks, attachments\n\nOverall remarks\n\n[Not publishable]\n\n### Attachments\n\n### Applicant's summary and conclusion\n\nInterpretation of results\n\nCategory 4 based on GHS criteria\n\nConclusions\n\nThe substance has a LD50 (mouse) of 1700 mg/kg bw.\n\nExecutive summary\n\n[Empty]\n\nBack to top",
          "content_length": 3715,
          "status": "success"
        },
        "003 | Other | Experimental study": {
          "document_id": "631ed667-062a-4b41-88ca-59b7078405f5_d18b246e-13d7-423f-a045-5da4c757759e",
          "markdown_content": "#### Acute toxicity: oral\n\nJump to\n\nHide empty fields\n\n### Administrative data\n\nConfidentiality\n\n[Not publishable]\n\nJustification\n\n[Not publishable]\n\nUse restricted to selected regulatory programmes\n\n[Not publishable]\n\nEndpoint\n\nacute toxicity: oral\n\nType of information\n\nexperimental study\n\nAdequacy of study\n\nother information\n\nRobust study summary\n\n[Not publishable]\n\nUsed for classification\n\n[Not publishable]\n\nUsed for SDS\n\n[Not publishable]\n\nStudy period: start date\n\n[Empty]\n\nEnd date\n\n[Empty]\n\nRemark\n\n[Empty]\n\nReliability\n\n4 (not assignable)\n\nRationale for reliability incl. deficiencies\n\nsecondary literature\n\nData waiving\n\n[Empty]\n\nJustification for data waiving\n\n[Empty]\n\nJustification for type of information\n\n[Empty]\n\n### Attached justification\n\n### Cross-reference\n\n### Data source\n\nReference\n\n* [Sulpiride [USAN:INN:BAN:JAN]](0ceeeb3b-c053-4339-95c5-f18f831aceff_d18b246e-13d7-423f-a045-5da4c757759e)\n\nData access\n\n[Not publishable]\n\nData protection claimed\n\n[Not publishable]\n\n### Materials and methods\n\n### Test guideline\n\nPrinciples of method if other than guideline\n\n[Empty]\n\nGLP compliance\n\nnot specified\n\nTest type\n\nother:\nnot specified.\n\nLimit test\n\n[Empty]\n\n### Test material\n\nTest material information\n\n[Test material information](58f5f39d-02e9-43fd-bfb1-bb2cde8000ff_d18b246e-13d7-423f-a045-5da4c757759e)\n\nAdditional test material information\n\n[Empty]\n\nSpecific details on test material used for the study\n\nSulpiride and sulpiride HCl are expected to be similar for this endpoint.\n\nSpecific details on test material used for the study (confidential)\n\n[Not publishable]\n\n### Test animals\n\nSpecies\n\nrat\n\nStrain\n\nnot specified\n\nSex\n\nnot specified\n\nDetails on test animals or test system and environmental conditions\n\n[Empty]\n\n### Administration / exposure\n\nRoute of administration\n\noral: unspecified\n\nVehicle\n\nnot specified\n\nDetails on oral exposure\n\n[Empty]\n\nDoses\n\n[Empty]\n\nNo. of animals per sex per dose\n\n[Empty]\n\nControl animals\n\n[Empty]\n\nDetails on study design\n\n[Empty]\n\nStatistics\n\n[Empty]\n\nHigh dose level used\n\n[Empty]\n\nJustification for deviation from the high dose level\n\n[Not publishable]\n\n### Model and software\n\nModel name and version\n\n[Empty]\n\nSoftware name and version\n\n[Empty]\n\nRemarks\n\n[Not publishable]\n\n### Any other information on materials and methods incl. tables\n\n[Not publishable]\n\n### Results and discussion\n\nPreliminary study\n\n[Empty]\n\n### Effect levels\n\n### #1 - Effect levels\n\nKey result\n\nSex\n\nnot specified\n\nDose descriptor\n\nLD50\n\nEffect level\n\n9,800 \n\n\n \n\nmg/kg bw\n\nBased on\n\n[Empty]\n\n95% CL\n\n[Empty]\n\nRemarks on result\n\n[Empty]\n\nMortality\n\n[Empty]\n\nClinical signs\n\n* other:\n  Lungs, thorax, or respiration: respiratory depression.\n  Behavioral: somnolence (general depressed activity).\n  Gastrointestinal: hypermotility, diarrhea.\n\nBody weight\n\n[Empty]\n\nGross pathology\n\n[Empty]\n\nOther findings\n\n[Empty]\n\n### Additional information about applicability domain and reliability of (Q)SAR predictions\n\nFit with the applicability domain\n\n[Empty]\n\nJustification for the fit with the applicability domain\n\n[Empty]\n\nFit with the space defined by the training set of the model\n\n[Empty]\n\nMechanistic and metabolic considerations\n\n[Empty]\n\n### Similar substances with experimental data\n\nPerformance of the model for similar substances\n\n[Empty]\n\nConclusions on applicability domain and reliability\n\n[Empty]\n\nUncertainty\n\n[Empty]\n\n### Any other information on results incl. tables\n\n[Empty]\n\n### Overall remarks, attachments\n\nOverall remarks\n\n[Not publishable]\n\n### Attachments\n\n### Applicant's summary and conclusion\n\nInterpretation of results\n\nGHS criteria not met\n\nConclusions\n\nThe substance has a LD50 (rat) of 9800 mg/kg bw.\n\nExecutive summary\n\n[Empty]\n\nBack to top",
          "content_length": 3712,
          "status": "success"
        },
        "004 | Weight of evidence | Experimental study": {
          "document_id": "567130e8-16b4-4cbd-95a4-2c24794c1c4c_d18b246e-13d7-423f-a045-5da4c757759e",
          "markdown_content": "#### Acute toxicity: oral\n\nJump to\n\nHide empty fields\n\n### Administrative data\n\nConfidentiality\n\n[Not publishable]\n\nJustification\n\n[Not publishable]\n\nUse restricted to selected regulatory programmes\n\n[Not publishable]\n\nEndpoint\n\nacute toxicity: oral\n\nType of information\n\nexperimental study\n\nAdequacy of study\n\nweight of evidence\n\nRobust study summary\n\n[Not publishable]\n\nUsed for classification\n\n[Not publishable]\n\nUsed for SDS\n\n[Not publishable]\n\nStudy period: start date\n\n[Empty]\n\nEnd date\n\n[Empty]\n\nRemark\n\n[Empty]\n\nReliability\n\n4 (not assignable)\n\nRationale for reliability incl. deficiencies\n\nsecondary literature\n\nData waiving\n\n[Empty]\n\nJustification for data waiving\n\n[Empty]\n\nJustification for type of information\n\n[Empty]\n\n### Attached justification\n\n### Cross-reference\n\n### Data source\n\nReference\n\n* [Pharmacotoxicological aspects of levosulpiride.](0bba3384-7bf4-4c6d-983d-78a29e387ee6_d18b246e-13d7-423f-a045-5da4c757759e)\n\nData access\n\n[Not publishable]\n\nData protection claimed\n\n[Not publishable]\n\n### Materials and methods\n\n### Test guideline\n\n### #1 - Test guideline\n\nQualifier\n\n[Empty]\n\nGuideline\n\nother:\nnot specified\n\nVersion / remarks\n\n[Empty]\n\nDeviations\n\n[Empty]\n\nPrinciples of method if other than guideline\n\n[Empty]\n\nGLP compliance\n\nnot specified\n\nTest type\n\n[Empty]\n\nLimit test\n\n[Empty]\n\n### Test material\n\nTest material information\n\n[Test material information](4e39367f-bcf9-4a5f-bd70-64ddd6fbf79e_d18b246e-13d7-423f-a045-5da4c757759e)\n\nAdditional test material information\n\n[Empty]\n\nSpecific details on test material used for the study\n\n[Empty]\n\nSpecific details on test material used for the study (confidential)\n\n[Not publishable]\n\n### Test animals\n\nSpecies\n\n[Empty]\n\nStrain\n\n[Empty]\n\nSex\n\n[Empty]\n\nDetails on test animals or test system and environmental conditions\n\n[Empty]\n\n### Administration / exposure\n\nRoute of administration\n\n[Empty]\n\nVehicle\n\n[Empty]\n\nDetails on oral exposure\n\n[Empty]\n\nDoses\n\n[Empty]\n\nNo. of animals per sex per dose\n\n[Empty]\n\nControl animals\n\n[Empty]\n\nDetails on study design\n\n[Empty]\n\nStatistics\n\n[Empty]\n\nHigh dose level used\n\n[Empty]\n\nJustification for deviation from the high dose level\n\n[Not publishable]\n\n### Model and software\n\nModel name and version\n\n[Empty]\n\nSoftware name and version\n\n[Empty]\n\nRemarks\n\n[Not publishable]\n\n### Any other information on materials and methods incl. tables\n\n[Not publishable]\n\n### Results and discussion\n\nPreliminary study\n\n[Empty]\n\n### Effect levels\n\n### #1 - Effect levels\n\nKey result\n\nSex\n\nmale/female\n\nDose descriptor\n\nLD50\n\nEffect level\n\n>=\n2,280 \n\n\n \n\nmg/kg bw\n\nBased on\n\nother:\nD-Sulpiride\n\n95% CL\n\n[Empty]\n\nRemarks on result\n\nother:\nTested on mice\n\n### #2 - Effect levels\n\nKey result\n\nSex\n\nmale/female\n\nDose descriptor\n\nLD50\n\nEffect level\n\n>=\n2,450 \n\n\n \n\nmg/kg bw\n\nBased on\n\nother:\nL-Sulpiride\n\n95% CL\n\n[Empty]\n\nRemarks on result\n\nother:\nTested on mice\n\n### #3 - Effect levels\n\nKey result\n\nSex\n\nmale/female\n\nDose descriptor\n\nLD50\n\nEffect level\n\n>=\n2,600 \n\n\n \n\nmg/kg bw\n\nBased on\n\nother:\nL-Sulpiride\n\n95% CL\n\n[Empty]\n\nRemarks on result\n\nother:\nTested on rats\n\n### #4 - Effect levels\n\nKey result\n\nSex\n\nmale/female\n\nDose descriptor\n\nLD50\n\nEffect level\n\n>=\n2,200 \n\n\n \n\nmg/kg bw\n\nBased on\n\nother:\nD-Sulpiride\n\n95% CL\n\n[Empty]\n\nRemarks on result\n\nother:\nTested on rats\n\nMortality\n\n[Empty]\n\nClinical signs\n\n[Empty]\n\nBody weight\n\n[Empty]\n\nGross pathology\n\n[Empty]\n\nOther findings\n\n[Empty]\n\n### Additional information about applicability domain and reliability of (Q)SAR predictions\n\nFit with the applicability domain\n\n[Empty]\n\nJustification for the fit with the applicability domain\n\n[Empty]\n\nFit with the space defined by the training set of the model\n\n[Empty]\n\nMechanistic and metabolic considerations\n\n[Empty]\n\n### Similar substances with experimental data\n\nPerformance of the model for similar substances\n\n[Empty]\n\nConclusions on applicability domain and reliability\n\n[Empty]\n\nUncertainty\n\n[Empty]\n\n### Any other information on results incl. tables\n\nTrials on acute toxicity have been carried out on different animal species (mice, rats and rabbits) and using different administration routes (intravenous, oral and intraperitoneal). These studies demonstrated that the levosulpiride is well tolerated by all the animal species examined and by using different administration routes. In fact, signs of toxicity are encountered only with doses of some magnitude greater than those foreseen in therapy (2250-3250 mg/kg) (See Figure). Racemic sulpiride administered by intraperitoneal route is responsible for an LD50 of 210 mg/kg in mice and 270 mg/kg in rats. On considering that LD50 is more or less the same for both racemic compound and levosulpiride, it appears evident that when only the active levoisomer is used in human therapy at half the racemic dosage, the toxic component of the compound is halved.\n\n### Overall remarks, attachments\n\nOverall remarks\n\n[Not publishable]\n\n### Attachments\n\n#1\n\n[Not publishable]\n\n### Applicant's summary and conclusion\n\nInterpretation of results\n\nGHS criteria not met\n\nConclusions\n\nLD50 p.o. (mice, rats) >= 2000 mg/kg bw.\n\nExecutive summary\n\nTrials on acute toxicity have been carried out on different animal species (mice, rats and rabbits) and using different administration routes (intravenous, oral and intraperitoneal). These studies demonstrated that the levosulpiride is well tolerated by all the animal species examined and by using different administration routes. In fact, signs of toxicity are encountered only with doses of some magnitude greater than those foreseen in therapy (2250-3250 mg/kg) (See Figure). Racemic sulpiride administered by intraperitoneal route is responsible for an LD50 of 210 mg/kg in mice and 270 mg/kg in rats. On considering that LD50 is more or less the same for both racemic compound and levosulpiride, it appears evident that when only the active levoisomer is used in human therapy at half the racemic dosage, the toxic component of the compound is halved.\n\nBack to top",
          "content_length": 5953,
          "status": "success"
        },
        "005 | Other | Experimental study": {
          "document_id": "d85da4ff-ad9f-45d2-bf64-ace2b40a273d_d18b246e-13d7-423f-a045-5da4c757759e",
          "markdown_content": "#### Acute toxicity: oral\n\nJump to\n\nHide empty fields\n\n### Administrative data\n\nConfidentiality\n\n[Not publishable]\n\nJustification\n\n[Not publishable]\n\nUse restricted to selected regulatory programmes\n\n[Not publishable]\n\nEndpoint\n\nacute toxicity: oral\n\nType of information\n\nexperimental study\n\nAdequacy of study\n\nother information\n\nRobust study summary\n\n[Not publishable]\n\nUsed for classification\n\n[Not publishable]\n\nUsed for SDS\n\n[Not publishable]\n\nStudy period: start date\n\n[Empty]\n\nEnd date\n\n[Empty]\n\nRemark\n\n[Empty]\n\nReliability\n\n4 (not assignable)\n\nRationale for reliability incl. deficiencies\n\nabstract\n\nData waiving\n\n[Empty]\n\nJustification for data waiving\n\n[Empty]\n\nJustification for type of information\n\n[Empty]\n\n### Attached justification\n\n### Cross-reference\n\n### Data source\n\nReference\n\n* [Toxicity assessment of sulpiride as the basis of its hygienic standardization.](6540798d-a490-4653-9824-72ac0fac81ce_d18b246e-13d7-423f-a045-5da4c757759e)\n\nData access\n\n[Not publishable]\n\nData protection claimed\n\n[Not publishable]\n\n### Materials and methods\n\n### Test guideline\n\nPrinciples of method if other than guideline\n\n[Empty]\n\nGLP compliance\n\nnot specified\n\nTest type\n\nother:\nnot specified.\n\nLimit test\n\n[Empty]\n\n### Test material\n\nTest material information\n\n[Test material information](58f5f39d-02e9-43fd-bfb1-bb2cde8000ff_d18b246e-13d7-423f-a045-5da4c757759e)\n\nAdditional test material information\n\n[Empty]\n\nSpecific details on test material used for the study\n\nSulpiride and sulpiride HCl are expected to be similar for this endpoint.\n\nSpecific details on test material used for the study (confidential)\n\n[Not publishable]\n\n### Test animals\n\nSpecies\n\nmouse\n\nStrain\n\nnot specified\n\nSex\n\nmale/female\n\nDetails on test animals or test system and environmental conditions\n\n[Empty]\n\n### Administration / exposure\n\nRoute of administration\n\noral: gavage\n\nVehicle\n\nnot specified\n\nDetails on oral exposure\n\n[Empty]\n\nDoses\n\n[Empty]\n\nNo. of animals per sex per dose\n\n[Empty]\n\nControl animals\n\n[Empty]\n\nDetails on study design\n\n[Empty]\n\nStatistics\n\n[Empty]\n\nHigh dose level used\n\n[Empty]\n\nJustification for deviation from the high dose level\n\n[Not publishable]\n\n### Model and software\n\nModel name and version\n\n[Empty]\n\nSoftware name and version\n\n[Empty]\n\nRemarks\n\n[Not publishable]\n\n### Any other information on materials and methods incl. tables\n\n[Not publishable]\n\n### Results and discussion\n\nPreliminary study\n\n[Empty]\n\n### Effect levels\n\n### #1 - Effect levels\n\nKey result\n\nSex\n\nmale\n\nDose descriptor\n\nLD50\n\nEffect level\n\n3,400 \n\n\n \n\nmg/kg bw\n\nBased on\n\n[Empty]\n\n95% CL\n\n[Empty]\n\nRemarks on result\n\n[Empty]\n\n### #2 - Effect levels\n\nKey result\n\nSex\n\nfemale\n\nDose descriptor\n\nLD50\n\nEffect level\n\n2,300 \n\n\n \n\nmg/kg bw\n\nBased on\n\n[Empty]\n\n95% CL\n\n[Empty]\n\nRemarks on result\n\n[Empty]\n\nMortality\n\n[Empty]\n\nClinical signs\n\n[Empty]\n\nBody weight\n\n[Empty]\n\nGross pathology\n\n[Empty]\n\nOther findings\n\n[Empty]\n\n### Additional information about applicability domain and reliability of (Q)SAR predictions\n\nFit with the applicability domain\n\n[Empty]\n\nJustification for the fit with the applicability domain\n\n[Empty]\n\nFit with the space defined by the training set of the model\n\n[Empty]\n\nMechanistic and metabolic considerations\n\n[Empty]\n\n### Similar substances with experimental data\n\nPerformance of the model for similar substances\n\n[Empty]\n\nConclusions on applicability domain and reliability\n\n[Empty]\n\nUncertainty\n\n[Empty]\n\n### Any other information on results incl. tables\n\n[Empty]\n\n### Overall remarks, attachments\n\nOverall remarks\n\n[Not publishable]\n\n### Attachments\n\n### Applicant's summary and conclusion\n\nInterpretation of results\n\nGHS criteria not met\n\nConclusions\n\nLD50 (mouse) >= 2000 mg/kg bw. No significant differences were noted in the sex sensitivity of animals to a substance.\n\nExecutive summary\n\nLD50 of sulpiride in administration into the stomach of male rats and mice is 7200 and 3400 mg/kg, for female rats and mice 6000 and 2300 mg/kg. No significant differences were noted in the species and sex sensitivity of animals to a substance. In intraperitoneal administration LD50 for male rats is 220 mg/kg, for female rats 150 mg/kg. It has not a local irritant effect on the skin. There were no identified skin-resorptive and sensitizing effects. It causes a slight irritant effect on the mucous membranes of the eyes. It has a toxic effect on the central nervous system, liver, kidneys.\n\nBack to top",
          "content_length": 4406,
          "status": "success"
        },
        "006 | Weight of evidence | Experimental study": {
          "document_id": "46123d8e-1e32-422b-b669-4d6d855cf0d6_d18b246e-13d7-423f-a045-5da4c757759e",
          "markdown_content": "#### Acute toxicity: oral\n\nJump to\n\nHide empty fields\n\n### Administrative data\n\nConfidentiality\n\n[Not publishable]\n\nJustification\n\n[Not publishable]\n\nUse restricted to selected regulatory programmes\n\n[Not publishable]\n\nEndpoint\n\nacute toxicity: oral\n\nType of information\n\nexperimental study\n\nAdequacy of study\n\nweight of evidence\n\nRobust study summary\n\n[Not publishable]\n\nUsed for classification\n\n[Not publishable]\n\nUsed for SDS\n\n[Not publishable]\n\nStudy period: start date\n\n[Empty]\n\nEnd date\n\n[Empty]\n\nRemark\n\n[Empty]\n\nReliability\n\n4 (not assignable)\n\nRationale for reliability incl. deficiencies\n\nabstract\n\nData waiving\n\n[Empty]\n\nJustification for data waiving\n\n[Empty]\n\nJustification for type of information\n\n[Empty]\n\n### Attached justification\n\n### Cross-reference\n\n### Data source\n\nReference\n\n* [Toxicity assessment of sulpiride as the basis of its hygienic standardization.](6540798d-a490-4653-9824-72ac0fac81ce_d18b246e-13d7-423f-a045-5da4c757759e)\n\nData access\n\n[Not publishable]\n\nData protection claimed\n\n[Not publishable]\n\n### Materials and methods\n\n### Test guideline\n\n### #1 - Test guideline\n\nQualifier\n\n[Empty]\n\nGuideline\n\nother:\nnot specified\n\nVersion / remarks\n\n[Empty]\n\nDeviations\n\n[Empty]\n\nPrinciples of method if other than guideline\n\n[Empty]\n\nGLP compliance\n\nnot specified\n\nabstract\n\nTest type\n\nother:\nnot specified.\n\nLimit test\n\n[Empty]\n\n### Test material\n\nTest material information\n\n[Test material information](58f5f39d-02e9-43fd-bfb1-bb2cde8000ff_d18b246e-13d7-423f-a045-5da4c757759e)\n\nAdditional test material information\n\n[Empty]\n\nSpecific details on test material used for the study\n\nSulpiride and sulpiride HCl are expected to be similar for this endpoint.\n\nSpecific details on test material used for the study (confidential)\n\n[Not publishable]\n\n### Test animals\n\nSpecies\n\nrat\n\nStrain\n\nnot specified\n\nSex\n\nmale/female\n\nDetails on test animals or test system and environmental conditions\n\n[Empty]\n\n### Administration / exposure\n\nRoute of administration\n\noral: gavage\n\nVehicle\n\nnot specified\n\nDetails on oral exposure\n\n[Empty]\n\nDoses\n\n[Empty]\n\nNo. of animals per sex per dose\n\n[Empty]\n\nControl animals\n\n[Empty]\n\nDetails on study design\n\n[Empty]\n\nStatistics\n\n[Empty]\n\nHigh dose level used\n\n[Empty]\n\nJustification for deviation from the high dose level\n\n[Not publishable]\n\n### Model and software\n\nModel name and version\n\n[Empty]\n\nSoftware name and version\n\n[Empty]\n\nRemarks\n\n[Not publishable]\n\n### Any other information on materials and methods incl. tables\n\n[Not publishable]\n\n### Results and discussion\n\nPreliminary study\n\n[Empty]\n\n### Effect levels\n\n### #1 - Effect levels\n\nKey result\n\nSex\n\nmale\n\nDose descriptor\n\nLD50\n\nEffect level\n\n7,200 \n\n\n \n\nmg/kg bw\n\nBased on\n\n[Empty]\n\n95% CL\n\n[Empty]\n\nRemarks on result\n\n[Empty]\n\n### #2 - Effect levels\n\nKey result\n\nSex\n\nfemale\n\nDose descriptor\n\nLD50\n\nEffect level\n\n6,000 \n\n\n \n\nmg/kg bw\n\nBased on\n\n[Empty]\n\n95% CL\n\n[Empty]\n\nRemarks on result\n\n[Empty]\n\nMortality\n\n[Empty]\n\nClinical signs\n\n[Empty]\n\nBody weight\n\n[Empty]\n\nGross pathology\n\n[Empty]\n\nOther findings\n\n[Empty]\n\n### Additional information about applicability domain and reliability of (Q)SAR predictions\n\nFit with the applicability domain\n\n[Empty]\n\nJustification for the fit with the applicability domain\n\n[Empty]\n\nFit with the space defined by the training set of the model\n\n[Empty]\n\nMechanistic and metabolic considerations\n\n[Empty]\n\n### Similar substances with experimental data\n\nPerformance of the model for similar substances\n\n[Empty]\n\nConclusions on applicability domain and reliability\n\n[Empty]\n\nUncertainty\n\n[Empty]\n\n### Any other information on results incl. tables\n\n[Empty]\n\n### Overall remarks, attachments\n\nOverall remarks\n\n[Not publishable]\n\n### Attachments\n\n### Applicant's summary and conclusion\n\nInterpretation of results\n\nGHS criteria not met\n\nConclusions\n\nThe substance has a LD50 (rat) >= 6000 mg/kg bw. No significant differences were noted in the sex sensitivity of animals to a substance.\n\nExecutive summary\n\nLD50 of sulpiride in administration into the stomach of male rats and mice is 7200 and 3400 mg/kg, for female rats and mice 6000 and 2300 mg/kg. No significant differences were noted in the species and sex sensitivity of animals to a substance. In intraperitoneal administration LD50 for male rats is 220 mg/kg, for female rats 150 mg/kg. It has not a local irritant effect on the skin. There were no identified skin-resorptive and sensitizing effects. It causes a slight irritant effect on the mucous membranes of the eyes. It has a toxic effect on the central nervous system, liver, kidneys.\n\nBack to top",
          "content_length": 4560,
          "status": "success"
        },
        "007 | Other | Experimental study": {
          "document_id": "193f90a8-f697-4ed1-8ef9-862f17bedee5_d18b246e-13d7-423f-a045-5da4c757759e",
          "markdown_content": "#### Acute toxicity: oral\n\nJump to\n\nHide empty fields\n\n### Administrative data\n\nConfidentiality\n\n[Not publishable]\n\nJustification\n\n[Not publishable]\n\nUse restricted to selected regulatory programmes\n\n[Not publishable]\n\nEndpoint\n\nacute toxicity: oral\n\nType of information\n\nexperimental study\n\nAdequacy of study\n\nother information\n\nRobust study summary\n\n[Not publishable]\n\nUsed for classification\n\n[Not publishable]\n\nUsed for SDS\n\n[Not publishable]\n\nStudy period: start date\n\n[Empty]\n\nEnd date\n\n[Empty]\n\nRemark\n\n[Empty]\n\nReliability\n\n4 (not assignable)\n\nRationale for reliability incl. deficiencies\n\nsecondary literature\n\nData waiving\n\n[Empty]\n\nJustification for data waiving\n\n[Empty]\n\nJustification for type of information\n\n[Empty]\n\n### Attached justification\n\n### Cross-reference\n\n### Data source\n\nReference\n\n* [Sulpiride [USAN:INN:BAN:JAN]](0ceeeb3b-c053-4339-95c5-f18f831aceff_d18b246e-13d7-423f-a045-5da4c757759e)\n\nData access\n\n[Not publishable]\n\nData protection claimed\n\n[Not publishable]\n\n### Materials and methods\n\n### Test guideline\n\nPrinciples of method if other than guideline\n\n[Empty]\n\nGLP compliance\n\nnot specified\n\nTest type\n\nother:\nnot specified.\n\nLimit test\n\n[Empty]\n\n### Test material\n\nTest material information\n\n[Test material information](58f5f39d-02e9-43fd-bfb1-bb2cde8000ff_d18b246e-13d7-423f-a045-5da4c757759e)\n\nAdditional test material information\n\n[Empty]\n\nSpecific details on test material used for the study\n\nSulpiride and sulpiride HCl are expected to be similar for this endpoint.\n\nSpecific details on test material used for the study (confidential)\n\n[Not publishable]\n\n### Test animals\n\nSpecies\n\ndog\n\nStrain\n\nnot specified\n\nSex\n\nnot specified\n\nDetails on test animals or test system and environmental conditions\n\n[Empty]\n\n### Administration / exposure\n\nRoute of administration\n\noral: unspecified\n\nVehicle\n\nnot specified\n\nDetails on oral exposure\n\n[Empty]\n\nDoses\n\n[Empty]\n\nNo. of animals per sex per dose\n\n[Empty]\n\nControl animals\n\n[Empty]\n\nDetails on study design\n\n[Empty]\n\nStatistics\n\n[Empty]\n\nHigh dose level used\n\n[Empty]\n\nJustification for deviation from the high dose level\n\n[Not publishable]\n\n### Model and software\n\nModel name and version\n\n[Empty]\n\nSoftware name and version\n\n[Empty]\n\nRemarks\n\n[Not publishable]\n\n### Any other information on materials and methods incl. tables\n\n[Not publishable]\n\n### Results and discussion\n\nPreliminary study\n\n[Empty]\n\n### Effect levels\n\n### #1 - Effect levels\n\nKey result\n\nSex\n\nnot specified\n\nDose descriptor\n\nLD50\n\nEffect level\n\n2,000 \n\n\n \n\nmg/kg bw\n\nBased on\n\n[Empty]\n\n95% CL\n\n[Empty]\n\nRemarks on result\n\n[Empty]\n\nMortality\n\n[Empty]\n\nClinical signs\n\n* other:\n  Behavioral: somnolence (general depressed activity).\n  Lungs, thorax, or respiration: respiratory depression.\n  Gastrointestinal: hypermotility, diarrhea.\n\nBody weight\n\n[Empty]\n\nGross pathology\n\n[Empty]\n\nOther findings\n\n[Empty]\n\n### Additional information about applicability domain and reliability of (Q)SAR predictions\n\nFit with the applicability domain\n\n[Empty]\n\nJustification for the fit with the applicability domain\n\n[Empty]\n\nFit with the space defined by the training set of the model\n\n[Empty]\n\nMechanistic and metabolic considerations\n\n[Empty]\n\n### Similar substances with experimental data\n\nPerformance of the model for similar substances\n\n[Empty]\n\nConclusions on applicability domain and reliability\n\n[Empty]\n\nUncertainty\n\n[Empty]\n\n### Any other information on results incl. tables\n\n[Empty]\n\n### Overall remarks, attachments\n\nOverall remarks\n\n[Not publishable]\n\n### Attachments\n\n### Applicant's summary and conclusion\n\nInterpretation of results\n\nCategory 4 based on GHS criteria\n\nConclusions\n\nThe substance has a LD50 of 2000 mg/kg bw.\n\nExecutive summary\n\n[Empty]\n\nBack to top",
          "content_length": 3718,
          "status": "success"
        }
      },
      "7.2.2 Acute toxicity: inhalation": {},
      "7.2.3 Acute toxicity: dermal": {},
      "7.2.4 Acute toxicity: other routes": {},
      "S-01 | Summary": {
        "document_id": "f5e546da-2f6c-49af-af02-04fc44c69d51_d18b246e-13d7-423f-a045-5da4c757759e",
        "markdown_content": "#### Acute Toxicity\n\nJump to\n\nHide empty fields\n\n### Administrative data\n\nConfidentiality\n\n[Empty]\n\nJustification\n\n[Empty]\n\nUse restricted to selected regulatory programmes\n\n[Empty]\n\n### Description of key information\n\nLD50 values for several animal species are available in the scientific literature. Those values are almost all higher than 2000 mg/kg (a LD50 of 1700 mg/kg bw also is reported for mouse).\n\n### Key value for chemical safety assessment\n\n### Acute toxicity: via oral route\n\nLink to relevant study record(s)\n\n* [007 | Other | Experimental study](193f90a8-f697-4ed1-8ef9-862f17bedee5_d18b246e-13d7-423f-a045-5da4c757759e)\n* [001 | Other | Experimental study](203ca9b0-557b-44b2-950e-4cf2e0fcb254_d18b246e-13d7-423f-a045-5da4c757759e)\n* [002 | Other | Experimental study](88e385fe-827d-4929-9a49-baa625a26f09_d18b246e-13d7-423f-a045-5da4c757759e)\n* [003 | Other | Experimental study](631ed667-062a-4b41-88ca-59b7078405f5_d18b246e-13d7-423f-a045-5da4c757759e)\n* [005 | Other | Experimental study](d85da4ff-ad9f-45d2-bf64-ace2b40a273d_d18b246e-13d7-423f-a045-5da4c757759e)\n* [006 | Weight of evidence | Experimental study](46123d8e-1e32-422b-b669-4d6d855cf0d6_d18b246e-13d7-423f-a045-5da4c757759e)\n* [004 | Weight of evidence | Experimental study](567130e8-16b4-4cbd-95a4-2c24794c1c4c_d18b246e-13d7-423f-a045-5da4c757759e)\n\nEndpoint conclusion\n\nadverse effect observed\n\nDose descriptor\n\nLD50\n\nEffect level\n\n6,000 \n\n\n \n\nmg/kg bw\n\n### Acute toxicity: via dermal route\n\nLink to relevant study record(s)\n\n[Empty]\n\nEndpoint conclusion\n\nno information available\n\nDose descriptor\n\n[Empty]\n\nEffect level\n\n[Empty]\n\n### Acute toxicity: via inhalation route\n\nLink to relevant study record(s)\n\n[Empty]\n\nEndpoint conclusion\n\nno information available\n\nDose descriptor\n\n[Empty]\n\nEffect level\n\n[Empty]\n\nPhysical form\n\n[Empty]\n\n### Acute toxicity: other routes\n\nLink to relevant study record(s)\n\n[Empty]\n\n### Justification for classification or non-classification\n\nOverall, the data available are demmed to be conclusive but not sufficient for classification for the acute oral toxicity. No data are available for acute dermal/inhalation toxicity.\n\n### Additional information\n\n[Empty]\n\n### Attached background material\n\nBack to top",
        "content_length": 2225,
        "status": "success"
      }
    },
    "7.3 Irritation / corrosion": {
      "7.3.1 Skin irritation / corrosion": {
        "001 | Other | Experimental study": {
          "document_id": "050e3161-037f-4142-9af5-cd8d726f3d7d_d18b246e-13d7-423f-a045-5da4c757759e",
          "markdown_content": "#### Skin irritation / corrosion\n\nJump to\n\nHide empty fields\n\n### Administrative data\n\nConfidentiality\n\n[Not publishable]\n\nJustification\n\n[Not publishable]\n\nUse restricted to selected regulatory programmes\n\n[Not publishable]\n\nEndpoint\n\nskin irritation: in vivo\n\nType of information\n\nexperimental study\n\nAdequacy of study\n\nother information\n\nRobust study summary\n\n[Not publishable]\n\nUsed for classification\n\n[Not publishable]\n\nUsed for SDS\n\n[Not publishable]\n\nStudy period: start date\n\n[Empty]\n\nEnd date\n\n[Empty]\n\nRemark\n\n[Empty]\n\nReliability\n\n4 (not assignable)\n\nRationale for reliability incl. deficiencies\n\nabstract\n\nData waiving\n\n[Empty]\n\nJustification for data waiving\n\n[Empty]\n\nJustification for type of information\n\n[Empty]\n\n### Attached justification\n\n### Cross-reference\n\n### Data source\n\nReference\n\n* [Toxicity assessment of sulpiride as the basis of its hygienic standardization.](6540798d-a490-4653-9824-72ac0fac81ce_d18b246e-13d7-423f-a045-5da4c757759e)\n\nData access\n\n[Not publishable]\n\nData protection claimed\n\n[Not publishable]\n\n### Materials and methods\n\n### Test guideline\n\n### #1 - Test guideline\n\nQualifier\n\n[Empty]\n\nGuideline\n\nother:\nnot specified\n\nVersion / remarks\n\n[Empty]\n\nDeviations\n\n[Empty]\n\nPrinciples of method if other than guideline\n\n[Empty]\n\nGLP compliance\n\nnot specified\n\n### Test material\n\nTest material information\n\n[Test material information](58f5f39d-02e9-43fd-bfb1-bb2cde8000ff_d18b246e-13d7-423f-a045-5da4c757759e)\n\nAdditional test material information\n\n[Empty]\n\nSpecific details on test material used for the study\n\nSulpiride and sulpiride HCl are expected to be similar for this endpoint.\n\nSpecific details on test material used for the study (confidential)\n\n[Not publishable]\n\n### In vitro test system\n\nTest system\n\n[Empty]\n\nSource species\n\n[Empty]\n\nCell type\n\n[Empty]\n\nCell source\n\n[Empty]\n\nSource strain\n\n[Empty]\n\nDetails on animal used as source of test system\n\n[Empty]\n\nJustification for test system used\n\n[Empty]\n\nVehicle\n\n[Empty]\n\nDetails on test system\n\n[Empty]\n\nControl samples\n\n[Empty]\n\nAmount/concentration applied\n\n[Empty]\n\nDuration of treatment / exposure\n\n[Empty]\n\nDuration of post-treatment incubation (if applicable)\n\n[Empty]\n\nNumber of replicates\n\n[Empty]\n\n### Test animals\n\nSpecies\n\nother:\nnot specified.\n\nStrain\n\nnot specified\n\nDetails on test animals or test system and environmental conditions\n\n[Empty]\n\n### Test system\n\nType of coverage\n\nnot specified\n\nPreparation of test site\n\nnot specified\n\nVehicle\n\nnot specified\n\nControls\n\n[Empty]\n\nAmount / concentration applied\n\n[Empty]\n\nDuration of treatment / exposure\n\n[Empty]\n\nObservation period\n\n[Empty]\n\nNumber of animals\n\n[Empty]\n\nDetails on study design\n\n[Empty]\n\nHigh dose level used\n\n[Empty]\n\nJustification for deviation from the high dose level\n\n[Not publishable]\n\n### Model and software\n\nModel name and version\n\n[Empty]\n\nSoftware name and version\n\n[Empty]\n\nRemarks\n\n[Not publishable]\n\n### Any other information on materials and methods incl. tables\n\n[Not publishable]\n\n### Results and discussion\n\n### In vitro\n\n### Results\n\nOther effects / acceptance of results\n\n[Empty]\n\n### In vivo\n\n### Results\n\nIrritant / corrosive response data\n\nNot irritant to the skin.\n\nOther effects\n\n[Empty]\n\n### Additional information about applicability domain and reliability of (Q)SAR predictions\n\nFit with the applicability domain\n\n[Empty]\n\nJustification for the fit with the applicability domain\n\n[Empty]\n\nFit with the space defined by the training set of the model\n\n[Empty]\n\nMechanistic and metabolic considerations\n\n[Empty]\n\n### Similar substances with experimental data\n\nPerformance of the model for similar substances\n\n[Empty]\n\nConclusions on applicability domain and reliability\n\n[Empty]\n\nUncertainty\n\n[Empty]\n\n### Any other information on results incl. tables\n\n[Empty]\n\n### Overall remarks, attachments\n\nOverall remarks\n\n[Not publishable]\n\n### Attachments\n\n### Applicant's summary and conclusion\n\nInterpretation of results\n\nGHS criteria not met\n\nConclusions\n\nNot irritant to the skin.\n\nExecutive summary\n\nLD50 of sulpiride in administration into the stomach of male rats and mice is 7200 and 3400 mg/kg, for female rats and mice 6000 and 2300 mg/kg. No significant differences were noted in the species and sex sensitivity of animals to a substance. In intraperitoneal administration LD50 for male rats is 220 mg/kg, for female rats 150 mg/kg. It has not a local irritant effect on the skin. There were no identified skin-resorptive and sensitizing effects. It causes a slight irritant effect on the mucous membranes of the eyes. It has a toxic effect on the central nervous system, liver, kidneys.\n\nBack to top",
          "content_length": 4612,
          "status": "success"
        }
      },
      "7.3.2 Eye irritation": {
        "001 | Other | Experimental study": {
          "document_id": "27bdcd81-508b-4cc2-8df2-9882a12787aa_d18b246e-13d7-423f-a045-5da4c757759e",
          "markdown_content": "#### Eye irritation\n\nJump to\n\nHide empty fields\n\n### Administrative data\n\nConfidentiality\n\n[Not publishable]\n\nJustification\n\n[Not publishable]\n\nUse restricted to selected regulatory programmes\n\n[Not publishable]\n\nEndpoint\n\neye irritation: in vivo\n\nType of information\n\nexperimental study\n\nAdequacy of study\n\nother information\n\nRobust study summary\n\n[Not publishable]\n\nUsed for classification\n\n[Not publishable]\n\nUsed for SDS\n\n[Not publishable]\n\nStudy period: start date\n\n[Empty]\n\nEnd date\n\n[Empty]\n\nRemark\n\n[Empty]\n\nReliability\n\n4 (not assignable)\n\nRationale for reliability incl. deficiencies\n\nabstract\n\nData waiving\n\n[Empty]\n\nJustification for data waiving\n\n[Empty]\n\nJustification for type of information\n\n[Empty]\n\n### Attached justification\n\n### Cross-reference\n\n### Data source\n\nReference\n\n* [Toxicity assessment of sulpiride as the basis of its hygienic standardization.](6540798d-a490-4653-9824-72ac0fac81ce_d18b246e-13d7-423f-a045-5da4c757759e)\n\nData access\n\n[Not publishable]\n\nData protection claimed\n\n[Not publishable]\n\n### Materials and methods\n\n### Test guideline\n\n### #1 - Test guideline\n\nQualifier\n\n[Empty]\n\nGuideline\n\nother:\nnot specified\n\nVersion / remarks\n\n[Empty]\n\nDeviations\n\n[Empty]\n\nPrinciples of method if other than guideline\n\n[Empty]\n\nGLP compliance\n\nnot specified\n\n### Test material\n\nTest material information\n\n[Test material information](58f5f39d-02e9-43fd-bfb1-bb2cde8000ff_d18b246e-13d7-423f-a045-5da4c757759e)\n\nAdditional test material information\n\n[Empty]\n\nSpecific details on test material used for the study\n\nSulpiride and sulpiride HCl are expected to be similar for this endpoint.\n\nSpecific details on test material used for the study (confidential)\n\n[Not publishable]\n\nTest material physicochemical properties\n\n[Empty]\n\n### Test animals / tissue source\n\nSpecies\n\nother:\nnot specified.\n\nStrain\n\nnot specified\n\nDetails on test animals / tissues or test method\n\n[Empty]\n\n### Test system\n\nVehicle\n\nnot specified\n\nControls\n\n[Empty]\n\nAmount / concentration applied\n\n[Empty]\n\nDuration of treatment / exposure\n\n[Empty]\n\nObservation period (in vivo)\n\n[Empty]\n\nDuration of post- treatment incubation (in vitro)\n\n[Empty]\n\nNumber of animals or in vitro replicates\n\n[Empty]\n\nDetails on study design\n\n[Empty]\n\nHigh dose level used\n\n[Empty]\n\nJustification for deviation from the high dose level\n\n[Not publishable]\n\n### Model and software\n\nModel name and version\n\n[Empty]\n\nSoftware name and version\n\n[Empty]\n\nRemarks\n\n[Not publishable]\n\n### Any other information on materials and methods incl. tables\n\n[Not publishable]\n\n### Results and discussion\n\n### In vitro / ex vivo / in chemico\n\n### Results\n\nOther effects / acceptance of results\n\n[Empty]\n\n### In vivo\n\n### Results\n\nIrritant / corrosive response data\n\nSlightly irritant to the mucous membranes of the eyes.\n\nOther effects\n\n[Empty]\n\n### Additional information about applicability domain and reliability of (Q)SAR predictions\n\nFit with the applicability domain\n\n[Empty]\n\nJustification for the fit with the applicability domain\n\n[Empty]\n\nFit with the space defined by the training set of the model\n\n[Empty]\n\nMechanistic and metabolic considerations\n\n[Empty]\n\n### Similar substances with experimental data\n\nPerformance of the model for similar substances\n\n[Empty]\n\nConclusions on applicability domain and reliability\n\n[Empty]\n\nUncertainty\n\n[Empty]\n\n### Any other information on results incl. tables\n\n[Empty]\n\n### Overall remarks, attachments\n\nOverall remarks\n\n[Not publishable]\n\n### Attachments\n\n### Applicant's summary and conclusion\n\nInterpretation of results\n\nGHS criteria not met\n\nConclusions\n\nThe substance is slightly irritant to the eye.\n\nExecutive summary\n\nLD50 of sulpiride in administration into the stomach of male rats and mice is 7200 and 3400 mg/kg, for female rats and mice 6000 and 2300 mg/kg. No significant differences were noted in the species and sex sensitivity of animals to a substance. In intraperitoneal administration LD50 for male rats is 220 mg/kg, for female rats 150 mg/kg. It has not a local irritant effect on the skin. There were no identified skin-resorptive and sensitizing effects. It causes a slight irritant effect on the mucous membranes of the eyes. It has a toxic effect on the central nervous system, liver, kidneys.\n\nBack to top",
          "content_length": 4242,
          "status": "success"
        }
      },
      "S-01 | Summary": {
        "document_id": "f9210710-f720-4111-b235-2cd9ad0191ec_d18b246e-13d7-423f-a045-5da4c757759e",
        "markdown_content": "#### Irritation / corrosion\n\nJump to\n\nHide empty fields\n\n### Administrative data\n\nConfidentiality\n\n[Empty]\n\nJustification\n\n[Empty]\n\nUse restricted to selected regulatory programmes\n\n[Empty]\n\n### Description of key information\n\nThe substance has not a local irritant effect on the skin. Instead, it causes a slight irritant effect on the mucous membranes of the eyes.\n\n### Key value for chemical safety assessment\n\n### Skin irritation / corrosion\n\nLink to relevant study record(s)\n\n* [001 | Other | Experimental study](050e3161-037f-4142-9af5-cd8d726f3d7d_d18b246e-13d7-423f-a045-5da4c757759e)\n\nEndpoint conclusion\n\nno adverse effect observed (not irritating)\n\n### Eye irritation\n\nLink to relevant study record(s)\n\n* [001 | Other | Experimental study](27bdcd81-508b-4cc2-8df2-9882a12787aa_d18b246e-13d7-423f-a045-5da4c757759e)\n\nEndpoint conclusion\n\nadverse effect observed (irritating)\n\n### Respiratory irritation\n\nEndpoint conclusion\n\n[Empty]\n\n### Justification for classification or non-classification\n\nData available are deemed to be inconclusive for the classification for skin/eye irritation.\n\n### Additional information\n\nDue to little information available, the quality of the database cannot be assessed.\n\n### Attached background material\n\nBack to top",
        "content_length": 1257,
        "status": "success"
      }
    },
    "7.4 Sensitisation": {
      "7.4.1 Skin sensitisation": {
        "001 | Other | Experimental study": {
          "document_id": "f2026390-555c-40f7-bacb-78840282a40e_d18b246e-13d7-423f-a045-5da4c757759e",
          "markdown_content": "#### Skin sensitisation\n\nJump to\n\nHide empty fields\n\n### Administrative data\n\nConfidentiality\n\n[Not publishable]\n\nJustification\n\n[Not publishable]\n\nUse restricted to selected regulatory programmes\n\n[Not publishable]\n\nEndpoint\n\nskin sensitisation, other\n\nnot specified.\n\nType of information\n\nexperimental study\n\nAdequacy of study\n\nother information\n\nRobust study summary\n\n[Not publishable]\n\nUsed for classification\n\n[Not publishable]\n\nUsed for SDS\n\n[Not publishable]\n\nStudy period: start date\n\n[Empty]\n\nEnd date\n\n[Empty]\n\nRemark\n\n[Empty]\n\nReliability\n\n4 (not assignable)\n\nRationale for reliability incl. deficiencies\n\nabstract\n\nData waiving\n\n[Empty]\n\nJustification for data waiving\n\n[Empty]\n\nJustification for type of information\n\n[Empty]\n\n### Attached justification\n\n### Cross-reference\n\n### Data source\n\nReference\n\n* [Toxicity assessment of sulpiride as the basis of its hygienic standardization.](6540798d-a490-4653-9824-72ac0fac81ce_d18b246e-13d7-423f-a045-5da4c757759e)\n\nData access\n\n[Not publishable]\n\nData protection claimed\n\n[Not publishable]\n\n### Materials and methods\n\n### Test guideline\n\n### #1 - Test guideline\n\nQualifier\n\n[Empty]\n\nGuideline\n\nother:\nnot specified\n\nVersion / remarks\n\n[Empty]\n\nDeviations\n\n[Empty]\n\nPrinciples of method if other than guideline\n\n[Empty]\n\nGLP compliance\n\nnot specified\n\nType of study\n\nnot specified\n\nJustification for non-LLNA method\n\n[Empty]\n\n### Test material\n\nTest material information\n\n[Test material information](58f5f39d-02e9-43fd-bfb1-bb2cde8000ff_d18b246e-13d7-423f-a045-5da4c757759e)\n\nAdditional test material information\n\n[Empty]\n\nSpecific details on test material used for the study\n\nSulpiride and sulpiride HCl are expected to be similar for this endpoint.\n\nSpecific details on test material used for the study (confidential)\n\n[Not publishable]\n\n### In vitro test system\n\nDetails of test system\n\n[Empty]\n\nDetails on the study design\n\n[Empty]\n\nVehicle / solvent control\n\n[Empty]\n\nNegative control\n\n[Empty]\n\nPositive control\n\n[Empty]\n\n### In chemico test system\n\nDetails of test system\n\n[Empty]\n\nDetails on the study design\n\n[Empty]\n\nVehicle / solvent\n\n[Empty]\n\nPositive control\n\n[Empty]\n\n### In silico test system\n\nDetails of test system\n\n[Empty]\n\nDetails on the study design\n\n[Empty]\n\n### In vivo test system\n\n### Test animals\n\nSpecies\n\nother:\nnot specified.\n\nStrain\n\nnot specified\n\nSex\n\nnot specified\n\nDetails on test animals and environmental conditions\n\n[Empty]\n\n### Study design: in vivo (non-LLNA)\n\n### Induction\n\n### Challenge\n\nNo. of animals per dose\n\n[Empty]\n\nDetails on study design\n\n[Empty]\n\nChallenge controls\n\n[Empty]\n\nPositive control substance(s)\n\n[Empty]\n\n### Study design: in vivo (LLNA)\n\nVehicle\n\n[Empty]\n\nConcentration\n\n[Empty]\n\nNo. of animals per dose\n\n[Empty]\n\nDetails on study design\n\n[Empty]\n\nPositive control substance(s)\n\n[Empty]\n\nStatistics\n\n[Empty]\n\nHigh dose level used\n\n[Empty]\n\nJustification for deviation from the high dose level\n\n[Not publishable]\n\n### Model and software\n\nModel name and version\n\n[Empty]\n\nSoftware name and version\n\n[Empty]\n\nRemarks\n\n[Not publishable]\n\n### Any other information on materials and methods incl. tables\n\n[Not publishable]\n\n### Results and discussion\n\nPositive control results\n\n[Empty]\n\n### In vitro / in chemico\n\n### Results\n\nOutcome of the prediction model\n\n[Empty]\n\nOther effects / acceptance of results\n\n[Empty]\n\n### In silico\n\n### Results\n\nOutcome of the prediction model\n\n[Empty]\n\n### In vivo (non-LLNA)\n\n### Results\n\n### #1 - Results\n\nKey result\n\nReading\n\n[Empty]\n\nHours after challenge\n\n[Empty]\n\nGroup\n\n[Empty]\n\nDose level\n\n[Empty]\n\nNo. with + reactions\n\nTotal no. in group\n\nClinical observations\n\n[Empty]\n\nRemarks on result\n\nno indication of skin sensitisation\n\n### In vivo (LLNA)\n\n### Results\n\nCellular proliferation data / Observations\n\n[Empty]\n\n### Additional information about applicability domain and reliability of (Q)SAR predictions\n\nFit with the applicability domain\n\n[Empty]\n\nJustification for the fit with the applicability domain\n\n[Empty]\n\nFit with the space defined by the training set of the model\n\n[Empty]\n\nMechanistic and metabolic considerations\n\n[Empty]\n\n### Similar substances with experimental data\n\nPerformance of the model for similar substances\n\n[Empty]\n\nConclusions on applicability domain and reliability\n\n[Empty]\n\nUncertainty\n\n[Empty]\n\n### Any other information on results incl. tables\n\n[Empty]\n\n### Overall remarks, attachments\n\nOverall remarks\n\n[Not publishable]\n\n### Attachments\n\n### Applicant's summary and conclusion\n\nInterpretation of results\n\nGHS criteria not met\n\nConclusions\n\nThe substance does not have sensitizing effects.\n\nExecutive summary\n\nLD50 of sulpiride in administration into the stomach of male rats and mice is 7200 and 3400 mg/kg, for female rats and mice 6000 and 2300 mg/kg. No significant differences were noted in the species and sex sensitivity of animals to a substance. In intraperitoneal administration LD50 for male rats is 220 mg/kg, for female rats 150 mg/kg. It has not a local irritant effect on the skin. There were no identified skin-resorptive and sensitizing effects. It causes a slight irritant effect on the mucous membranes of the eyes. It has a toxic effect on the central nervous system, liver, kidneys.\n\nBack to top",
          "content_length": 5208,
          "status": "success"
        },
        "002 | Disregarded | (Q)SAR": {
          "document_id": "884c4a3a-c1b5-4cc5-991f-632819f40aee_d18b246e-13d7-423f-a045-5da4c757759e",
          "markdown_content": "#### Skin sensitisation\n\nJump to\n\nHide empty fields\n\n### Administrative data\n\nConfidentiality\n\n[Not publishable]\n\nJustification\n\n[Not publishable]\n\nUse restricted to selected regulatory programmes\n\n[Not publishable]\n\nEndpoint\n\nskin sensitisation, other\n\nin vivo\n\nType of information\n\n(Q)SAR\n\nAdequacy of study\n\ndisregarded due to major methodological deficiencies\n\nRobust study summary\n\n[Not publishable]\n\nUsed for classification\n\n[Not publishable]\n\nUsed for SDS\n\n[Not publishable]\n\nStudy period: start date\n\n[Empty]\n\nEnd date\n\n[Empty]\n\nRemark\n\n[Empty]\n\nReliability\n\n3 (not reliable)\n\nRationale for reliability incl. deficiencies\n\nresults derived from a valid (Q)SAR model, but not (completely) falling into its applicability domain, and documentation / justification is limited\n\nData waiving\n\n[Empty]\n\nJustification for data waiving\n\n[Empty]\n\nJustification for type of information\n\n[Empty]\n\n### Attached justification\n\n### Cross-reference\n\n### Data source\n\nReference\n\n* [Skin Sensitization model (CAESAR) 2.1.6](06d5f54e-db96-4483-bd67-e95d537ca3f0_d18b246e-13d7-423f-a045-5da4c757759e)\n\nData access\n\n[Not publishable]\n\nData protection claimed\n\n[Not publishable]\n\n### Materials and methods\n\n### Test guideline\n\n### #1 - Test guideline\n\nQualifier\n\nequivalent or similar to guideline\n\nGuideline\n\nother:\nECHA guidance on information requirements and chemical safety assessment Chapter R.6: QSARs and grouping of chemicals.\n\nVersion / remarks\n\n[Empty]\n\nDeviations\n\n[Empty]\n\nPrinciples of method if other than guideline\n\n[Empty]\n\nGLP compliance\n\n[Empty]\n\nType of study\n\n[Empty]\n\nJustification for non-LLNA method\n\n[Empty]\n\n### Test material\n\nTest material information\n\n[Test material information](58f5f39d-02e9-43fd-bfb1-bb2cde8000ff_d18b246e-13d7-423f-a045-5da4c757759e)\n\nAdditional test material information\n\n[Empty]\n\nSpecific details on test material used for the study\n\n[Empty]\n\nSpecific details on test material used for the study (confidential)\n\n[Not publishable]\n\n### In vitro test system\n\nDetails of test system\n\n[Empty]\n\nDetails on the study design\n\n[Empty]\n\nVehicle / solvent control\n\n[Empty]\n\nNegative control\n\n[Empty]\n\nPositive control\n\n[Empty]\n\n### In chemico test system\n\nDetails of test system\n\n[Empty]\n\nDetails on the study design\n\n[Empty]\n\nVehicle / solvent\n\n[Empty]\n\nPositive control\n\n[Empty]\n\n### In silico test system\n\nDetails of test system\n\n[Empty]\n\nDetails on the study design\n\n[Empty]\n\n### In vivo test system\n\n### Test animals\n\nSpecies\n\n[Empty]\n\nStrain\n\n[Empty]\n\nSex\n\n[Empty]\n\nDetails on test animals and environmental conditions\n\n[Empty]\n\n### Study design: in vivo (non-LLNA)\n\n### Induction\n\n### Challenge\n\nNo. of animals per dose\n\n[Empty]\n\nDetails on study design\n\n[Empty]\n\nChallenge controls\n\n[Empty]\n\nPositive control substance(s)\n\n[Empty]\n\n### Study design: in vivo (LLNA)\n\nVehicle\n\n[Empty]\n\nConcentration\n\n[Empty]\n\nNo. of animals per dose\n\n[Empty]\n\nDetails on study design\n\n[Empty]\n\nPositive control substance(s)\n\n[Empty]\n\nStatistics\n\n[Empty]\n\nHigh dose level used\n\n[Empty]\n\nJustification for deviation from the high dose level\n\n[Not publishable]\n\n### Model and software\n\nModel name and version\n\n[Empty]\n\nSoftware name and version\n\n[Empty]\n\nRemarks\n\n[Not publishable]\n\n### Any other information on materials and methods incl. tables\n\n[Not publishable]\n\n### Results and discussion\n\nPositive control results\n\n[Empty]\n\n### In vitro / in chemico\n\n### Results\n\nOutcome of the prediction model\n\n[Empty]\n\nOther effects / acceptance of results\n\nThe substance is predicted to be a skin sensitizer.\n\n### In silico\n\n### Results\n\nOutcome of the prediction model\n\n[Empty]\n\n### In vivo (non-LLNA)\n\n### Results\n\n### In vivo (LLNA)\n\n### Results\n\nCellular proliferation data / Observations\n\n[Empty]\n\n### Additional information about applicability domain and reliability of (Q)SAR predictions\n\nFit with the applicability domain\n\n[Empty]\n\nJustification for the fit with the applicability domain\n\n[Empty]\n\nFit with the space defined by the training set of the model\n\n[Empty]\n\nMechanistic and metabolic considerations\n\n[Empty]\n\n### Similar substances with experimental data\n\nPerformance of the model for similar substances\n\n[Empty]\n\nConclusions on applicability domain and reliability\n\n[Empty]\n\nUncertainty\n\n[Empty]\n\n### Any other information on results incl. tables\n\nThe result appears non-reliable as the predicted compound is outside the applicability domain of the model.\n\n### Overall remarks, attachments\n\nOverall remarks\n\n[Not publishable]\n\n### Attachments\n\n#1\n\n[Not publishable]\n\n#2\n\n[Not publishable]\n\n### Applicant's summary and conclusion\n\nInterpretation of results\n\nCategory 1 (skin sensitising) based on GHS criteria\n\nConclusions\n\nThe substance is predicted to be a skin sensitizer.\n\nExecutive summary\n\n[Empty]\n\nBack to top",
          "content_length": 4741,
          "status": "success"
        }
      },
      "7.4.2 Respiratory sensitisation": {},
      "S-01 | Summary": {
        "document_id": "80b4d791-28b2-41bd-a64e-6ed449c23b55_d18b246e-13d7-423f-a045-5da4c757759e",
        "markdown_content": "#### Sensitisation\n\nJump to\n\nHide empty fields\n\n### Administrative data\n\nConfidentiality\n\n[Empty]\n\nJustification\n\n[Empty]\n\nUse restricted to selected regulatory programmes\n\n[Empty]\n\n### Description of key information\n\nThe substance does not have sensitizing effects.\n\n### Key value for chemical safety assessment\n\n### Skin sensitisation\n\nLink to relevant study record(s)\n\n* [001 | Other | Experimental study](f2026390-555c-40f7-bacb-78840282a40e_d18b246e-13d7-423f-a045-5da4c757759e)\n\nEndpoint conclusion\n\nno adverse effect observed (not sensitising)\n\n### Respiratory sensitisation\n\nLink to relevant study record(s)\n\n[Empty]\n\nEndpoint conclusion\n\nno information available\n\n### Justification for classification or non-classification\n\nData available are deemed to be inconclusive for the classification for skin sensitization.\n\n### Additional information\n\nDue to little information available, the quality of the database is limited.\n\n### Attached background material\n\nBack to top",
        "content_length": 977,
        "status": "success"
      }
    },
    "7.5 Repeated dose toxicity": {
      "7.5.1 Repeated dose toxicity: oral": {
        "001 | Other | Experimental study": {
          "document_id": "1187313e-28d5-407d-a961-1c6004f6939b_d18b246e-13d7-423f-a045-5da4c757759e",
          "markdown_content": "#### Repeated dose toxicity: oral\n\nJump to\n\nHide empty fields\n\n### Administrative data\n\nConfidentiality\n\n[Not publishable]\n\nJustification\n\n[Not publishable]\n\nUse restricted to selected regulatory programmes\n\n[Not publishable]\n\nEndpoint\n\nshort-term repeated dose toxicity: oral\n\nType of information\n\nexperimental study\n\nAdequacy of study\n\nother information\n\nRobust study summary\n\n[Not publishable]\n\nUsed for classification\n\n[Not publishable]\n\nUsed for SDS\n\n[Not publishable]\n\nStudy period: start date\n\n[Empty]\n\nEnd date\n\n[Empty]\n\nRemark\n\n[Empty]\n\nReliability\n\n4 (not assignable)\n\nRationale for reliability incl. deficiencies\n\nsecondary literature\n\nData waiving\n\n[Empty]\n\nJustification for data waiving\n\n[Empty]\n\nJustification for type of information\n\n[Empty]\n\n### Attached justification\n\n### Cross-reference\n\n### Data source\n\nReference\n\n* [Pharmacotoxicological aspects of levosulpiride.](0bba3384-7bf4-4c6d-983d-78a29e387ee6_d18b246e-13d7-423f-a045-5da4c757759e)\n\nData access\n\n[Not publishable]\n\nData protection claimed\n\n[Not publishable]\n\n### Materials and methods\n\n### Test guideline\n\n### #1 - Test guideline\n\nQualifier\n\n[Empty]\n\nGuideline\n\nother:\nnot specified\n\nVersion / remarks\n\n[Empty]\n\nDeviations\n\n[Empty]\n\nPrinciples of method if other than guideline\n\n[Empty]\n\nGLP compliance\n\nnot specified\n\nLimit test\n\n[Empty]\n\n### Test material\n\nTest material information\n\n[Test material information](4e39367f-bcf9-4a5f-bd70-64ddd6fbf79e_d18b246e-13d7-423f-a045-5da4c757759e)\n\nAdditional test material information\n\n[Empty]\n\nSpecific details on test material used for the study\n\n[Empty]\n\nSpecific details on test material used for the study (confidential)\n\n[Not publishable]\n\n### Test animals\n\nSpecies\n\n[Empty]\n\nStrain\n\n[Empty]\n\nDetails on species / strain selection\n\n[Empty]\n\nSex\n\n[Empty]\n\nDetails on test animals or test system and environmental conditions\n\n[Empty]\n\n### Administration / exposure\n\nRoute of administration\n\n[Empty]\n\nDetails on route of administration\n\n[Empty]\n\nVehicle\n\n[Empty]\n\nDetails on oral exposure\n\n[Empty]\n\nAnalytical verification of doses or concentrations\n\n[Empty]\n\nDetails on analytical verification of doses or concentrations\n\n[Empty]\n\nDuration of treatment / exposure\n\n[Empty]\n\nFrequency of treatment\n\n[Empty]\n\n### Doses / concentrations\n\nNo. of animals per sex per dose\n\n[Empty]\n\nControl animals\n\n[Empty]\n\nDetails on study design\n\n[Empty]\n\nPositive control\n\n[Empty]\n\nHigh dose level used\n\n[Empty]\n\nJustification for deviation from the high dose level\n\n[Not publishable]\n\n### Examinations\n\nObservations and examinations performed and frequency\n\n[Empty]\n\nSacrifice and pathology\n\n[Empty]\n\nOptional endpoint(s)\n\n[Empty]\n\nOther examinations\n\n[Empty]\n\nStatistics\n\n[Empty]\n\n### Model and software\n\nModel name and version\n\n[Empty]\n\nSoftware name and version\n\n[Empty]\n\nRemarks\n\n[Not publishable]\n\n### Any other information on materials and methods incl. tables\n\n[Not publishable]\n\n### Results and discussion\n\n### Results of examinations\n\nClinical signs\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nMortality\n\n[Empty]\n\nDescription (incidence)\n\n[Empty]\n\nBody weight and weight changes\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nFood consumption and compound intake (if feeding study)\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nFood efficiency\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nWater consumption and compound intake (if drinking water study)\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nOphthalmological findings\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nHaematological findings\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nClinical biochemistry findings\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nEndocrine findings\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nUrinalysis findings\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nBehaviour (functional findings)\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nImmunological findings\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nOrgan weight findings including organ / body weight ratios\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nGross pathological findings\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nNeuropathological findings\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nHistopathological findings: non-neoplastic\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nHistopathological findings: neoplastic\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nOther effects\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nDetails on results\n\n[Empty]\n\n### Effect levels\n\n### Target system / organ toxicity\n\n### Detailed toxicology results\n\n### Detailed toxicology results\n\n### Additional information about applicability domain and reliability of (Q)SAR predictions\n\nFit with the applicability domain\n\n[Empty]\n\nJustification for the fit with the applicability domain\n\n[Empty]\n\nFit with the space defined by the training set of the model\n\n[Empty]\n\nMechanistic and metabolic considerations\n\n[Empty]\n\n### Similar substances with experimental data\n\nPerformance of the model for similar substances\n\n[Empty]\n\nConclusions on applicability domain and reliability\n\n[Empty]\n\nUncertainty\n\n[Empty]\n\n### Any other information on results incl. tables\n\nRats, rabbits and dogs were used for subacute toxicity trials. Haematology and blood chemistry analyses have been selected to have an overall picture of the treatment effects on metabolism, on liver and renal functions and on complete blood count. The necropsy was carried out on major organs and apparatuses. This was performed on each animal, while each organ was subjected to histologic examination (See Figure). The subacute oral administration of levosulpiride in rats at 150-300 mg/kg for 12 weeks is well tolerated as shown by the haematology, blood chemistry and urine analysis, and does not significantly differ from controls. There are, however, a slight reduction in body weight and food consumption and some variations in liver function at the highest dosage (300 mg/kg) The subacute administration of levosulpiride by subcutaneous route in rats at 12.5-25 mg/kg/day for 12 weeks is well-tolerated as shown by laboratory analysis. A slight drop in body weight and variations in liver functions were documented with highest dosage (50 mg/kg/day). Similar results were obtained by studying the effects of the subacute oral (125-250 mg/kg/day for 12 weeks) or intramuscular (6.25-12.5 mg/kg/day) administration of levosulpiride in rabbits. In another trial the subacute oral administration of levosulpiride in rats for 13 weeks at 25, 150 and 900 mg/kg/day and racemic sulpiride at 50, 300 and 1800 mg/kg/day, no toxic effect was identified for either compound. However, findings obtained for both tested compounds, notably clinical signs, clinical pathology and mammary gland/vaginal changes are considered to be related to the exaggerated pharmacological action of the compounds. The only toxic effect noted was mortality among females receiving the highest treatment level of racemic sulpiride. In particular, two females receiving the highest dose of racemic sulpiride died during the course of the study. These deaths as a result of treatment cannot be excluded. Clinical signs of somnolence were noted among rats of the highest dose groups of either test substance, but they were predominant among females, particularly those treated with racemic sulpiride. Blood chemistry investigations showed a decrease in creatinine kinase among males receiving racemic sulpiride after 13 weeks of treatment. This decrease was still apparent at the end of the recovery phase, particularly in males receiving the middle and highest dose levels. Indeed, females receiving racemic sulpiride and rats of both sexes receiving levosulpiride were not affected. Several minor differences were noted between control and treated rats in pituitary and adrenal gland weights, vagina/mammary gland hyperplasia and vaginal mucification. It is considered that these changes, which show a marked degree of consistency for both L- and racemic sulpiride, reflect a physiological response to treatment. These changes could be originated from an increase in circulating prolactin concentration. It is known that treatment with dopamine D2 receptor antagonist (such as L- or racemic sulpiride) may cause a blockade of the tubero-infundibular pathway, in which dopamine is believed to act physiologically, via D2-receptors, as an inhibitor of prolactin secretion. The result of this blockade is responsible for an increase in circulating prolactin. It could be considered that an increased circulating level of this hormone could promote the observed vagina/mammary gland hyperplasia and vaginal mucification and may also give rise to the slight changes in pituitary and adrenal gland weights. L- and racemic sulpiride were administered orally (25-200 mg/kg), as capsules, to pure-bred beagle dogs for a period of 13 weeks. The study consisted of six groups, each containing three male and three female or five male and five female dogs. An additional group including five male and five female dogs served as control. Mortality did not occur in any experimental group. Initiation of treatment with L- or racemic sulpiride was associated in most dogs with the following clinical signs: decreased activity, tremor, abnormal gait, stereotyped behaviour, erythema of the mucous membranes of the buccal cavity, and salivation. Treatment with either compound at 200 mg/kg was associated in some dogs with collapse, ptosis, deep respiration and/or bradypnea. Vomiting was also recorded in some dogs treated with either compound; however, in view of the incidence and distribution throughout the groups, no definite association with treatment could be made. In view of the persistence of several of these signs and since animals from all treatment groups were affected, a decision was made to reduce the daily dose of each group by half from day 7. With the exception of salivation, decreased activity and ptosis (L- or racemic sulpiride, 100-200 mg/kg only), the clinical signs described above disappear within 1 or 2 weeks of reducing the dose levels. From the beginning of week 3 slight to moderate mammary development is detected in females receiving either L- or racemic sulpiride. The degree of development is similar for both compounds and shows no relationship to dose. There were also documented: a transient reduction in food consumption during week 1 (levosulpiride or racemic sulpiride, 100 or 200 mg/kg); a slight, transient loss in body weight during week 1 (levosulpiride 200 mg/kg, racemic sulpiride 100-200 mg/kg); increases in plasma cholesterol and phospholipid concentrations during weeks 7 and/or 13, without any relationship to dose. No treatment related change was documented in haematology or urine profiles. A clear reduction in prostate weight is apparent in males treated with L- or racemic sulpiride at all dose. The microscopic study documented hyperplasia and active secretion of the mammary glands of treated females, and atrophy of the prostate glands of treated males.\n\n### Overall remarks, attachments\n\nOverall remarks\n\n[Not publishable]\n\n### Attachments\n\n#1\n\n[Not publishable]\n\n### Applicant's summary and conclusion\n\nConclusions\n\nAlthough treatment related effects can be observed after oral sulpiride administration, they do not support the classification as STOT RE in accordance with Regulation (EC) 1272/2008.\n\nExecutive summary\n\nRats, rabbits and dogs were used for subacute toxicity trials. Haematology and blood chemistry analyses have been selected to have an overall picture of the treatment effects on metabolism, on liver and renal functions and on complete blood count. The necropsy was carried out on major organs and apparatuses. This was performed on each animal, while each organ was subjected to histologic examination (See Figure). The subacute oral administration of levosulpiride in rats at 150-300 mg/kg for 12 weeks is well tolerated as shown by the haematology, blood chemistry and urine analysis, and does not significantly differ from controls. There are, however, a slight reduction in body weight and food consumption and some variations in liver function at the highest dosage (300 mg/kg) The subacute administration of levosulpiride by subcutaneous route in rats at 12.5-25 mg/kg/day for 12 weeks is well-tolerated as shown by laboratory analysis. A slight drop in body weight and variations in liver functions were documented with highest dosage (50 mg/kg/day). Similar results were obtained by studying the effects of the subacute oral (125-250 mg/kg/day for 12 weeks) or intramuscular (6.25-12.5 mg/kg/day) administration of levosulpiride in rabbits. In another trial the subacute oral administration of levosulpiride in rats for 13 weeks at 25, 150 and 900 mg/kg/day and racemic sulpiride at 50, 300 and 1800 mg/kg/day, no toxic effect was identified for either compound. However, findings obtained for both tested compounds, notably clinical signs, clinical pathology and mammary gland/vaginal changes are considered to be related to the exaggerated pharmacological action of the compounds. The only toxic effect noted was mortality among females receiving the highest treatment level of racemic sulpiride. In particular, two females receiving the highest dose of racemic sulpiride died during the course of the study. These deaths as a result of treatment cannot be excluded. Clinical signs of somnolence were noted among rats of the highest dose groups of either test substance, but they were predominant among females, particularly those treated with racemic sulpiride. Blood chemistry investigations showed a decrease in creatinine kinase among males receiving racemic sulpiride after 13 weeks of treatment. This decrease was still apparent at the end of the recovery phase, particularly in males receiving the middle and highest dose levels. Indeed, females receiving racemic sulpiride and rats of both sexes receiving levosulpiride were not affected. Several minor differences were noted between control and treated rats in pituitary and adrenal gland weights, vagina/mammary gland hyperplasia and vaginal mucification. It is considered that these changes, which show a marked degree of consistency for both L- and racemic sulpiride, reflect a physiological response to treatment. These changes could be originated from an increase in circulating prolactin concentration. It is known that treatment with dopamine D2 receptor antagonist (such as L- or racemic sulpiride) may cause a blockade of the tubero-infundibular pathway, in which dopamine is believed to act physiologically, via D2-receptors, as an inhibitor of prolactin secretion. The result of this blockade is responsible for an increase in circulating prolactin. It could be considered that an increased circulating level of this hormone could promote the observed vagina/mammary gland hyperplasia and vaginal mucification and may also give rise to the slight changes in pituitary and adrenal gland weights. L- and racemic sulpiride were administered orally (25-200 mg/kg), as capsules, to pure-bred beagle dogs for a period of 13 weeks. The study consisted of six groups, each containing three male and three female or five male and five female dogs. An additional group including five male and five female dogs served as control. Mortality did not occur in any experimental group. Initiation of treatment with L- or racemic sulpiride was associated in most dogs with the following clinical signs: decreased activity, tremor, abnormal gait, stereotyped behaviour, erythema of the mucous membranes of the buccal cavity, and salivation. Treatment with either compound at 200 mg/kg was associated in some dogs with collapse, ptosis, deep respiration and/or bradypnea. Vomiting was also recorded in some dogs treated with either compound; however, in view of the incidence and distribution throughout the groups, no definite association with treatment could be made. In view of the persistence of several of these signs and since animals from all treatment groups were affected, a decision was made to reduce the daily dose of each group by half from day 7. With the exception of salivation, decreased activity and ptosis (L- or racemic sulpiride, 100-200 mg/kg only), the clinical signs described above disappear within 1 or 2 weeks of reducing the dose levels. From the beginning of week 3 slight to moderate mammary development is detected in females receiving either L- or racemic sulpiride. The degree of development is similar for both compounds and shows no relationship to dose. There were also documented: a transient reduction in food consumption during week 1 (levosulpiride or racemic sulpiride, 100 or 200 mg/kg); a slight, transient loss in body weight during week 1 (levosulpiride 200 mg/kg, racemic sulpiride 100-200 mg/kg); increases in plasma cholesterol and phospholipid concentrations during weeks 7 and/or 13, without any relationship to dose. No treatment related change was documented in haematology or urine profiles. A clear reduction in prostate weight is apparent in males treated with L- or racemic sulpiride at all dose. The microscopic study documented hyperplasia and active secretion of the mammary glands of treated females, and atrophy of the prostate glands of treated males.\n\nBack to top",
          "content_length": 17445,
          "status": "success"
        },
        "002 | Other | Experimental study": {
          "document_id": "9dd36b38-89fe-4029-9fb5-5709710c16e7_d18b246e-13d7-423f-a045-5da4c757759e",
          "markdown_content": "#### Repeated dose toxicity: oral\n\nJump to\n\nHide empty fields\n\n### Administrative data\n\nConfidentiality\n\n[Not publishable]\n\nJustification\n\n[Not publishable]\n\nUse restricted to selected regulatory programmes\n\n[Not publishable]\n\nEndpoint\n\nsub-chronic toxicity: oral\n\nType of information\n\nexperimental study\n\nAdequacy of study\n\nother information\n\nRobust study summary\n\n[Not publishable]\n\nUsed for classification\n\n[Not publishable]\n\nUsed for SDS\n\n[Not publishable]\n\nStudy period: start date\n\n[Empty]\n\nEnd date\n\n[Empty]\n\nRemark\n\n[Empty]\n\nReliability\n\n4 (not assignable)\n\nRationale for reliability incl. deficiencies\n\nsecondary literature\n\nData waiving\n\n[Empty]\n\nJustification for data waiving\n\n[Empty]\n\nJustification for type of information\n\n[Empty]\n\n### Attached justification\n\n### Cross-reference\n\n### Data source\n\nReference\n\n* [Pharmacotoxicological aspects of levosulpiride.](0bba3384-7bf4-4c6d-983d-78a29e387ee6_d18b246e-13d7-423f-a045-5da4c757759e)\n\nData access\n\n[Not publishable]\n\nData protection claimed\n\n[Not publishable]\n\n### Materials and methods\n\n### Test guideline\n\n### #1 - Test guideline\n\nQualifier\n\n[Empty]\n\nGuideline\n\nother:\nnot specified\n\nVersion / remarks\n\n[Empty]\n\nDeviations\n\n[Empty]\n\nPrinciples of method if other than guideline\n\n[Empty]\n\nGLP compliance\n\nnot specified\n\nLimit test\n\n[Empty]\n\n### Test material\n\nTest material information\n\n[Test material information](4e39367f-bcf9-4a5f-bd70-64ddd6fbf79e_d18b246e-13d7-423f-a045-5da4c757759e)\n\nAdditional test material information\n\n[Empty]\n\nSpecific details on test material used for the study\n\n[Empty]\n\nSpecific details on test material used for the study (confidential)\n\n[Not publishable]\n\n### Test animals\n\nSpecies\n\n[Empty]\n\nStrain\n\n[Empty]\n\nDetails on species / strain selection\n\n[Empty]\n\nSex\n\n[Empty]\n\nDetails on test animals or test system and environmental conditions\n\n[Empty]\n\n### Administration / exposure\n\nRoute of administration\n\n[Empty]\n\nDetails on route of administration\n\n[Empty]\n\nVehicle\n\n[Empty]\n\nDetails on oral exposure\n\n[Empty]\n\nAnalytical verification of doses or concentrations\n\n[Empty]\n\nDetails on analytical verification of doses or concentrations\n\n[Empty]\n\nDuration of treatment / exposure\n\n[Empty]\n\nFrequency of treatment\n\n[Empty]\n\n### Doses / concentrations\n\nNo. of animals per sex per dose\n\n[Empty]\n\nControl animals\n\n[Empty]\n\nDetails on study design\n\n[Empty]\n\nPositive control\n\n[Empty]\n\nHigh dose level used\n\n[Empty]\n\nJustification for deviation from the high dose level\n\n[Not publishable]\n\n### Examinations\n\nObservations and examinations performed and frequency\n\n[Empty]\n\nSacrifice and pathology\n\n[Empty]\n\nOptional endpoint(s)\n\n[Empty]\n\nOther examinations\n\n[Empty]\n\nStatistics\n\n[Empty]\n\n### Model and software\n\nModel name and version\n\n[Empty]\n\nSoftware name and version\n\n[Empty]\n\nRemarks\n\n[Not publishable]\n\n### Any other information on materials and methods incl. tables\n\n[Not publishable]\n\n### Results and discussion\n\n### Results of examinations\n\nClinical signs\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nMortality\n\n[Empty]\n\nDescription (incidence)\n\n[Empty]\n\nBody weight and weight changes\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nFood consumption and compound intake (if feeding study)\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nFood efficiency\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nWater consumption and compound intake (if drinking water study)\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nOphthalmological findings\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nHaematological findings\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nClinical biochemistry findings\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nEndocrine findings\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nUrinalysis findings\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nBehaviour (functional findings)\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nImmunological findings\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nOrgan weight findings including organ / body weight ratios\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nGross pathological findings\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nNeuropathological findings\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nHistopathological findings: non-neoplastic\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nHistopathological findings: neoplastic\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nOther effects\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nDetails on results\n\n[Empty]\n\n### Effect levels\n\n### Target system / organ toxicity\n\n### Detailed toxicology results\n\n### Detailed toxicology results\n\n### Additional information about applicability domain and reliability of (Q)SAR predictions\n\nFit with the applicability domain\n\n[Empty]\n\nJustification for the fit with the applicability domain\n\n[Empty]\n\nFit with the space defined by the training set of the model\n\n[Empty]\n\nMechanistic and metabolic considerations\n\n[Empty]\n\n### Similar substances with experimental data\n\nPerformance of the model for similar substances\n\n[Empty]\n\nConclusions on applicability domain and reliability\n\n[Empty]\n\nUncertainty\n\n[Empty]\n\n### Any other information on results incl. tables\n\nChronic toxicity trials were carried out in rats, rabbits and dogs for 180 days. Analyses regarding haematology and blood chemistry were selected to have an overall picture, within limits of the effects from treatment on metabolism, on liver function, on renal function, and on complete blood count. The necroscopy was carried out on major organs and apparatuses and was performed on each animal and on each organ by microscopy. The doses used were 10, 20 or 30 mg/kg/day subcutaneously or 50 or 100 mg/kg/day orally for rats, 5, 10 or 15 mg/kg/day intramuscularly for rabbits, and 50 or 100 mg/kg/day orally for dogs. In the study on 120 rats six animals died during the trials. The necroptic exam revealed that all six animals had bronchopulmonary complications affecting both lungs. This was unrelated to the drug administration. Only in the group of rats treated with the dose of 30 mg/kg/day by subcutaneous route there was a mild reduction in weight gain with a slight decrease in food consumption. The haematology and blood chemistry analyses have shown that treatment with levosulpiride subcutaneously at 10-20 mg/kg/day for 190 days is well tolerated in rats. The findings of the pathologic and histopathologic exams in the treated animals were unremarkable (See Figure). In the study carried out on rats treated for 180 days with 50-100 mg/kg/day of levosulpiride by oral route, the general health of all animals in all groups remained normal. From a behavioural point of view there was no difference between the groups treated with levosulpiride and the control group. No change in urine analyses were noted in spite of a weight gain trend. This shows that levosulpiride neither determines renal damage, nor influences weight gain after chronic use. The white cell count and the complete blood count, as well as the weight, necroptic and histologic examinations of internal organs carried out in treated animals and in controls, excluded any damage caused by levosulpiride. In trials carried out in rabbits there was a mild, not statistically significant decline in growth compared to controls in the group with the highest dosage (15 mg/kg/day). Haematology, blood chemistry analyses and gross pathologic, histopathologic analyses have shown that treatment with levosulpiride at 5, 10 or 15 mg/kg/day by intramuscular route for 180 days is well tolerated in rabbits. In the study carried out on dogs treated for 180 days with 50-100 mg/kg/day of levosulpiride by oral route, none of the treated animals had behavioural modifications worth noting. Even in the group receiving the highest dose provoked no episode of gastrointestinal intolerance, or symptoms linked to neurotoxicity. No change in blood cell count, blood chemistry, urine composition and body weight, which could be linked to levosulpiride use, was documented. The necroptic and histologic evaluations showed no gross anatomical or microscopic pathologies in the major organs.\n\n### Overall remarks, attachments\n\nOverall remarks\n\n[Not publishable]\n\n### Attachments\n\n#1\n\n[Not publishable]\n\n### Applicant's summary and conclusion\n\nConclusions\n\nAlthough treatment related effects can be observed after oral sulpiride administration, they do not support the classification as STOT RE in accordance with Regulation (EC) 1272/2008.\n\nExecutive summary\n\nChronic toxicity trials were carried out in rats, rabbits and dogs for 180 days. Analyses regarding haematology and blood chemistry were selected to have an overall picture, within limits of the effects from treatment on metabolism, on liver function, on renal function, and on complete blood count. The necroscopy was carried out on major organs and apparatuses and was performed on each animal and on each organ by microscopy. The doses used were 10, 20 or 30 mg/kg/day subcutaneously or 50 or 100 mg/kg/day orally for rats, 5, 10 or 15 mg/kg/day intramuscularly for rabbits, and 50 or 100 mg/kg/day orally for dogs. In the study on 120 rats six animals died during the trials. The necroptic exam revealed that all six animals had bronchopulmonary complications affecting both lungs. This was unrelated to the drug administration. Only in the group of rats treated with the dose of 30 mg/kg/day by subcutaneous route there was a mild reduction in weight gain with a slight decrease in food consumption. The haematology and blood chemistry analyses have shown that treatment with levosulpiride subcutaneously at 10-20 mg/kg/day for 190 days is well tolerated in rats. The findings of the pathologic and histopathologic exams in the treated animals were unremarkable (See Figure). In the study carried out on rats treated for 180 days with 50-100 mg/kg/day of levosulpiride by oral route, the general health of all animals in all groups remained normal. From a behavioural point of view there was no difference between the groups treated with levosulpiride and the control group. No change in urine analyses were noted in spite of a weight gain trend. This shows that levosulpiride neither determines renal damage, nor influences weight gain after chronic use. The white cell count and the complete blood count, as well as the weight, necroptic and histologic examinations of internal organs carried out in treated animals and in controls, excluded any damage caused by levosulpiride. In trials carried out in rabbits there was a mild, not statistically significant decline in growth compared to controls in the group with the highest dosage (15 mg/kg/day). Haematology, blood chemistry analyses and gross pathologic, histopathologic analyses have shown that treatment with levosulpiride at 5, 10 or 15 mg/kg/day by intramuscular route for 180 days is well tolerated in rabbits. In the study carried out on dogs treated for 180 days with 50-100 mg/kg/day of levosulpiride by oral route, none of the treated animals had behavioural modifications worth noting. Even in the group receiving the highest dose provoked no episode of gastrointestinal intolerance, or symptoms linked to neurotoxicity. No change in blood cell count, blood chemistry, urine composition and body weight, which could be linked to levosulpiride use, was documented. The necroptic and histologic evaluations showed no gross anatomical or microscopic pathologies in the major organs.\n\nBack to top",
          "content_length": 11588,
          "status": "success"
        }
      },
      "7.5.2 Repeated dose toxicity: inhalation": {},
      "7.5.3 Repeated dose toxicity: dermal": {},
      "7.5.4 Repeated dose toxicity: other routes": {},
      "S-01 | Summary": {
        "document_id": "38853ee9-8f0e-4243-aea7-08107081dc64_d18b246e-13d7-423f-a045-5da4c757759e",
        "markdown_content": "#### Repeated dose toxicity\n\nJump to\n\nHide empty fields\n\n### Administrative data\n\nConfidentiality\n\n[Empty]\n\nJustification\n\n[Empty]\n\nUse restricted to selected regulatory programmes\n\n[Empty]\n\n### Description of key information\n\nNo adverse effects were observed after subacute and subchronic levosulpiride administration.\n\n### Key value for chemical safety assessment\n\nToxic effect type\n\n[Empty]\n\nEndpoint conclusion â systemic effects, oral route\n\nno adverse effect observed\n\nEndpoint conclusion â systemic effects, dermal\n\nno information available\n\nEndpoint conclusion â systemic effects, inhalation\n\nno information available\n\n### Short-term repeated dose toxicity â systemic effects\n\n### Oral route\n\nLink to relevant study record(s)\n\n* [001 | Other | Experimental study](1187313e-28d5-407d-a961-1c6004f6939b_d18b246e-13d7-423f-a045-5da4c757759e)\n* [002 | Other | Experimental study](9dd36b38-89fe-4029-9fb5-5709710c16e7_d18b246e-13d7-423f-a045-5da4c757759e)\n\nDose descriptor\n\n[Empty]\n\nEffect level\n\n[Empty]\n\nExperimental exposure time per week\n\nhours/week\n\nSpecies\n\n[Empty]\n\nSystem\n\n[Empty]\n\nOrgan\n\n[Empty]\n\n### Dermal\n\nLink to relevant study record(s)\n\n[Empty]\n\nDose descriptor\n\n[Empty]\n\nEffect level\n\n[Empty]\n\nExperimental exposure time per week\n\nhours/week\n\nSpecies\n\n[Empty]\n\nSystem\n\n[Empty]\n\nOrgan\n\n[Empty]\n\n### Inhalation\n\nLink to relevant study record(s)\n\n[Empty]\n\nDose descriptor\n\n[Empty]\n\nEffect level\n\n[Empty]\n\nExperimental exposure time per week\n\nhours/week\n\nSpecies\n\n[Empty]\n\nSystem\n\n[Empty]\n\nOrgan\n\n[Empty]\n\n### Sub-chronic toxicity â systemic effects\n\n### Oral route\n\nLink to relevant study record(s)\n\n[Empty]\n\nDose descriptor\n\n[Empty]\n\nEffect level\n\n[Empty]\n\nExperimental exposure time per week\n\nhours/week\n\nSpecies\n\n[Empty]\n\nSystem\n\n[Empty]\n\nOrgan\n\n[Empty]\n\n### Dermal\n\nLink to relevant study record(s)\n\n[Empty]\n\nDose descriptor\n\n[Empty]\n\nEffect level\n\n[Empty]\n\nExperimental exposure time per week\n\nhours/week\n\nSpecies\n\n[Empty]\n\nSystem\n\n[Empty]\n\nOrgan\n\n[Empty]\n\n### Inhalation\n\nLink to relevant study record(s)\n\n[Empty]\n\nDose descriptor\n\n[Empty]\n\nEffect level\n\n[Empty]\n\nExperimental exposure time per week\n\nhours/week\n\nSpecies\n\n[Empty]\n\nSystem\n\n[Empty]\n\nOrgan\n\n[Empty]\n\n### Chronic toxicity â systemic effects\n\n### Oral route\n\nLink to relevant study record(s)\n\n[Empty]\n\nDose descriptor\n\n[Empty]\n\nEffect level\n\n[Empty]\n\nExperimental exposure time per week\n\nhours/week\n\nSpecies\n\n[Empty]\n\nSystem\n\n[Empty]\n\nOrgan\n\n[Empty]\n\n### Dermal\n\nLink to relevant study record(s)\n\n[Empty]\n\nDose descriptor\n\n[Empty]\n\nEffect level\n\n[Empty]\n\nExperimental exposure time per week\n\nhours/week\n\nSpecies\n\n[Empty]\n\nSystem\n\n[Empty]\n\nOrgan\n\n[Empty]\n\n### Inhalation\n\nLink to relevant study record(s)\n\n[Empty]\n\nDose descriptor\n\n[Empty]\n\nEffect level\n\n[Empty]\n\nExperimental exposure time per week\n\nhours/week\n\nSpecies\n\n[Empty]\n\nSystem\n\n[Empty]\n\nOrgan\n\n[Empty]\n\n### Repeated dose toxicity â local effects\n\n### Dermal\n\nLink to relevant study record(s)\n\n[Empty]\n\nEndpoint conclusion\n\nno information available\n\nDose descriptor\n\n[Empty]\n\nEffect level\n\n[Empty]\n\nStudy duration\n\n[Empty]\n\nSpecies\n\n[Empty]\n\n### Inhalation\n\nLink to relevant study record(s)\n\n[Empty]\n\nEndpoint conclusion\n\nno information available\n\nDose descriptor\n\n[Empty]\n\nEffect level\n\n[Empty]\n\nStudy duration\n\n[Empty]\n\nSpecies\n\n[Empty]\n\n### Repeated dose toxicity: other routes\n\nLink to relevant study record(s)\n\n[Empty]\n\n### Mode of Action Analysis / Human Relevance Framework\n\n[Empty]\n\n### Justification for classification or non-classification\n\nOverall, data available are deemed to be conclusive but not sufficient for classification.\n\n### Additional information\n\n[Empty]\n\n### Attached background material\n\nBack to top",
        "content_length": 3682,
        "status": "success"
      }
    },
    "7.6 Genetic toxicity": {
      "7.6.1 Genetic toxicity in vitro": {
        "001 | Other | Experimental study": {
          "document_id": "8d862c5c-3901-4f47-b810-ef2f5c3ada52_d18b246e-13d7-423f-a045-5da4c757759e",
          "markdown_content": "#### Genetic toxicity in vitro\n\nJump to\n\nHide empty fields\n\n### Administrative data\n\nConfidentiality\n\n[Not publishable]\n\nJustification\n\n[Not publishable]\n\nUse restricted to selected regulatory programmes\n\n[Not publishable]\n\nEndpoint\n\nin vitro chromosome aberration study in mammalian cells\n\nType of information\n\nexperimental study\n\nAdequacy of study\n\nother information\n\nRobust study summary\n\n[Not publishable]\n\nUsed for classification\n\n[Not publishable]\n\nUsed for SDS\n\n[Not publishable]\n\nStudy period: start date\n\n[Empty]\n\nEnd date\n\n[Empty]\n\nRemark\n\n[Empty]\n\nReliability\n\n4 (not assignable)\n\nRationale for reliability incl. deficiencies\n\nsecondary literature\n\nData waiving\n\n[Empty]\n\nJustification for data waiving\n\n[Empty]\n\nJustification for type of information\n\n[Empty]\n\n### Attached justification\n\n### Cross-reference\n\n### Data source\n\nReference\n\n* [Pharmacotoxicological aspects of levosulpiride.](0bba3384-7bf4-4c6d-983d-78a29e387ee6_d18b246e-13d7-423f-a045-5da4c757759e)\n\nData access\n\n[Not publishable]\n\nData protection claimed\n\n[Not publishable]\n\n### Materials and methods\n\n### Test guideline\n\n### #1 - Test guideline\n\nQualifier\n\n[Empty]\n\nGuideline\n\nother:\nnot specified\n\nVersion / remarks\n\n[Empty]\n\nDeviations\n\n[Empty]\n\nPrinciples of method if other than guideline\n\n[Empty]\n\nGLP compliance\n\nnot specified\n\nType of assay\n\nother:\nsee executive summary\n\n### Test material\n\nTest material information\n\n[Test material information](4e39367f-bcf9-4a5f-bd70-64ddd6fbf79e_d18b246e-13d7-423f-a045-5da4c757759e)\n\nAdditional test material information\n\n[Empty]\n\nSpecific details on test material used for the study\n\n[Empty]\n\nSpecific details on test material used for the study (confidential)\n\n[Not publishable]\n\n### Method\n\nTarget gene\n\n[Empty]\n\n### Species / strain\n\nCytokinesis block (if used)\n\n[Empty]\n\nMetabolic activation\n\n[Empty]\n\nMetabolic activation system\n\n[Empty]\n\nTest concentrations\n\n[Empty]\n\nHigh dose level used\n\n[Empty]\n\nJustification for deviation from the high dose level\n\n[Empty]\n\nVehicle / solvent\n\n[Empty]\n\n### Controls\n\nDetails on test system and experimental conditions\n\n[Empty]\n\nRationale for test conditions\n\n[Empty]\n\nEvaluation criteria\n\n[Empty]\n\nStatistics\n\n[Empty]\n\n### Model and software\n\nModel name and version\n\n[Empty]\n\nSoftware name and version\n\n[Empty]\n\nRemarks\n\n[Not publishable]\n\n### Any other information on materials and methods incl. tables\n\n[Not publishable]\n\n### Results and discussion\n\n### Test results\n\nAdditional information on results\n\n[Empty]\n\nRemarks on result\n\n[Empty]\n\n### Additional information about applicability domain and reliability of (Q)SAR predictions\n\nFit with the applicability domain\n\n[Empty]\n\nJustification for the fit with the applicability domain\n\n[Empty]\n\nFit with the space defined by the training set of the model\n\n[Empty]\n\nMechanistic and metabolic considerations\n\n[Empty]\n\n### Similar substances with experimental data\n\nPerformance of the model for similar substances\n\n[Empty]\n\nConclusions on applicability domain and reliability\n\n[Empty]\n\nUncertainty\n\n[Empty]\n\n### Any other information on results incl. tables\n\nThe mutagenic potential of levosulpiride was studied by using different methods. The point mutation test in Saccharomyces cerevisiae, the bacterial test of B. Ames on Salmonella tiphymurium, the study on the DNA repairing activity, the chromosomal aberration test in human diploid cells, the DNA repair and damage test (evaluated by mitotic crossing-over and by gene conversion in Saccharomyces cerevisiae), and the gene mutation test in Schizosaccharomyces Pombe Pl, did not document any increase in mutation rate induced by levosulpiride. Furthermore, levosulpiride was tested in vitro for possible induction of structural and numerical chromosome aberration in PHA-stimulated human lymphocytes. The compound was added to the medium at various concentrations 48 h after the culture had been set up. The mean structural aberration rates for the levosulpiride cultures were between 0.5 and 3.0% (for aberrant metaphases including gaps) or 0 and 1.5% (for aberrant metaphases excluding gaps) and were thus found within the range of variation of long-term in-house negative controls. No aberration other than gaps, breaks and isolated isochromatid fragments was observed. There was no substance-related increase in comparison to the concurrent negative controls. Numerically aberrant metaphases were also included in the evaluation for structural aberrations. Under these experimental conditions the induction of structural chromosomal aberrations and numerical aberrations in the form of hypoploid and polyploid metaphases induced by levosulpiride is ruled out.\n\n### Overall remarks, attachments\n\nOverall remarks\n\n[Not publishable]\n\n### Attachments\n\n### Applicant's summary and conclusion\n\nConclusions\n\nLevosulpiride was studied by different test methods and was not found to be genotoxic.\n\nExecutive summary\n\nThe mutagenic potential of levosulpiride was studied by using different methods. The point mutation test in Saccharomyces cerevisiae, the bacterial test of B. Ames on Salmonella tiphymurium, the study on the DNA repairing activity, the chromosomal aberration test in human diploid cells, the DNA repair and damage test (evaluated by mitotic crossing-over and by gene conversion in Saccharomyces cerevisiae), and the gene mutation test in Schizosaccharomyces Pombe Pl, did not document any increase in mutation rate induced by levosulpiride. Furthermore, levosulpiride was tested in vitro for possible induction of structural and numerical chromosome aberration in PHA-stimulated human lymphocytes. The compound was added to the medium at various concentrations 48 h after the culture had been set up. The mean structural aberration rates for the levosulpiride cultures were between 0.5 and 3.0% (for aberrant metaphases including gaps) or 0 and 1.5% (for aberrant metaphases excluding gaps) and were thus found within the range of variation of long-term in-house negative controls. No aberration other than gaps, breaks and isolated isochromatid fragments was observed. There was no substance-related increase in comparison to the concurrent negative controls. Numerically aberrant metaphases were also included in the evaluation for structural aberrations. Under these experimental conditions the induction of structural chromosomal aberrations and numerical aberrations in the form of hypoploid and polyploid metaphases induced by levosulpiride is ruled out.\n\nBack to top",
          "content_length": 6456,
          "status": "success"
        },
        "002 | Other | (Q)SAR": {
          "document_id": "664ca5e2-0724-482f-8c2e-c809311cb18d_d18b246e-13d7-423f-a045-5da4c757759e",
          "markdown_content": "#### Genetic toxicity in vitro\n\nJump to\n\nHide empty fields\n\n### Administrative data\n\nConfidentiality\n\n[Not publishable]\n\nJustification\n\n[Not publishable]\n\nUse restricted to selected regulatory programmes\n\n[Not publishable]\n\nEndpoint\n\nin vitro gene mutation study in bacteria\n\nType of information\n\n(Q)SAR\n\nAdequacy of study\n\nother information\n\nRobust study summary\n\n[Not publishable]\n\nUsed for classification\n\n[Not publishable]\n\nUsed for SDS\n\n[Not publishable]\n\nStudy period: start date\n\n[Empty]\n\nEnd date\n\n[Empty]\n\nRemark\n\n[Empty]\n\nReliability\n\n2 (reliable with restrictions)\n\nRationale for reliability incl. deficiencies\n\nresults derived from a valid (Q)SAR model and falling into its applicability domain, with limited documentation / justification\n\nData waiving\n\n[Empty]\n\nJustification for data waiving\n\n[Empty]\n\nJustification for type of information\n\n[Empty]\n\n### Attached justification\n\n### Cross-reference\n\n### Data source\n\nReference\n\n* [Mutagenicity (Ames test) model (ISS) 1.0.2](113b640e-f185-4610-844c-ea07b19beb4a_d18b246e-13d7-423f-a045-5da4c757759e)\n\nData access\n\n[Not publishable]\n\nData protection claimed\n\n[Not publishable]\n\n### Materials and methods\n\n### Test guideline\n\n### #1 - Test guideline\n\nQualifier\n\nequivalent or similar to guideline\n\nGuideline\n\nother:\nECHA guidance on information requirements and chemical safety assessment Chapter R.6: QSARs and grouping of chemicals.\n\nVersion / remarks\n\n[Empty]\n\nDeviations\n\n[Empty]\n\nPrinciples of method if other than guideline\n\n[Empty]\n\nGLP compliance\n\n[Empty]\n\nType of assay\n\nbacterial reverse mutation assay\n\n### Test material\n\nTest material information\n\n[Test material information](58f5f39d-02e9-43fd-bfb1-bb2cde8000ff_d18b246e-13d7-423f-a045-5da4c757759e)\n\nAdditional test material information\n\n[Empty]\n\nSpecific details on test material used for the study\n\n[Empty]\n\nSpecific details on test material used for the study (confidential)\n\n[Not publishable]\n\n### Method\n\nTarget gene\n\n[Empty]\n\n### Species / strain\n\nCytokinesis block (if used)\n\n[Empty]\n\nMetabolic activation\n\n[Empty]\n\nMetabolic activation system\n\n[Empty]\n\nTest concentrations\n\n[Empty]\n\nHigh dose level used\n\n[Empty]\n\nJustification for deviation from the high dose level\n\n[Empty]\n\nVehicle / solvent\n\n[Empty]\n\n### Controls\n\nDetails on test system and experimental conditions\n\n[Empty]\n\nRationale for test conditions\n\n[Empty]\n\nEvaluation criteria\n\n[Empty]\n\nStatistics\n\nThe applicability domain of predictions is assessed using an Applicability Domain Index (ADI) that has values from 0 (worst case) to 1 (best case). The ADI is calculated by grouping several other indices, each one taking into account a particular issue of the applicability domain. Most of the indices are based on the calculation of the most similar compounds found in the training and test set of the model, calculated by a similarity index that consider molecule's fingerprint and structural aspects (count of atoms, rings and relevant fragments).\nFor each index, including the final ADI, three intervals for its values are defined, such that the first interval corresponds to a positive evaluation, the second one corresponds to a suspicious evaluation and the last one corresponds to a negative evaluation.\nList of indices:\n- Similar molecules with known experimental value.\n- Accuracy of prediction for similar molecules.\n- Concordance for similar molecules.\n- Atom Centered Fragments similarity check.\n- Global AD Index.\n\n### Model and software\n\nModel name and version\n\n[Empty]\n\nSoftware name and version\n\n[Empty]\n\nRemarks\n\n[Not publishable]\n\n### Any other information on materials and methods incl. tables\n\n[Not publishable]\n\n### Results and discussion\n\n### Test results\n\n### #1 - Test results\n\nKey result\n\nSpecies / strain\n\n[Empty]\n\nMetabolic activation\n\n[Empty]\n\nGenotoxicity\n\nnegative\n\nCytotoxicity / choice of top concentrations\n\n[Empty]\n\nVehicle controls validity\n\n[Empty]\n\nUntreated negative controls validity\n\n[Empty]\n\nTrue negative controls validity\n\n[Empty]\n\nPositive controls validity\n\n[Empty]\n\nAdditional information on results\n\n[Empty]\n\nRemarks on result\n\n[Empty]\n\n### Additional information about applicability domain and reliability of (Q)SAR predictions\n\nFit with the applicability domain\n\n[Empty]\n\nJustification for the fit with the applicability domain\n\n[Empty]\n\nFit with the space defined by the training set of the model\n\n[Empty]\n\nMechanistic and metabolic considerations\n\n[Empty]\n\n### Similar substances with experimental data\n\nPerformance of the model for similar substances\n\n[Empty]\n\nConclusions on applicability domain and reliability\n\n[Empty]\n\nUncertainty\n\n[Empty]\n\n### Any other information on results incl. tables\n\nThe result appears reliable as the predicted compound is into the applicability domain of the model.\n\n### Overall remarks, attachments\n\nOverall remarks\n\n[Not publishable]\n\n### Attachments\n\n#1\n\n[Not publishable]\n\n#2\n\n[Not publishable]\n\n### Applicant's summary and conclusion\n\nConclusions\n\nThe substance is predicted to be non-mutagenic.\n\nExecutive summary\n\n[Empty]\n\nBack to top",
          "content_length": 5020,
          "status": "success"
        },
        "003 | Other | (Q)SAR": {
          "document_id": "f107471e-0f95-4914-9da1-4edd5280e944_d18b246e-13d7-423f-a045-5da4c757759e",
          "markdown_content": "#### Genetic toxicity in vitro\n\nJump to\n\nHide empty fields\n\n### Administrative data\n\nConfidentiality\n\n[Not publishable]\n\nJustification\n\n[Not publishable]\n\nUse restricted to selected regulatory programmes\n\n[Not publishable]\n\nEndpoint\n\nin vitro gene mutation study in bacteria\n\nType of information\n\n(Q)SAR\n\nAdequacy of study\n\nother information\n\nRobust study summary\n\n[Not publishable]\n\nUsed for classification\n\n[Not publishable]\n\nUsed for SDS\n\n[Not publishable]\n\nStudy period: start date\n\n[Empty]\n\nEnd date\n\n[Empty]\n\nRemark\n\n[Empty]\n\nReliability\n\n2 (reliable with restrictions)\n\nRationale for reliability incl. deficiencies\n\nresults derived from a valid (Q)SAR model and falling into its applicability domain, with limited documentation / justification\n\nData waiving\n\n[Empty]\n\nJustification for data waiving\n\n[Empty]\n\nJustification for type of information\n\n[Empty]\n\n### Attached justification\n\n### Cross-reference\n\n### Data source\n\nReference\n\n* [Mutagenicity (Ames test) model (SarPy/IRFMN) 1.0.7](166ed459-bf84-4544-b78b-059154af61c8_d18b246e-13d7-423f-a045-5da4c757759e)\n\nData access\n\n[Not publishable]\n\nData protection claimed\n\n[Not publishable]\n\n### Materials and methods\n\n### Test guideline\n\n### #1 - Test guideline\n\nQualifier\n\nequivalent or similar to guideline\n\nGuideline\n\nother:\nECHA guidance on information requirements and chemical safety assessment Chapter R.6: QSARs and grouping of chemicals.\n\nVersion / remarks\n\n[Empty]\n\nDeviations\n\n[Empty]\n\nPrinciples of method if other than guideline\n\n[Empty]\n\nGLP compliance\n\n[Empty]\n\nType of assay\n\nbacterial reverse mutation assay\n\n### Test material\n\nTest material information\n\n[Test material information](58f5f39d-02e9-43fd-bfb1-bb2cde8000ff_d18b246e-13d7-423f-a045-5da4c757759e)\n\nAdditional test material information\n\n[Empty]\n\nSpecific details on test material used for the study\n\n[Empty]\n\nSpecific details on test material used for the study (confidential)\n\n[Not publishable]\n\n### Method\n\nTarget gene\n\n[Empty]\n\n### Species / strain\n\nCytokinesis block (if used)\n\n[Empty]\n\nMetabolic activation\n\n[Empty]\n\nMetabolic activation system\n\n[Empty]\n\nTest concentrations\n\n[Empty]\n\nHigh dose level used\n\n[Empty]\n\nJustification for deviation from the high dose level\n\n[Empty]\n\nVehicle / solvent\n\n[Empty]\n\n### Controls\n\nDetails on test system and experimental conditions\n\n[Empty]\n\nRationale for test conditions\n\n[Empty]\n\nEvaluation criteria\n\n[Empty]\n\nStatistics\n\nThe applicability domain of predictions is assessed using an Applicability Domain Index (ADI) that has values from 0 (worst case) to 1 (best case). The ADI is calculated by grouping several other indices, each one taking into account a particular issue of the applicability domain. Most of the indices are based on the calculation of the most similar compounds found in the training and test set of the model, calculated by a similarity index that consider molecule's fingerprint and structural aspects (count of atoms, rings and relevant fragments).\nFor each index, including the final ADI, three intervals for its values are defined, such that the first interval corresponds to a positive evaluation, the second one corresponds to a suspicious evaluation and the last one corresponds to a negative evaluation.\nList of indices:\n- Similar molecules with known experimental value.\n- Accuracy of prediction for similar molecules.\n- Concordance for similar molecules.\n- Atom Centered Fragments similarity check.\n- Global AD Index.\n\n### Model and software\n\nModel name and version\n\n[Empty]\n\nSoftware name and version\n\n[Empty]\n\nRemarks\n\n[Not publishable]\n\n### Any other information on materials and methods incl. tables\n\n[Not publishable]\n\n### Results and discussion\n\n### Test results\n\n### #1 - Test results\n\nKey result\n\nSpecies / strain\n\n[Empty]\n\nMetabolic activation\n\n[Empty]\n\nGenotoxicity\n\nnegative\n\nCytotoxicity / choice of top concentrations\n\n[Empty]\n\nVehicle controls validity\n\n[Empty]\n\nUntreated negative controls validity\n\n[Empty]\n\nTrue negative controls validity\n\n[Empty]\n\nPositive controls validity\n\n[Empty]\n\nAdditional information on results\n\n[Empty]\n\nRemarks on result\n\n[Empty]\n\n### Additional information about applicability domain and reliability of (Q)SAR predictions\n\nFit with the applicability domain\n\n[Empty]\n\nJustification for the fit with the applicability domain\n\n[Empty]\n\nFit with the space defined by the training set of the model\n\n[Empty]\n\nMechanistic and metabolic considerations\n\n[Empty]\n\n### Similar substances with experimental data\n\nPerformance of the model for similar substances\n\n[Empty]\n\nConclusions on applicability domain and reliability\n\n[Empty]\n\nUncertainty\n\n[Empty]\n\n### Any other information on results incl. tables\n\nThe result appears reliable as the predicted compound is into the applicability domain of the model.\n\n### Overall remarks, attachments\n\nOverall remarks\n\n[Not publishable]\n\n### Attachments\n\n#1\n\n[Not publishable]\n\n#2\n\n[Not publishable]\n\n### Applicant's summary and conclusion\n\nConclusions\n\nThe substance is predicted to be non-mutagenic.\n\nExecutive summary\n\n[Empty]\n\nBack to top",
          "content_length": 5028,
          "status": "success"
        },
        "004 | Other | (Q)SAR": {
          "document_id": "28465377-171a-4d01-a82e-b9faad52d4d4_d18b246e-13d7-423f-a045-5da4c757759e",
          "markdown_content": "#### Genetic toxicity in vitro\n\nJump to\n\nHide empty fields\n\n### Administrative data\n\nConfidentiality\n\n[Not publishable]\n\nJustification\n\n[Not publishable]\n\nUse restricted to selected regulatory programmes\n\n[Not publishable]\n\nEndpoint\n\nin vitro gene mutation study in bacteria\n\nType of information\n\n(Q)SAR\n\nAdequacy of study\n\nother information\n\nRobust study summary\n\n[Not publishable]\n\nUsed for classification\n\n[Not publishable]\n\nUsed for SDS\n\n[Not publishable]\n\nStudy period: start date\n\n[Empty]\n\nEnd date\n\n[Empty]\n\nRemark\n\n[Empty]\n\nReliability\n\n2 (reliable with restrictions)\n\nRationale for reliability incl. deficiencies\n\nresults derived from a valid (Q)SAR model and falling into its applicability domain, with limited documentation / justification\n\nData waiving\n\n[Empty]\n\nJustification for data waiving\n\n[Empty]\n\nJustification for type of information\n\n[Empty]\n\n### Attached justification\n\n### Cross-reference\n\n### Data source\n\nReference\n\n* [Mutagenicity (Ames test) model (CAESAR) 2.1.13](4e7fbf4d-833f-4930-9667-912f63c8cc7a_d18b246e-13d7-423f-a045-5da4c757759e)\n\nData access\n\n[Not publishable]\n\nData protection claimed\n\n[Not publishable]\n\n### Materials and methods\n\n### Test guideline\n\n### #1 - Test guideline\n\nQualifier\n\nequivalent or similar to guideline\n\nGuideline\n\nother:\nECHA guidance on information requirements and chemical safety assessment Chapter R.6: QSARs and grouping of chemicals.\n\nVersion / remarks\n\n[Empty]\n\nDeviations\n\n[Empty]\n\nPrinciples of method if other than guideline\n\n[Empty]\n\nGLP compliance\n\n[Empty]\n\nType of assay\n\nbacterial reverse mutation assay\n\n### Test material\n\nTest material information\n\n[Test material information](58f5f39d-02e9-43fd-bfb1-bb2cde8000ff_d18b246e-13d7-423f-a045-5da4c757759e)\n\nAdditional test material information\n\n[Empty]\n\nSpecific details on test material used for the study\n\n[Empty]\n\nSpecific details on test material used for the study (confidential)\n\n[Not publishable]\n\n### Method\n\nTarget gene\n\n[Empty]\n\n### Species / strain\n\nCytokinesis block (if used)\n\n[Empty]\n\nMetabolic activation\n\n[Empty]\n\nMetabolic activation system\n\n[Empty]\n\nTest concentrations\n\n[Empty]\n\nHigh dose level used\n\n[Empty]\n\nJustification for deviation from the high dose level\n\n[Empty]\n\nVehicle / solvent\n\n[Empty]\n\n### Controls\n\nDetails on test system and experimental conditions\n\n[Empty]\n\nRationale for test conditions\n\n[Empty]\n\nEvaluation criteria\n\n[Empty]\n\nStatistics\n\nThe applicability domain of predictions is assessed using an Applicability Domain Index (ADI) that has values from 0 (worst case) to 1 (best case). The ADI is calculated by grouping several other indices, each one taking into account a particular issue of the applicability domain. Most of the indices are based on the calculation of the most similar compounds found in the training and test set of the model, calculated by a similarity index that consider molecule's fingerprint and structural aspects (count of atoms, rings and relevant fragments).\nFor each index, including the final ADI, three intervals for its values are defined, such that the first interval corresponds to a positive evaluation, the second one corresponds to a suspicious evaluation and the last one corresponds to a negative evaluation.\nList of indices:\n- Similar molecules with known experimental value.\n- Accuracy of prediction for similar molecules.\n- Concordance for similar molecules.\n- Atom Centered Fragments similarity check.\n- Model descriptors range check.\n- Global AD Index.\n\n### Model and software\n\nModel name and version\n\n[Empty]\n\nSoftware name and version\n\n[Empty]\n\nRemarks\n\n[Not publishable]\n\n### Any other information on materials and methods incl. tables\n\n[Not publishable]\n\n### Results and discussion\n\n### Test results\n\n### #1 - Test results\n\nKey result\n\nSpecies / strain\n\n[Empty]\n\nMetabolic activation\n\n[Empty]\n\nGenotoxicity\n\nnegative\n\nCytotoxicity / choice of top concentrations\n\n[Empty]\n\nVehicle controls validity\n\n[Empty]\n\nUntreated negative controls validity\n\n[Empty]\n\nTrue negative controls validity\n\n[Empty]\n\nPositive controls validity\n\n[Empty]\n\nAdditional information on results\n\n[Empty]\n\nRemarks on result\n\n[Empty]\n\n### Additional information about applicability domain and reliability of (Q)SAR predictions\n\nFit with the applicability domain\n\n[Empty]\n\nJustification for the fit with the applicability domain\n\n[Empty]\n\nFit with the space defined by the training set of the model\n\n[Empty]\n\nMechanistic and metabolic considerations\n\n[Empty]\n\n### Similar substances with experimental data\n\nPerformance of the model for similar substances\n\n[Empty]\n\nConclusions on applicability domain and reliability\n\n[Empty]\n\nUncertainty\n\n[Empty]\n\n### Any other information on results incl. tables\n\nThe result appears reliable as the predicted compound is into the applicability domain of the model.\n\n### Overall remarks, attachments\n\nOverall remarks\n\n[Not publishable]\n\n### Attachments\n\n#1\n\n[Not publishable]\n\n#2\n\n[Not publishable]\n\n### Applicant's summary and conclusion\n\nConclusions\n\nThe substance is predicted to be non-mutagenic.\n\nExecutive summary\n\n[Empty]\n\nBack to top",
          "content_length": 5057,
          "status": "success"
        }
      },
      "7.6.2 Genetic toxicity in vivo": {},
      "S-01 | Summary": {
        "document_id": "7c2bab3f-9e9a-48ed-9166-38ea4a6d7d38_d18b246e-13d7-423f-a045-5da4c757759e",
        "markdown_content": "#### Genetic toxicity\n\nJump to\n\nHide empty fields\n\n### Administrative data\n\nConfidentiality\n\n[Empty]\n\nJustification\n\n[Empty]\n\nUse restricted to selected regulatory programmes\n\n[Empty]\n\n### Description of key information\n\nLevosulpiride was studied by different test methods and was not found to be genotoxic.\n\nMoreover, the substance was predicted to be non-mutagenic by 3 individual QSAR models. The predictions show good reliability.\n\n### Key value for chemical safety assessment\n\n### Genetic toxicity in vitro\n\nLink to relevant study record(s)\n\n* [004 | Other | (Q)SAR](28465377-171a-4d01-a82e-b9faad52d4d4_d18b246e-13d7-423f-a045-5da4c757759e)\n* [002 | Other | (Q)SAR](664ca5e2-0724-482f-8c2e-c809311cb18d_d18b246e-13d7-423f-a045-5da4c757759e)\n* [003 | Other | (Q)SAR](f107471e-0f95-4914-9da1-4edd5280e944_d18b246e-13d7-423f-a045-5da4c757759e)\n* [001 | Other | Experimental study](8d862c5c-3901-4f47-b810-ef2f5c3ada52_d18b246e-13d7-423f-a045-5da4c757759e)\n\nEndpoint conclusion\n\nno adverse effect observed (negative)\n\n### Genetic toxicity in vivo\n\nLink to relevant study record(s)\n\n[Empty]\n\nEndpoint conclusion\n\n[Empty]\n\n### Mode of Action Analysis / Human Relevance Framework\n\n[Empty]\n\n### Justification for classification or non-classification\n\nOverall, data available are conclusive but not sufficient for classification.\n\n### Additional information\n\nAvailable information allows to rule out genotoxicity of sulpiride.\n\n### Attached background material\n\nBack to top",
        "content_length": 1470,
        "status": "success"
      }
    },
    "7.7 Carcinogenicity": {
      "S-01 | Summary": {
        "document_id": "a06b2c04-4345-4858-9639-3eb6304ea98d_d18b246e-13d7-423f-a045-5da4c757759e",
        "markdown_content": "#### Carcinogenicity\n\nJump to\n\nHide empty fields\n\n### Administrative data\n\nConfidentiality\n\n[Empty]\n\nJustification\n\n[Empty]\n\nUse restricted to selected regulatory programmes\n\n[Empty]\n\n### Description of key information\n\nLevosulpiride was not found to be carcinogen in both rats and mice.\n\n### Key value for chemical safety assessment\n\n### Carcinogenicity: via oral route\n\nLink to relevant study record(s)\n\n* [002 | Key | Experimental study](6b7b1881-cd25-4c60-b8d4-d877fb838b06_d18b246e-13d7-423f-a045-5da4c757759e)\n\nEndpoint conclusion\n\n[Empty]\n\nDose descriptor\n\n[Empty]\n\nEffect level\n\n[Empty]\n\nStudy duration\n\n[Empty]\n\nSpecies\n\n[Empty]\n\nSystem\n\n[Empty]\n\nOrgan\n\n[Empty]\n\n### Carcinogenicity: via dermal route\n\nLink to relevant study record(s)\n\n[Empty]\n\nEndpoint conclusion\n\nno information available\n\nDose descriptor\n\n[Empty]\n\nEffect level\n\n[Empty]\n\nStudy duration\n\n[Empty]\n\nSpecies\n\n[Empty]\n\nSystem\n\n[Empty]\n\nOrgan\n\n[Empty]\n\n### Carcinogenicity: via inhalation route\n\nLink to relevant study record(s)\n\n[Empty]\n\nEndpoint conclusion\n\nno information available\n\nDose descriptor\n\n[Empty]\n\nEffect level\n\n[Empty]\n\nStudy duration\n\n[Empty]\n\nSpecies\n\n[Empty]\n\nSystem\n\n[Empty]\n\nOrgan\n\n[Empty]\n\n### Carcinogenicity: via other routes\n\nLink to relevant study record(s)\n\n[Empty]\n\n### Mode of Action Analysis / Human Relevance Framework\n\n[Empty]\n\n### Justification for classification or non-classification\n\nOverall, data available are conclusive but not sufficient for classification.\n\n### Additional information\n\n[Empty]\n\n### Attached background material\n\nBack to top",
        "content_length": 1553,
        "status": "success"
      },
      "001 | Disregarded | (Q)SAR": {
        "document_id": "82cf2f69-48c2-45bc-8bfd-183a341614f9_d18b246e-13d7-423f-a045-5da4c757759e",
        "markdown_content": "#### Carcinogenicity\n\nJump to\n\nHide empty fields\n\n### Administrative data\n\nConfidentiality\n\n[Not publishable]\n\nJustification\n\n[Not publishable]\n\nUse restricted to selected regulatory programmes\n\n[Not publishable]\n\nEndpoint\n\ncarcinogenicity: oral\n\nType of information\n\n(Q)SAR\n\nAdequacy of study\n\ndisregarded due to major methodological deficiencies\n\nRobust study summary\n\n[Not publishable]\n\nUsed for classification\n\n[Not publishable]\n\nUsed for SDS\n\n[Not publishable]\n\nStudy period: start date\n\n[Empty]\n\nEnd date\n\n[Empty]\n\nRemark\n\n[Empty]\n\nReliability\n\n3 (not reliable)\n\nRationale for reliability incl. deficiencies\n\nresults derived from a valid (Q)SAR model, but not (completely) falling into its applicability domain, and documentation / justification is limited\n\nData waiving\n\n[Empty]\n\nJustification for data waiving\n\n[Empty]\n\nJustification for type of information\n\n[Empty]\n\n### Attached justification\n\n### Cross-reference\n\n### Data source\n\nReference\n\n* [Carcinogenicity model (IRFMN/ISSCAN-CGX) 1.0.0](d574d75f-e5ae-42e0-92ea-63aa5eecf9ea_d18b246e-13d7-423f-a045-5da4c757759e)\n\nData access\n\n[Not publishable]\n\nData protection claimed\n\n[Not publishable]\n\n### Materials and methods\n\n### Test guideline\n\n### #1 - Test guideline\n\nQualifier\n\nequivalent or similar to guideline\n\nGuideline\n\nother:\nECHA guidance on information requirements and chemical safety assessment Chapter R.6: QSARs and grouping of chemicals.\n\nVersion / remarks\n\n[Empty]\n\nDeviations\n\n[Empty]\n\nPrinciples of method if other than guideline\n\n[Empty]\n\nGLP compliance\n\n[Empty]\n\n### Test material\n\nTest material information\n\n[Test material information](58f5f39d-02e9-43fd-bfb1-bb2cde8000ff_d18b246e-13d7-423f-a045-5da4c757759e)\n\nAdditional test material information\n\n[Empty]\n\nSpecific details on test material used for the study\n\nThis endpoint has been predicted by a QSAR model for sulpiride (instead of sulpiride HCl) as salts are not included in the applicability domain of QSAR models. Sulpiride and sulpiride HCl are expected to be similar for this endpoint.\n\nSpecific details on test material used for the study (confidential)\n\n[Not publishable]\n\n### Test animals\n\nSpecies\n\n[Empty]\n\nStrain\n\n[Empty]\n\nDetails on species / strain selection\n\n[Empty]\n\nSex\n\n[Empty]\n\nDetails on test animals or test system and environmental conditions\n\n[Empty]\n\n### Administration / exposure\n\nRoute of administration\n\n[Empty]\n\nType of inhalation exposure (if applicable)\n\n[Empty]\n\nVehicle\n\n[Empty]\n\nMass median aerodynamic diameter (MMAD)\n\n[Empty]\n\nGeometric standard deviation (GSD)\n\n[Empty]\n\nRemarks on MMAD\n\n[Empty]\n\nDetails on exposure\n\n[Empty]\n\nAnalytical verification of doses or concentrations\n\n[Empty]\n\nDetails on analytical verification of doses or concentrations\n\n[Empty]\n\nDuration of treatment / exposure\n\n[Empty]\n\nFrequency of treatment\n\n[Empty]\n\nPost exposure period\n\n[Empty]\n\n### Doses / concentrations\n\nNo. of animals per sex per dose\n\n[Empty]\n\nControl animals\n\n[Empty]\n\nDetails on study design\n\n[Empty]\n\nPositive control\n\n[Empty]\n\nHigh dose level used\n\n[Empty]\n\nJustification for deviation from the high dose level\n\n[Not publishable]\n\n### Examinations\n\nObservations and examinations performed and frequency\n\n[Empty]\n\nSacrifice and pathology\n\n[Empty]\n\nOther examinations\n\n[Empty]\n\nStatistics\n\nThe applicability domain of predictions is assessed using an Applicability Domain Index (ADI) that has values from 0 (worst case) to 1 (best case). The ADI is calculated by grouping several other indices, each one taking into account a particular issue of the applicability domain. Most of the indices are based on the calculation of the most similar compounds found in the training and test set of the model, calculated by a similarity index that consider molecule's fingerprint and structural aspects (count of atoms, rings and relevant fragments).\nFor each index, including the final ADI, three intervals for its values are defined, such that the first interval corresponds to a positive evaluation, the second one corresponds to a suspicious evaluation and the last one corresponds to a negative evaluation.\nList of indices:\n- Similar molecules with known experimental value.\n- Accuracy of prediction for similar molecules.\n- Concordance for similar molecules.\n- Atom Centered Fragments similarity check.\n- Global AD Index.\n\n### Model and software\n\nModel name and version\n\n[Empty]\n\nSoftware name and version\n\n[Empty]\n\nRemarks\n\n[Not publishable]\n\n### Any other information on materials and methods incl. tables\n\n[Not publishable]\n\n### Results and discussion\n\n### Results of examinations\n\nClinical signs\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nDermal irritation (if dermal study)\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nMortality\n\n[Empty]\n\nDescription (incidence)\n\n[Empty]\n\nBody weight and weight changes\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nFood consumption and compound intake (if feeding study)\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nFood efficiency\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nWater consumption and compound intake (if drinking water study)\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nOphthalmological findings\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nHaematological findings\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nClinical biochemistry findings\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nEndocrine findings\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nUrinalysis findings\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nBehaviour (functional findings)\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nImmunological findings\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nOrgan weight findings including organ / body weight ratios\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nGross pathological findings\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nNeuropathological findings\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nHistopathological findings: non-neoplastic\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nHistopathological findings: neoplastic\n\n[Empty]\n\nDescription (incidence and severity)\n\nCarcinogen.\n\nOther effects\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nDetails on results\n\n[Empty]\n\nRelevance of carcinogenic effects / potential\n\n[Empty]\n\n### Effect levels\n\n### Target system / organ toxicity\n\n### Additional information about applicability domain and reliability of (Q)SAR predictions\n\nFit with the applicability domain\n\n[Empty]\n\nJustification for the fit with the applicability domain\n\n[Empty]\n\nFit with the space defined by the training set of the model\n\n[Empty]\n\nMechanistic and metabolic considerations\n\n[Empty]\n\n### Similar substances with experimental data\n\nPerformance of the model for similar substances\n\n[Empty]\n\nConclusions on applicability domain and reliability\n\n[Empty]\n\nUncertainty\n\n[Empty]\n\n### Any other information on results incl. tables\n\nThe result appears non-reliable as the predicted compound is outside the applicability domain of the model.\n\n### Overall remarks, attachments\n\nOverall remarks\n\n[Not publishable]\n\n### Attachments\n\n#1\n\n[Not publishable]\n\n#2\n\n[Not publishable]\n\n### Applicant's summary and conclusion\n\nConclusions\n\nThe substance is predicted to be carcinogen.\n\nExecutive summary\n\n[Empty]\n\nBack to top",
        "content_length": 7374,
        "status": "success"
      },
      "002 | Key | Experimental study": {
        "document_id": "6b7b1881-cd25-4c60-b8d4-d877fb838b06_d18b246e-13d7-423f-a045-5da4c757759e",
        "markdown_content": "#### Carcinogenicity\n\nJump to\n\nHide empty fields\n\n### Administrative data\n\nConfidentiality\n\n[Not publishable]\n\nJustification\n\n[Not publishable]\n\nUse restricted to selected regulatory programmes\n\n[Not publishable]\n\nEndpoint\n\ncarcinogenicity: oral\n\nType of information\n\nexperimental study\n\nAdequacy of study\n\nkey study\n\nRobust study summary\n\n[Not publishable]\n\nUsed for classification\n\n[Not publishable]\n\nUsed for SDS\n\n[Not publishable]\n\nStudy period: start date\n\n[Empty]\n\nEnd date\n\n[Empty]\n\nRemark\n\n[Empty]\n\nReliability\n\n4 (not assignable)\n\nRationale for reliability incl. deficiencies\n\nsecondary literature\n\nData waiving\n\n[Empty]\n\nJustification for data waiving\n\n[Empty]\n\nJustification for type of information\n\n[Empty]\n\n### Attached justification\n\n### Cross-reference\n\n### Data source\n\nReference\n\n* [Pharmacotoxicological aspects of levosulpiride.](0bba3384-7bf4-4c6d-983d-78a29e387ee6_d18b246e-13d7-423f-a045-5da4c757759e)\n\nData access\n\n[Not publishable]\n\nData protection claimed\n\n[Not publishable]\n\n### Materials and methods\n\n### Test guideline\n\n### #1 - Test guideline\n\nQualifier\n\n[Empty]\n\nGuideline\n\nother:\nnot specified\n\nVersion / remarks\n\n[Empty]\n\nDeviations\n\n[Empty]\n\nPrinciples of method if other than guideline\n\n[Empty]\n\nGLP compliance\n\nnot specified\n\n### Test material\n\nTest material information\n\n[Test material information](4e39367f-bcf9-4a5f-bd70-64ddd6fbf79e_d18b246e-13d7-423f-a045-5da4c757759e)\n\nAdditional test material information\n\n[Empty]\n\nSpecific details on test material used for the study\n\n[Empty]\n\nSpecific details on test material used for the study (confidential)\n\n[Not publishable]\n\n### Test animals\n\nSpecies\n\n[Empty]\n\nStrain\n\n[Empty]\n\nDetails on species / strain selection\n\n[Empty]\n\nSex\n\n[Empty]\n\nDetails on test animals or test system and environmental conditions\n\n[Empty]\n\n### Administration / exposure\n\nRoute of administration\n\n[Empty]\n\nType of inhalation exposure (if applicable)\n\n[Empty]\n\nVehicle\n\n[Empty]\n\nMass median aerodynamic diameter (MMAD)\n\n[Empty]\n\nGeometric standard deviation (GSD)\n\n[Empty]\n\nRemarks on MMAD\n\n[Empty]\n\nDetails on exposure\n\n[Empty]\n\nAnalytical verification of doses or concentrations\n\n[Empty]\n\nDetails on analytical verification of doses or concentrations\n\n[Empty]\n\nDuration of treatment / exposure\n\n[Empty]\n\nFrequency of treatment\n\n[Empty]\n\nPost exposure period\n\n[Empty]\n\n### Doses / concentrations\n\nNo. of animals per sex per dose\n\n[Empty]\n\nControl animals\n\n[Empty]\n\nDetails on study design\n\n[Empty]\n\nPositive control\n\n[Empty]\n\nHigh dose level used\n\n[Empty]\n\nJustification for deviation from the high dose level\n\n[Not publishable]\n\n### Examinations\n\nObservations and examinations performed and frequency\n\n[Empty]\n\nSacrifice and pathology\n\n[Empty]\n\nOther examinations\n\n[Empty]\n\nStatistics\n\n[Empty]\n\n### Model and software\n\nModel name and version\n\n[Empty]\n\nSoftware name and version\n\n[Empty]\n\nRemarks\n\n[Not publishable]\n\n### Any other information on materials and methods incl. tables\n\n[Not publishable]\n\n### Results and discussion\n\n### Results of examinations\n\nClinical signs\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nDermal irritation (if dermal study)\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nMortality\n\n[Empty]\n\nDescription (incidence)\n\n[Empty]\n\nBody weight and weight changes\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nFood consumption and compound intake (if feeding study)\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nFood efficiency\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nWater consumption and compound intake (if drinking water study)\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nOphthalmological findings\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nHaematological findings\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nClinical biochemistry findings\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nEndocrine findings\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nUrinalysis findings\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nBehaviour (functional findings)\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nImmunological findings\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nOrgan weight findings including organ / body weight ratios\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nGross pathological findings\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nNeuropathological findings\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nHistopathological findings: non-neoplastic\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nHistopathological findings: neoplastic\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nOther effects\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nDetails on results\n\n[Empty]\n\nRelevance of carcinogenic effects / potential\n\n[Empty]\n\n### Effect levels\n\n### Target system / organ toxicity\n\n### Additional information about applicability domain and reliability of (Q)SAR predictions\n\nFit with the applicability domain\n\n[Empty]\n\nJustification for the fit with the applicability domain\n\n[Empty]\n\nFit with the space defined by the training set of the model\n\n[Empty]\n\nMechanistic and metabolic considerations\n\n[Empty]\n\n### Similar substances with experimental data\n\nPerformance of the model for similar substances\n\n[Empty]\n\nConclusions on applicability domain and reliability\n\n[Empty]\n\nUncertainty\n\n[Empty]\n\n### Any other information on results incl. tables\n\nThe oncogenic/carcinogenic toxicity of levosulpiride was tested in 600 Wistar rats and NMRI mice by long-term oral administration. 200 further rats and 200 further mice served as controls. Levosulpiride was given over 104 weeks in rats and 100 weeks in mice in daily dosage of 12.5, 25.0 and 50.0 mg/kg/day in the food. The control rats and mice remained untreated. The final mortality was significantly higher, in respect to controls, in rats and mice treated with levosulpiride at the dose of 50.0 mg/kg/day and it was similar or identic to controls in the groups treated with levosulpiride at doses of 12.5 and 25.0 mg/kg/day. The researches in rats showed that the lowest and medium tested dosage of levosulpiride (12.5 and 25.0 mg/kg/day in the food) were in the range of the estimated good tolerated doses and did not influence the behaviour, the external appearance, the faeces, the mortality, the food and drinking water consumption, the haematological and urinary profiles, the body weight development, the weight of examinated organs, sight, hearing, dentition and the number of palpable masses. The highest dose of levosulpiride (50.0 mg/kg/day in the food) did not modify the behaviour, the external appearance, faeces, the drinking water consumption, the haematological and urinary profiles, sight, hearing, dentition or the number of palpable masses, but it induced a significant decrease of food consumption, of body weight development and organ weights, and a significant increase in SGOT and SGPT. Moreover, in rats of both sexes treated with levosulpiride at all tested doses a significant increase of plasma prolactin and a moderate increase of corticosterone and aldosterone were shown. Macroscopically and microscopically there were no signs of oncogenic properties with all the doses of levosulpiride tested. At histopathologic examinations benign neoplasms of skin (epithelial and connectival turnours), soft tissues (lipomas, angiomas, leiomiomas), thyroid gland (follicular adenomas), ovaries (thecagranulosa cell tumours), liver (adenomas) and adrenal medulla (phaeochromocytomas) were observed. Microscopic alterations of liver were observed only with the highest dose of levosulpiride (50.0 mg/kg/day). With levosulpiride at all doses tested microscopic aspect of hyperactivity of mammary and pituitary glands has been observed. Moreover, in control and treated rats of both sexes aspecific alterations of lungs, kidneys, heart, spleen and liver were documented. Similar results dropped out from the trials on mice by using the same doses of levosulpiride (12.5, 25.0 and 50.0 mg/kg/day in the food).\n\n### Overall remarks, attachments\n\nOverall remarks\n\n[Not publishable]\n\n### Attachments\n\n### Applicant's summary and conclusion\n\nConclusions\n\nLevosulpiride was not found to be carcinogen in both rats and mice.\n\nExecutive summary\n\nThe oncogenic/carcinogenic toxicity of levosulpiride was tested in 600 Wistar rats and NMRI mice by long-term oral administration. 200 further rats and 200 further mice served as controls. Levosulpiride was given over 104 weeks in rats and 100 weeks in mice in daily dosage of 12.5, 25.0 and 50.0 mg/kg/day in the food. The control rats and mice remained untreated. The final mortality was significantly higher, in respect to controls, in rats and mice treated with levosulpiride at the dose of 50.0 mg/kg/day and it was similar or identic to controls in the groups treated with levosulpiride at doses of 12.5 and 25.0 mg/kg/day. The researches in rats showed that the lowest and medium tested dosage of levosulpiride (12.5 and 25.0 mg/kg/day in the food) were in the range of the estimated good tolerated doses and did not influence the behaviour, the external appearance, the faeces, the mortality, the food and drinking water consumption, the haematological and urinary profiles, the body weight development, the weight of examinated organs, sight, hearing, dentition and the number of palpable masses. The highest dose of levosulpiride (50.0 mg/kg/day in the food) did not modify the behaviour, the external appearance, faeces, the drinking water consumption, the haematological and urinary profiles, sight, hearing, dentition or the number of palpable masses, but it induced a significant decrease of food consumption, of body weight development and organ weights, and a significant increase in SGOT and SGPT. Moreover, in rats of both sexes treated with levosulpiride at all tested doses a significant increase of plasma prolactin and a moderate increase of corticosterone and aldosterone were shown. Macroscopically and microscopically there were no signs of oncogenic properties with all the doses of levosulpiride tested. At histopathologic examinations benign neoplasms of skin (epithelial and connectival turnours), soft tissues (lipomas, angiomas, leiomiomas), thyroid gland (follicular adenomas), ovaries (thecagranulosa cell tumours), liver (adenomas) and adrenal medulla (phaeochromocytomas) were observed. Microscopic alterations of liver were observed only with the highest dose of levosulpiride (50.0 mg/kg/day). With levosulpiride at all doses tested microscopic aspect of hyperactivity of mammary and pituitary glands has been observed. Moreover, in control and treated rats of both sexes aspecific alterations of lungs, kidneys, heart, spleen and liver were documented. Similar results dropped out from the trials on mice by using the same doses of levosulpiride (12.5, 25.0 and 50.0 mg/kg/day in the food).\n\nBack to top",
        "content_length": 10962,
        "status": "success"
      },
      "003 | Disregarded | (Q)SAR": {
        "document_id": "cd18e84b-7648-4760-a458-b29c4a2c689a_d18b246e-13d7-423f-a045-5da4c757759e",
        "markdown_content": "#### Carcinogenicity\n\nJump to\n\nHide empty fields\n\n### Administrative data\n\nConfidentiality\n\n[Not publishable]\n\nJustification\n\n[Not publishable]\n\nUse restricted to selected regulatory programmes\n\n[Not publishable]\n\nEndpoint\n\ncarcinogenicity: oral\n\nType of information\n\n(Q)SAR\n\nAdequacy of study\n\ndisregarded due to major methodological deficiencies\n\nRobust study summary\n\n[Not publishable]\n\nUsed for classification\n\n[Not publishable]\n\nUsed for SDS\n\n[Not publishable]\n\nStudy period: start date\n\n[Empty]\n\nEnd date\n\n[Empty]\n\nRemark\n\n[Empty]\n\nReliability\n\n3 (not reliable)\n\nRationale for reliability incl. deficiencies\n\nresults derived from a valid (Q)SAR model, but not (completely) falling into its applicability domain, and documentation / justification is limited\n\nData waiving\n\n[Empty]\n\nJustification for data waiving\n\n[Empty]\n\nJustification for type of information\n\n[Empty]\n\n### Attached justification\n\n### Cross-reference\n\n### Data source\n\nReference\n\n* [Carcinogenicity model (CAESAR) 2.1.9](9731e758-4cca-42f5-b3cd-a9a59ebb3539_d18b246e-13d7-423f-a045-5da4c757759e)\n\nData access\n\n[Not publishable]\n\nData protection claimed\n\n[Not publishable]\n\n### Materials and methods\n\n### Test guideline\n\n### #1 - Test guideline\n\nQualifier\n\nequivalent or similar to guideline\n\nGuideline\n\nother:\nECHA guidance on information requirements and chemical safety assessment Chapter R.6: QSARs and grouping of chemicals.\n\nVersion / remarks\n\n[Empty]\n\nDeviations\n\n[Empty]\n\nPrinciples of method if other than guideline\n\n[Empty]\n\nGLP compliance\n\n[Empty]\n\n### Test material\n\nTest material information\n\n[Test material information](58f5f39d-02e9-43fd-bfb1-bb2cde8000ff_d18b246e-13d7-423f-a045-5da4c757759e)\n\nAdditional test material information\n\n[Empty]\n\nSpecific details on test material used for the study\n\nThis endpoint has been predicted by a QSAR model for sulpiride (instead of sulpiride HCl) as salts are not included in the applicability domain of QSAR models. Sulpiride and sulpiride HCl are expected to be similar for this endpoint.\n\nSpecific details on test material used for the study (confidential)\n\n[Not publishable]\n\n### Test animals\n\nSpecies\n\n[Empty]\n\nStrain\n\n[Empty]\n\nDetails on species / strain selection\n\n[Empty]\n\nSex\n\n[Empty]\n\nDetails on test animals or test system and environmental conditions\n\n[Empty]\n\n### Administration / exposure\n\nRoute of administration\n\n[Empty]\n\nType of inhalation exposure (if applicable)\n\n[Empty]\n\nVehicle\n\n[Empty]\n\nMass median aerodynamic diameter (MMAD)\n\n[Empty]\n\nGeometric standard deviation (GSD)\n\n[Empty]\n\nRemarks on MMAD\n\n[Empty]\n\nDetails on exposure\n\n[Empty]\n\nAnalytical verification of doses or concentrations\n\n[Empty]\n\nDetails on analytical verification of doses or concentrations\n\n[Empty]\n\nDuration of treatment / exposure\n\n[Empty]\n\nFrequency of treatment\n\n[Empty]\n\nPost exposure period\n\n[Empty]\n\n### Doses / concentrations\n\nNo. of animals per sex per dose\n\n[Empty]\n\nControl animals\n\n[Empty]\n\nDetails on study design\n\n[Empty]\n\nPositive control\n\n[Empty]\n\nHigh dose level used\n\n[Empty]\n\nJustification for deviation from the high dose level\n\n[Not publishable]\n\n### Examinations\n\nObservations and examinations performed and frequency\n\n[Empty]\n\nSacrifice and pathology\n\n[Empty]\n\nOther examinations\n\n[Empty]\n\nStatistics\n\nThe applicability domain of predictions is assessed using an Applicability Domain Index (ADI) that has values from 0 (worst case) to 1 (best case). The ADI is calculated by grouping several other indices, each one taking into account a particular issue of the applicability domain. Most of the indices are based on the calculation of the most similar compounds found in the training and test set of the model, calculated by a similarity index that consider molecule's fingerprint and structural aspects (count of atoms, rings and relevant fragments).\nFor each index, including the final ADI, three intervals for its values are defined, such that the first interval corresponds to a positive evaluation, the second one corresponds to a suspicious evaluation and the last one corresponds to a negative evaluation.\nList of indices:\n- Similar molecules with known experimental value.\n- Accuracy of prediction for similar molecules.\n- Concordance for similar molecules.\n- Atom Centered Fragments similarity check.\n- Model assignment reliability.\n- Neural map neurons concordance.\n- Model descriptors range check.\n- Global AD Index.\n\n### Model and software\n\nModel name and version\n\n[Empty]\n\nSoftware name and version\n\n[Empty]\n\nRemarks\n\n[Not publishable]\n\n### Any other information on materials and methods incl. tables\n\n[Not publishable]\n\n### Results and discussion\n\n### Results of examinations\n\nClinical signs\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nDermal irritation (if dermal study)\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nMortality\n\n[Empty]\n\nDescription (incidence)\n\n[Empty]\n\nBody weight and weight changes\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nFood consumption and compound intake (if feeding study)\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nFood efficiency\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nWater consumption and compound intake (if drinking water study)\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nOphthalmological findings\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nHaematological findings\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nClinical biochemistry findings\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nEndocrine findings\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nUrinalysis findings\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nBehaviour (functional findings)\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nImmunological findings\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nOrgan weight findings including organ / body weight ratios\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nGross pathological findings\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nNeuropathological findings\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nHistopathological findings: non-neoplastic\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nHistopathological findings: neoplastic\n\n[Empty]\n\nDescription (incidence and severity)\n\nCarcinogen.\n\nOther effects\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nDetails on results\n\n[Empty]\n\nRelevance of carcinogenic effects / potential\n\n[Empty]\n\n### Effect levels\n\n### Target system / organ toxicity\n\n### Additional information about applicability domain and reliability of (Q)SAR predictions\n\nFit with the applicability domain\n\n[Empty]\n\nJustification for the fit with the applicability domain\n\n[Empty]\n\nFit with the space defined by the training set of the model\n\n[Empty]\n\nMechanistic and metabolic considerations\n\n[Empty]\n\n### Similar substances with experimental data\n\nPerformance of the model for similar substances\n\n[Empty]\n\nConclusions on applicability domain and reliability\n\n[Empty]\n\nUncertainty\n\n[Empty]\n\n### Any other information on results incl. tables\n\nThe result appears non-reliable as the predicted compound is outside the applicability domain of the model.\n\n### Overall remarks, attachments\n\nOverall remarks\n\n[Not publishable]\n\n### Attachments\n\n#1\n\n[Not publishable]\n\n#2\n\n[Not publishable]\n\n### Applicant's summary and conclusion\n\nConclusions\n\nThe substance is predicted to be carcinogen.\n\nExecutive summary\n\n[Empty]\n\nBack to top",
        "content_length": 7463,
        "status": "success"
      },
      "004 | Disregarded | (Q)SAR": {
        "document_id": "2be0382d-2ed5-4389-bfa3-8b9b1535cf5a_d18b246e-13d7-423f-a045-5da4c757759e",
        "markdown_content": "#### Carcinogenicity\n\nJump to\n\nHide empty fields\n\n### Administrative data\n\nConfidentiality\n\n[Not publishable]\n\nJustification\n\n[Not publishable]\n\nUse restricted to selected regulatory programmes\n\n[Not publishable]\n\nEndpoint\n\ncarcinogenicity: oral\n\nType of information\n\n(Q)SAR\n\nAdequacy of study\n\ndisregarded due to major methodological deficiencies\n\nRobust study summary\n\n[Not publishable]\n\nUsed for classification\n\n[Not publishable]\n\nUsed for SDS\n\n[Not publishable]\n\nStudy period: start date\n\n[Empty]\n\nEnd date\n\n[Empty]\n\nRemark\n\n[Empty]\n\nReliability\n\n3 (not reliable)\n\nRationale for reliability incl. deficiencies\n\nresults derived from a valid (Q)SAR model, but not (completely) falling into its applicability domain, and documentation / justification is limited\n\nData waiving\n\n[Empty]\n\nJustification for data waiving\n\n[Empty]\n\nJustification for type of information\n\n[Empty]\n\n### Attached justification\n\n### Cross-reference\n\n### Data source\n\nReference\n\n* [Carcinogenicity model (ISS) 1.0.2](e9ef80df-6702-48a4-8231-18d1289ff52b_d18b246e-13d7-423f-a045-5da4c757759e)\n\nData access\n\n[Not publishable]\n\nData protection claimed\n\n[Not publishable]\n\n### Materials and methods\n\n### Test guideline\n\n### #1 - Test guideline\n\nQualifier\n\nequivalent or similar to guideline\n\nGuideline\n\nother:\nECHA guidance on information requirements and chemical safety assessment Chapter R.6: QSARs and grouping of chemicals.\n\nVersion / remarks\n\n[Empty]\n\nDeviations\n\n[Empty]\n\nPrinciples of method if other than guideline\n\n[Empty]\n\nGLP compliance\n\n[Empty]\n\n### Test material\n\nTest material information\n\n[Test material information](58f5f39d-02e9-43fd-bfb1-bb2cde8000ff_d18b246e-13d7-423f-a045-5da4c757759e)\n\nAdditional test material information\n\n[Empty]\n\nSpecific details on test material used for the study\n\nThis endpoint has been predicted by a QSAR model for sulpiride (instead of sulpiride HCl) as salts are not included in the applicability domain of QSAR models. Sulpiride and sulpiride HCl are expected to be similar for this endpoint.\n\nSpecific details on test material used for the study (confidential)\n\n[Not publishable]\n\n### Test animals\n\nSpecies\n\n[Empty]\n\nStrain\n\n[Empty]\n\nDetails on species / strain selection\n\n[Empty]\n\nSex\n\n[Empty]\n\nDetails on test animals or test system and environmental conditions\n\n[Empty]\n\n### Administration / exposure\n\nRoute of administration\n\n[Empty]\n\nType of inhalation exposure (if applicable)\n\n[Empty]\n\nVehicle\n\n[Empty]\n\nMass median aerodynamic diameter (MMAD)\n\n[Empty]\n\nGeometric standard deviation (GSD)\n\n[Empty]\n\nRemarks on MMAD\n\n[Empty]\n\nDetails on exposure\n\n[Empty]\n\nAnalytical verification of doses or concentrations\n\n[Empty]\n\nDetails on analytical verification of doses or concentrations\n\n[Empty]\n\nDuration of treatment / exposure\n\n[Empty]\n\nFrequency of treatment\n\n[Empty]\n\nPost exposure period\n\n[Empty]\n\n### Doses / concentrations\n\nNo. of animals per sex per dose\n\n[Empty]\n\nControl animals\n\n[Empty]\n\nDetails on study design\n\n[Empty]\n\nPositive control\n\n[Empty]\n\nHigh dose level used\n\n[Empty]\n\nJustification for deviation from the high dose level\n\n[Not publishable]\n\n### Examinations\n\nObservations and examinations performed and frequency\n\n[Empty]\n\nSacrifice and pathology\n\n[Empty]\n\nOther examinations\n\n[Empty]\n\nStatistics\n\nThe applicability domain of predictions is assessed using an Applicability Domain Index (ADI) that has values from 0 (worst case) to 1 (best case). The ADI is calculated by grouping several other indices, each one taking into account a particular issue of the applicability domain. Most of the indices are based on the calculation of the most similar compounds found in the training and test set of the model, calculated by a similarity index that consider molecule's fingerprint and structural aspects (count of atoms, rings and relevant fragments).\nFor each index, including the final ADI, three intervals for its values are defined, such that the first interval corresponds to a positive evaluation, the second one corresponds to a suspicious evaluation and the last one corresponds to a negative evaluation.\nList of indices:\n- Similar molecules with known experimental value.\n- Accuracy of prediction for similar molecules.\n- Concordance for similar molecules.\n- Global AD Index.\n\n### Model and software\n\nModel name and version\n\n[Empty]\n\nSoftware name and version\n\n[Empty]\n\nRemarks\n\n[Not publishable]\n\n### Any other information on materials and methods incl. tables\n\n[Not publishable]\n\n### Results and discussion\n\n### Results of examinations\n\nClinical signs\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nDermal irritation (if dermal study)\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nMortality\n\n[Empty]\n\nDescription (incidence)\n\n[Empty]\n\nBody weight and weight changes\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nFood consumption and compound intake (if feeding study)\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nFood efficiency\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nWater consumption and compound intake (if drinking water study)\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nOphthalmological findings\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nHaematological findings\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nClinical biochemistry findings\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nEndocrine findings\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nUrinalysis findings\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nBehaviour (functional findings)\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nImmunological findings\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nOrgan weight findings including organ / body weight ratios\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nGross pathological findings\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nNeuropathological findings\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nHistopathological findings: non-neoplastic\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nHistopathological findings: neoplastic\n\n[Empty]\n\nDescription (incidence and severity)\n\nNON-Carcinogen.\n\nOther effects\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nDetails on results\n\n[Empty]\n\nRelevance of carcinogenic effects / potential\n\n[Empty]\n\n### Effect levels\n\n### Target system / organ toxicity\n\n### Additional information about applicability domain and reliability of (Q)SAR predictions\n\nFit with the applicability domain\n\n[Empty]\n\nJustification for the fit with the applicability domain\n\n[Empty]\n\nFit with the space defined by the training set of the model\n\n[Empty]\n\nMechanistic and metabolic considerations\n\n[Empty]\n\n### Similar substances with experimental data\n\nPerformance of the model for similar substances\n\n[Empty]\n\nConclusions on applicability domain and reliability\n\n[Empty]\n\nUncertainty\n\n[Empty]\n\n### Any other information on results incl. tables\n\nThe result appears non-reliable as the predicted compound is outside the applicability domain of the model.\n\n### Overall remarks, attachments\n\nOverall remarks\n\n[Not publishable]\n\n### Attachments\n\n#1\n\n[Not publishable]\n\n#2\n\n[Not publishable]\n\n### Applicant's summary and conclusion\n\nConclusions\n\nThe substance is predicted to be non-carcinogen.\n\nExecutive summary\n\n[Empty]\n\nBack to top",
        "content_length": 7325,
        "status": "success"
      },
      "005 | Disregarded | (Q)SAR": {
        "document_id": "9dda2ab8-eafc-41a0-bed0-51bcdc289b9b_d18b246e-13d7-423f-a045-5da4c757759e",
        "markdown_content": "#### Carcinogenicity\n\nJump to\n\nHide empty fields\n\n### Administrative data\n\nConfidentiality\n\n[Not publishable]\n\nJustification\n\n[Not publishable]\n\nUse restricted to selected regulatory programmes\n\n[Not publishable]\n\nEndpoint\n\ncarcinogenicity: oral\n\nType of information\n\n(Q)SAR\n\nAdequacy of study\n\ndisregarded due to major methodological deficiencies\n\nRobust study summary\n\n[Not publishable]\n\nUsed for classification\n\n[Not publishable]\n\nUsed for SDS\n\n[Not publishable]\n\nStudy period: start date\n\n[Empty]\n\nEnd date\n\n[Empty]\n\nRemark\n\n[Empty]\n\nReliability\n\n3 (not reliable)\n\nRationale for reliability incl. deficiencies\n\nresults derived from a valid (Q)SAR model, but not (completely) falling into its applicability domain, and documentation / justification is limited\n\nData waiving\n\n[Empty]\n\nJustification for data waiving\n\n[Empty]\n\nJustification for type of information\n\n[Empty]\n\n### Attached justification\n\n### Cross-reference\n\n### Data source\n\nReference\n\n* [Carcinogenicity model (IRFMN/Antares) 1.0.0](4ec570c6-44dc-4afd-8941-73b41bf5faac_d18b246e-13d7-423f-a045-5da4c757759e)\n\nData access\n\n[Not publishable]\n\nData protection claimed\n\n[Not publishable]\n\n### Materials and methods\n\n### Test guideline\n\n### #1 - Test guideline\n\nQualifier\n\nequivalent or similar to guideline\n\nGuideline\n\nother:\nECHA guidance on information requirements and chemical safety assessment Chapter R.6: QSARs and grouping of chemicals.\n\nVersion / remarks\n\n[Empty]\n\nDeviations\n\n[Empty]\n\nPrinciples of method if other than guideline\n\n[Empty]\n\nGLP compliance\n\n[Empty]\n\n### Test material\n\nTest material information\n\n[Test material information](58f5f39d-02e9-43fd-bfb1-bb2cde8000ff_d18b246e-13d7-423f-a045-5da4c757759e)\n\nAdditional test material information\n\n[Empty]\n\nSpecific details on test material used for the study\n\nThis endpoint has been predicted by a QSAR model for sulpiride (instead of sulpiride HCl) as salts are not included in the applicability domain of QSAR models. Sulpiride and sulpiride HCl are expected to be similar for this endpoint.\n\nSpecific details on test material used for the study (confidential)\n\n[Not publishable]\n\n### Test animals\n\nSpecies\n\n[Empty]\n\nStrain\n\n[Empty]\n\nDetails on species / strain selection\n\n[Empty]\n\nSex\n\n[Empty]\n\nDetails on test animals or test system and environmental conditions\n\n[Empty]\n\n### Administration / exposure\n\nRoute of administration\n\n[Empty]\n\nType of inhalation exposure (if applicable)\n\n[Empty]\n\nVehicle\n\n[Empty]\n\nMass median aerodynamic diameter (MMAD)\n\n[Empty]\n\nGeometric standard deviation (GSD)\n\n[Empty]\n\nRemarks on MMAD\n\n[Empty]\n\nDetails on exposure\n\n[Empty]\n\nAnalytical verification of doses or concentrations\n\n[Empty]\n\nDetails on analytical verification of doses or concentrations\n\n[Empty]\n\nDuration of treatment / exposure\n\n[Empty]\n\nFrequency of treatment\n\n[Empty]\n\nPost exposure period\n\n[Empty]\n\n### Doses / concentrations\n\nNo. of animals per sex per dose\n\n[Empty]\n\nControl animals\n\n[Empty]\n\nDetails on study design\n\n[Empty]\n\nPositive control\n\n[Empty]\n\nHigh dose level used\n\n[Empty]\n\nJustification for deviation from the high dose level\n\n[Not publishable]\n\n### Examinations\n\nObservations and examinations performed and frequency\n\n[Empty]\n\nSacrifice and pathology\n\n[Empty]\n\nOther examinations\n\n[Empty]\n\nStatistics\n\nThe applicability domain of predictions is assessed using an Applicability Domain Index (ADI) that has values from 0 (worst case) to 1 (best case). The ADI is calculated by grouping several other indices, each one taking into account a particular issue of the applicability domain. Most of the indices are based on the calculation of the most similar compounds found in the training and test set of the model, calculated by a similarity index that consider molecule's fingerprint and structural aspects (count of atoms, rings and relevant fragments).\nFor each index, including the final ADI, three intervals for its values are defined, such that the first interval corresponds to a positive evaluation, the second one corresponds to a suspicious evaluation and the last one corresponds to a negative evaluation.\nList of indices:\n- Similar molecules with known experimental value.\n- Accuracy of prediction for similar molecules.\n- Concordance for similar molecules.\n- Atom Centered Fragments similarity check.\n- Global AD Index.\n\n### Model and software\n\nModel name and version\n\n[Empty]\n\nSoftware name and version\n\n[Empty]\n\nRemarks\n\n[Not publishable]\n\n### Any other information on materials and methods incl. tables\n\n[Not publishable]\n\n### Results and discussion\n\n### Results of examinations\n\nClinical signs\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nDermal irritation (if dermal study)\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nMortality\n\n[Empty]\n\nDescription (incidence)\n\n[Empty]\n\nBody weight and weight changes\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nFood consumption and compound intake (if feeding study)\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nFood efficiency\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nWater consumption and compound intake (if drinking water study)\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nOphthalmological findings\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nHaematological findings\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nClinical biochemistry findings\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nEndocrine findings\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nUrinalysis findings\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nBehaviour (functional findings)\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nImmunological findings\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nOrgan weight findings including organ / body weight ratios\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nGross pathological findings\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nNeuropathological findings\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nHistopathological findings: non-neoplastic\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nHistopathological findings: neoplastic\n\n[Empty]\n\nDescription (incidence and severity)\n\nPossible NON-Carcinogen.\n\nOther effects\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nDetails on results\n\n[Empty]\n\nRelevance of carcinogenic effects / potential\n\n[Empty]\n\n### Effect levels\n\n### Target system / organ toxicity\n\n### Additional information about applicability domain and reliability of (Q)SAR predictions\n\nFit with the applicability domain\n\n[Empty]\n\nJustification for the fit with the applicability domain\n\n[Empty]\n\nFit with the space defined by the training set of the model\n\n[Empty]\n\nMechanistic and metabolic considerations\n\n[Empty]\n\n### Similar substances with experimental data\n\nPerformance of the model for similar substances\n\n[Empty]\n\nConclusions on applicability domain and reliability\n\n[Empty]\n\nUncertainty\n\n[Empty]\n\n### Any other information on results incl. tables\n\nThe result appears non-reliable as the predicted compound is outside the applicability domain of the model.\n\n### Overall remarks, attachments\n\nOverall remarks\n\n[Not publishable]\n\n### Attachments\n\n#1\n\n[Not publishable]\n\n#2\n\n[Not publishable]\n\n### Applicant's summary and conclusion\n\nConclusions\n\nThe substance is predicted to be possible non-carcinogen.\n\nExecutive summary\n\n[Empty]\n\nBack to top",
        "content_length": 7397,
        "status": "success"
      }
    },
    "7.8 Toxicity to reproduction": {
      "7.8.1 Toxicity to reproduction": {
        "001 | Other | Experimental study": {
          "document_id": "b86001bf-a7d4-42f6-9451-7c8a508e4e7c_d18b246e-13d7-423f-a045-5da4c757759e",
          "markdown_content": "#### Toxicity to reproduction\n\nJump to\n\nHide empty fields\n\n### Administrative data\n\nConfidentiality\n\n[Not publishable]\n\nJustification\n\n[Not publishable]\n\nUse restricted to selected regulatory programmes\n\n[Not publishable]\n\nEndpoint\n\nscreening for reproductive / developmental toxicity\n\nType of information\n\nexperimental study\n\nAdequacy of study\n\nother information\n\nRobust study summary\n\n[Not publishable]\n\nUsed for classification\n\n[Not publishable]\n\nUsed for SDS\n\n[Not publishable]\n\nStudy period: start date\n\n[Empty]\n\nEnd date\n\n[Empty]\n\nRemark\n\n[Empty]\n\nReliability\n\n4 (not assignable)\n\nRationale for reliability incl. deficiencies\n\nsecondary literature\n\nData waiving\n\n[Empty]\n\nJustification for data waiving\n\n[Empty]\n\nJustification for type of information\n\n[Empty]\n\n### Attached justification\n\n### Cross-reference\n\n### Data source\n\nReference\n\n* [Pharmacotoxicological aspects of levosulpiride.](0bba3384-7bf4-4c6d-983d-78a29e387ee6_d18b246e-13d7-423f-a045-5da4c757759e)\n\nData access\n\n[Not publishable]\n\nData protection claimed\n\n[Not publishable]\n\n### Materials and methods\n\n### Test guideline\n\n### #1 - Test guideline\n\nQualifier\n\n[Empty]\n\nGuideline\n\nother:\nnot specified\n\nVersion / remarks\n\n[Empty]\n\nDeviations\n\n[Empty]\n\nPrinciples of method if other than guideline\n\n[Empty]\n\nGLP compliance\n\nnot specified\n\nLimit test\n\n[Empty]\n\nJustification for study design\n\n[Empty]\n\n### Test material\n\nTest material information\n\n[Test material information](4e39367f-bcf9-4a5f-bd70-64ddd6fbf79e_d18b246e-13d7-423f-a045-5da4c757759e)\n\nAdditional test material information\n\n[Empty]\n\nSpecific details on test material used for the study\n\n[Empty]\n\nSpecific details on test material used for the study (confidential)\n\n[Not publishable]\n\n### Test animals\n\nSpecies\n\n[Empty]\n\nStrain\n\n[Empty]\n\nDetails on species / strain selection\n\n[Empty]\n\nSex\n\n[Empty]\n\nDetails on test animals or test system and environmental conditions\n\n[Empty]\n\n### Administration / exposure\n\nRoute of administration\n\n[Empty]\n\nType of inhalation exposure (if applicable)\n\n[Empty]\n\nMass median aerodynamic diameter (MMAD)\n\n[Empty]\n\nGeometric standard deviation (GSD)\n\n[Empty]\n\nRemarks on MMAD\n\n[Empty]\n\nVehicle\n\n[Empty]\n\nDetails on exposure\n\n[Empty]\n\nDetails on mating procedure\n\n[Empty]\n\nAnalytical verification of doses or concentrations\n\n[Empty]\n\nDetails on analytical verification of doses or concentrations\n\n[Empty]\n\nDuration of treatment / exposure\n\n[Empty]\n\nFrequency of treatment\n\n[Empty]\n\nDetails on study schedule\n\n[Empty]\n\n### Doses / concentrations\n\nNo. of animals per sex per dose\n\n[Empty]\n\nControl animals\n\n[Empty]\n\nDetails on study design\n\n[Empty]\n\nPositive control\n\n[Empty]\n\nHigh dose level used\n\n[Empty]\n\nJustification for deviation from the high dose level\n\n[Not publishable]\n\n### Examinations\n\nParental animals: Observations and examinations\n\n[Empty]\n\nOestrous cyclicity (parental animals)\n\n[Empty]\n\nSperm parameters (parental animals)\n\n[Empty]\n\nLitter observations\n\n[Empty]\n\nPostmortem examinations (parental animals)\n\n[Empty]\n\nPostmortem examinations (offspring)\n\n[Empty]\n\nStatistics\n\n[Empty]\n\nReproductive indices\n\n[Empty]\n\nOffspring viability indices\n\n[Empty]\n\n### Model and software\n\nModel name and version\n\n[Empty]\n\nSoftware name and version\n\n[Empty]\n\nRemarks\n\n[Not publishable]\n\n### Any other information on materials and methods incl. tables\n\n[Not publishable]\n\n### Results and discussion\n\n### Results: P0 (first parental generation)\n\n### General toxicity (P0)\n\nClinical signs\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nDermal irritation (if dermal study)\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nMortality\n\n[Empty]\n\nDescription (incidence)\n\n[Empty]\n\nBody weight and weight changes\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nFood consumption and compound intake (if feeding study)\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nFood efficiency\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nWater consumption and compound intake (if drinking water study)\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nOphthalmological findings\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nHaematological findings\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nClinical biochemistry findings\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nEndocrine findings\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nUrinalysis findings\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nBehaviour (functional findings)\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nImmunological findings\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Not publishable]\n\nOrgan weight findings including organ / body weight ratios\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Not publishable]\n\nGross pathological findings\n\n[Not publishable]\n\nDescription (incidence and severity)\n\n[Not publishable]\n\nNeuropathological findings\n\n[Not publishable]\n\nDescription (incidence and severity)\n\n[Empty]\n\nHistopathological findings: non-neoplastic\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nHistopathological findings: neoplastic\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nOther effects\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\n### Reproductive function / performance (P0)\n\nReproductive function: oestrous cycle\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nReproductive function: sperm measures\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nReproductive performance\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\n### Details on results (P0)\n\n[Empty]\n\n### Effect levels (P0)\n\n### Target system / organ toxicity (P0)\n\n### Results: P1 (second parental generation)\n\n### General toxicity (P1)\n\nClinical signs\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nDermal irritation (if dermal study)\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nMortality\n\n[Empty]\n\nDescription (incidence)\n\n[Empty]\n\nBody weight and weight changes\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nFood consumption and compound intake (if feeding study)\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nFood efficiency\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nWater consumption and compound intake (if drinking water study)\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nOphthalmological findings\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nHaematological findings\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nClinical biochemistry findings\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nEndocrine findings\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nUrinalysis findings\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nBehaviour (functional findings)\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nImmunological findings\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nOrgan weight findings including organ / body weight ratios\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nGross pathological findings\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nNeuropathological findings\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nHistopathological findings: non-neoplastic\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nHistopathological findings: neoplastic\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nOther effects\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nDetails on results\n\n[Empty]\n\n### Reproductive function / performance (P1)\n\nReproductive function: oestrous cycle\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nReproductive function: sperm measures\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nReproductive performance\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\n### Details on results (P1)\n\n[Empty]\n\n### Effect levels (P1)\n\n### Target system / organ toxicity (P1)\n\n### Results: F1 generation\n\n### General toxicity (F1)\n\nClinical signs\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nDermal irritation (if dermal study)\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nMortality / viability\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nBody weight and weight changes\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nFood consumption and compound intake (if feeding study)\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nFood efficiency\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nWater consumption and compound intake (if drinking water study)\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nOphthalmological findings\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nHaematological findings\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nClinical biochemistry findings\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nUrinalysis findings\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nSexual maturation\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nAnogenital distance (AGD)\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nNipple retention in male pups\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nOrgan weight findings including organ / body weight ratios\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nGross pathological findings\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nHistopathological findings\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nOther effects\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\n### Developmental neurotoxicity (F1)\n\nBehaviour (functional findings)\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\n### Developmental immunotoxicity (F1)\n\nDevelopmental immunotoxicity\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\n### Details on results (F1)\n\n[Empty]\n\n### Effect levels (F1)\n\n### Target system / organ toxicity (F1)\n\n### Results: F2 generation\n\n### General toxicity (F2)\n\nClinical signs\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nDermal irritation (if dermal study)\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nMortality / viability\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nBody weight and weight changes\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nFood consumption and compound intake (if feeding study)\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nFood efficiency\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nWater consumption and compound intake (if drinking water study)\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nOphthalmological findings\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nHaematological findings\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nClinical biochemistry findings\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nUrinalysis findings\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nSexual maturation\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nAnogenital distance (AGD)\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nNipple retention in male pups\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nOrgan weight findings including organ / body weight ratios\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nGross pathological findings\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nHistopathological findings\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nOther effects\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\n### Developmental neurotoxicity (F2)\n\nBehaviour (functional findings)\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\n### Developmental immunotoxicity (F2)\n\nDevelopmental immunotoxicity\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\n### Details on results (F2)\n\n[Empty]\n\n### Effect levels (F2)\n\n### Target system / organ toxicity (F2)\n\n### Overall reproductive toxicity\n\n### Additional information about applicability domain and reliability of (Q)SAR predictions\n\nFit with the applicability domain\n\n[Empty]\n\nJustification for the fit with the applicability domain\n\n[Empty]\n\nFit with the space defined by the training set of the model\n\n[Empty]\n\nMechanistic and metabolic considerations\n\n[Empty]\n\n### Similar substances with experimental data\n\nPerformance of the model for similar substances\n\n[Empty]\n\nConclusions on applicability domain and reliability\n\n[Empty]\n\nUncertainty\n\n[Empty]\n\n### Any other information on results incl. tables\n\nThe oral administration of levosulpiride in rats at 75, 150 or 300 mg/kg/day is without direct effect on fertility, reproduction or organogenesis; more specifically, the administration of levosulpiride before coupling and 13 days after coupling showed that fertility in rats was unchanged, neither time periods nor sequence of gestation modified, newborn vitality was unaffected, no apparent damage to suckling occurred, and either preimplant or post-implant loss remained unchanged. Moreover, in the second generation coming from the zero generation treated with levosulpiride the newborn vitality overlapped with controls. The oral administration of levosulpiride at 10-25 mg/kg/day in rats and 25-50 mg/kg/day in rabbits during organogenesis caused no statistically significant change in weight gain by pregnant animals, in the number of foetal implants, in the number of dead or undeveloped foetuses, and in the weight of foetal offspring from animals treated compared to controls. In addition, some malformations were observed in treated rats and rabbits as well as in controls. Therefore, there is no substantial difference between control groups and treated animals. Teratogenic process in the two tested animal species can be excluded. Levosulpiride administered at dose of 75, 150 or 300 mg/kg/day by oral route in the final period of gestation and during the 21 days of suckling in rats neither changes fertility or gestation indices, nor modify newborn vitality indices. However, all treated groups have suckling indices somewhat lower than controls. The finding does not mean that there is decreased milk production following treatment. On the contrary, there is an increase in production that leads to better nutrition when there are many young and appearance of breast disease (congestion, inflammation) or when the young are few. These findings may be explained by the fact that levosulpiride under the right endocrine conditions and particularly at the end of pregnancy, induces an increase in milk production.\n\n### Overall remarks, attachments\n\nOverall remarks\n\n[Not publishable]\n\n### Attachments\n\n### Applicant's summary and conclusion\n\nConclusions\n\nStudy results show that levosulpiride does not cause any adverse effect to reproduction. An increase of milk production was observed following treatment.\n\nExecutive summary\n\nThe oral administration of levosulpiride in rats at 75, 150 or 300 mg/kg/day is without direct effect on fertility, reproduction or organogenesis; more specifically, the administration of levosulpiride before coupling and 13 days after coupling showed that fertility in rats was unchanged, neither time periods nor sequence of gestation modified, newborn vitality was unaffected, no apparent damage to suckling occurred, and either preimplant or post-implant loss remained unchanged. Moreover, in the second generation coming from the zero generation treated with levosulpiride the newborn vitality overlapped with controls. The oral administration of levosulpiride at 10-25 mg/kg/day in rats and 25-50 mg/kg/day in rabbits during organogenesis caused no statistically significant change in weight gain by pregnant animals, in the number of foetal implants, in the number of dead or undeveloped foetuses, and in the weight of foetal offspring from animals treated compared to controls. In addition, some malformations were observed in treated rats and rabbits as well as in controls. Therefore, there is no substantial difference between control groups and treated animals. Teratogenic process in the two tested animal species can be excluded. Levosulpiride administered at dose of 75, 150 or 300 mg/kg/day by oral route in the final period of gestation and during the 21 days of suckling in rats neither changes fertility or gestation indices, nor modify newborn vitality indices. However, all treated groups have suckling indices somewhat lower than controls. The finding does not mean that there is decreased milk production following treatment. On the contrary, there is an increase in production that leads to better nutrition when there are many young and appearance of breast disease (congestion, inflammation) or when the young are few. These findings may be explained by the fact that levosulpiride under the right endocrine conditions and particularly at the end of pregnancy, induces an increase in milk production.\n\nBack to top",
          "content_length": 16849,
          "status": "success"
        },
        "002 | Other | Experimental study": {
          "document_id": "86aebf25-4247-41d8-89fd-652d3ac6ea81_d18b246e-13d7-423f-a045-5da4c757759e",
          "markdown_content": "#### Toxicity to reproduction\n\nJump to\n\nHide empty fields\n\n### Administrative data\n\nConfidentiality\n\n[Not publishable]\n\nJustification\n\n[Not publishable]\n\nUse restricted to selected regulatory programmes\n\n[Not publishable]\n\nEndpoint\n\nfertility, other\n\nreproductive development of female offspring\n\nType of information\n\nexperimental study\n\nAdequacy of study\n\nother information\n\nRobust study summary\n\n[Not publishable]\n\nUsed for classification\n\n[Not publishable]\n\nUsed for SDS\n\n[Not publishable]\n\nStudy period: start date\n\n[Empty]\n\nEnd date\n\n[Empty]\n\nRemark\n\n[Empty]\n\nReliability\n\n4 (not assignable)\n\nRationale for reliability incl. deficiencies\n\nabstract\n\nData waiving\n\n[Empty]\n\nJustification for data waiving\n\n[Empty]\n\nJustification for type of information\n\n[Empty]\n\n### Attached justification\n\n### Cross-reference\n\n### Data source\n\nReference\n\n* [Effects of maternal exposure to the galactagogue Sulpiride on reproductive parameters in female rats.](4c50a208-7cb6-44f7-a0d5-fb6187c72567_d18b246e-13d7-423f-a045-5da4c757759e)\n\nData access\n\n[Not publishable]\n\nData protection claimed\n\n[Not publishable]\n\n### Materials and methods\n\n### Test guideline\n\n### #1 - Test guideline\n\nQualifier\n\nno guideline followed\n\nGuideline\n\n[Empty]\n\nVersion / remarks\n\n[Empty]\n\nDeviations\n\n[Empty]\n\nPrinciples of method if other than guideline\n\nThe aim of the study was to investigate whether maternal exposure to Sulpiride during lactation could impair reproductive development of female offspring.\n\nGLP compliance\n\nnot specified\n\nLimit test\n\nno\n\nJustification for study design\n\n[Empty]\n\n### Test material\n\nTest material information\n\n[Test material information](58f5f39d-02e9-43fd-bfb1-bb2cde8000ff_d18b246e-13d7-423f-a045-5da4c757759e)\n\nAdditional test material information\n\n[Empty]\n\nSpecific details on test material used for the study\n\nSulpiride and sulpiride HCl are expected to be similar for this endpoint.\n\nSpecific details on test material used for the study (confidential)\n\n[Not publishable]\n\n### Test animals\n\nSpecies\n\nrat\n\nStrain\n\nnot specified\n\nDetails on species / strain selection\n\n[Empty]\n\nSex\n\nfemale\n\nDetails on test animals or test system and environmental conditions\n\n[Empty]\n\n### Administration / exposure\n\nRoute of administration\n\noral: gavage\n\nType of inhalation exposure (if applicable)\n\n[Empty]\n\nMass median aerodynamic diameter (MMAD)\n\n[Empty]\n\nGeometric standard deviation (GSD)\n\n[Empty]\n\nRemarks on MMAD\n\n[Empty]\n\nVehicle\n\nwater\n\nDetails on exposure\n\n[Empty]\n\nDetails on mating procedure\n\n[Empty]\n\nAnalytical verification of doses or concentrations\n\n[Empty]\n\nDetails on analytical verification of doses or concentrations\n\n[Empty]\n\nDuration of treatment / exposure\n\nThe dams were treated throughout the lactation period.\n\nFrequency of treatment\n\nDaily.\n\nDetails on study schedule\n\n[Empty]\n\n### Doses / concentrations\n\n### #1 - Doses / concentrations\n\nDose / conc.\n\n2.5 \nmg/kg bw/day (nominal)\n\nRemarks\n\nSUL 2.5mg group\n\n### #2 - Doses / concentrations\n\nDose / conc.\n\n25 \nmg/kg bw/day (nominal)\n\nRemarks\n\nSUL 25mg group\n\nNo. of animals per sex per dose\n\n[Empty]\n\nControl animals\n\n* yes, concurrent vehicle\n\n  distilled water\n\nDetails on study design\n\n[Empty]\n\nPositive control\n\n[Empty]\n\nHigh dose level used\n\n[Empty]\n\nJustification for deviation from the high dose level\n\n[Not publishable]\n\n### Examinations\n\nParental animals: Observations and examinations\n\n[Empty]\n\nOestrous cyclicity (parental animals)\n\n[Empty]\n\nSperm parameters (parental animals)\n\n[Empty]\n\nLitter observations\n\nDuring early life, body weight, anogenital distance, and vaginal opening were analyzed on the female offspring. In adulthood, estrous cycle, sexual behavior, estrogen levels as well as the weight of the reproductive organs were evaluated.\n\nPostmortem examinations (parental animals)\n\n[Empty]\n\nPostmortem examinations (offspring)\n\n[Empty]\n\nStatistics\n\n[Empty]\n\nReproductive indices\n\n[Empty]\n\nOffspring viability indices\n\n[Empty]\n\n### Model and software\n\nModel name and version\n\n[Empty]\n\nSoftware name and version\n\n[Empty]\n\nRemarks\n\n[Not publishable]\n\n### Any other information on materials and methods incl. tables\n\n[Not publishable]\n\n### Results and discussion\n\n### Results: P0 (first parental generation)\n\n### General toxicity (P0)\n\nClinical signs\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nDermal irritation (if dermal study)\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nMortality\n\n[Empty]\n\nDescription (incidence)\n\n[Empty]\n\nBody weight and weight changes\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nFood consumption and compound intake (if feeding study)\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nFood efficiency\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nWater consumption and compound intake (if drinking water study)\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nOphthalmological findings\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nHaematological findings\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nClinical biochemistry findings\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nEndocrine findings\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nUrinalysis findings\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nBehaviour (functional findings)\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nImmunological findings\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Not publishable]\n\nOrgan weight findings including organ / body weight ratios\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Not publishable]\n\nGross pathological findings\n\n[Not publishable]\n\nDescription (incidence and severity)\n\n[Not publishable]\n\nNeuropathological findings\n\n[Not publishable]\n\nDescription (incidence and severity)\n\n[Empty]\n\nHistopathological findings: non-neoplastic\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nHistopathological findings: neoplastic\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nOther effects\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\n### Reproductive function / performance (P0)\n\nReproductive function: oestrous cycle\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nReproductive function: sperm measures\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nReproductive performance\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\n### Details on results (P0)\n\n[Empty]\n\n### Effect levels (P0)\n\n### Target system / organ toxicity (P0)\n\n### Results: P1 (second parental generation)\n\n### General toxicity (P1)\n\nClinical signs\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nDermal irritation (if dermal study)\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nMortality\n\n[Empty]\n\nDescription (incidence)\n\n[Empty]\n\nBody weight and weight changes\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nFood consumption and compound intake (if feeding study)\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nFood efficiency\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nWater consumption and compound intake (if drinking water study)\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nOphthalmological findings\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nHaematological findings\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nClinical biochemistry findings\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nEndocrine findings\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nUrinalysis findings\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nBehaviour (functional findings)\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nImmunological findings\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nOrgan weight findings including organ / body weight ratios\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nGross pathological findings\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nNeuropathological findings\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nHistopathological findings: non-neoplastic\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nHistopathological findings: neoplastic\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nOther effects\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nDetails on results\n\nThere were no differences regarding body weight, anogenital distance, puberty onset, frequency and duration of the estrous cycle and estradiol levels on female offspring. Nonetheless, there were changes in sexual behavior. There was an increase in the number of observations in reflex magnitude 0 (absence of lordosis) and reflex magnitude 2 as well as a reduction of reflex magnitude 3 in the rats of SUL 25mg group in relation to the Control group, suggesting a decrease in sexual receptivity of these animals.\n\n### Reproductive function / performance (P1)\n\nReproductive function: oestrous cycle\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nReproductive function: sperm measures\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nReproductive performance\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\n### Details on results (P1)\n\n[Empty]\n\n### Effect levels (P1)\n\n### Target system / organ toxicity (P1)\n\n### Results: F1 generation\n\n### General toxicity (F1)\n\nClinical signs\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nDermal irritation (if dermal study)\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nMortality / viability\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nBody weight and weight changes\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nFood consumption and compound intake (if feeding study)\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nFood efficiency\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nWater consumption and compound intake (if drinking water study)\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nOphthalmological findings\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nHaematological findings\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nClinical biochemistry findings\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nUrinalysis findings\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nSexual maturation\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nAnogenital distance (AGD)\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nNipple retention in male pups\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nOrgan weight findings including organ / body weight ratios\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nGross pathological findings\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nHistopathological findings\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nOther effects\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\n### Developmental neurotoxicity (F1)\n\nBehaviour (functional findings)\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\n### Developmental immunotoxicity (F1)\n\nDevelopmental immunotoxicity\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\n### Details on results (F1)\n\n[Empty]\n\n### Effect levels (F1)\n\n### Target system / organ toxicity (F1)\n\n### Results: F2 generation\n\n### General toxicity (F2)\n\nClinical signs\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nDermal irritation (if dermal study)\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nMortality / viability\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nBody weight and weight changes\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nFood consumption and compound intake (if feeding study)\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nFood efficiency\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nWater consumption and compound intake (if drinking water study)\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nOphthalmological findings\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nHaematological findings\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nClinical biochemistry findings\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nUrinalysis findings\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nSexual maturation\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nAnogenital distance (AGD)\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nNipple retention in male pups\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nOrgan weight findings including organ / body weight ratios\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nGross pathological findings\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nHistopathological findings\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nOther effects\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\n### Developmental neurotoxicity (F2)\n\nBehaviour (functional findings)\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\n### Developmental immunotoxicity (F2)\n\nDevelopmental immunotoxicity\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\n### Details on results (F2)\n\n[Empty]\n\n### Effect levels (F2)\n\n### Target system / organ toxicity (F2)\n\n### Overall reproductive toxicity\n\n### Additional information about applicability domain and reliability of (Q)SAR predictions\n\nFit with the applicability domain\n\n[Empty]\n\nJustification for the fit with the applicability domain\n\n[Empty]\n\nFit with the space defined by the training set of the model\n\n[Empty]\n\nMechanistic and metabolic considerations\n\n[Empty]\n\n### Similar substances with experimental data\n\nPerformance of the model for similar substances\n\n[Empty]\n\nConclusions on applicability domain and reliability\n\n[Empty]\n\nUncertainty\n\n[Empty]\n\n### Any other information on results incl. tables\n\n[Empty]\n\n### Overall remarks, attachments\n\nOverall remarks\n\n[Not publishable]\n\n### Attachments\n\n### Applicant's summary and conclusion\n\nConclusions\n\nStudy results suggest that maternal exposure to Sulpiride can alter reproductive function in female offspring rats.\n\nExecutive summary\n\nThe dams were treated daily by gavage with Sulpiride doses of 2.5mg/Kg (SUL 2.5mg group) and 25mg/Kg (SUL 25mg group), or distilled water (Control group) throughout the lactation period. During early life, body weight, anogenital distance, and vaginal opening were analyzed on the female offspring. In adulthood, estrous cycle, sexual behavior, estrogen levels as well as the weight of the reproductive organs were evaluated. There were no differences regarding body weight, anogenital distance, puberty onset, frequency and duration of the estrous cycle and estradiol levels on female offspring. Nonetheless, there were changes in sexual behavior. There was an increase in the number of observations in reflex magnitude 0 (absence of lordosis) and reflex magnitude 2 as well as a reduction of reflex magnitude 3 in the rats of SUL 25mg group in relation to the Control group, suggesting a decrease in sexual receptivity of these animals. These results demonstrate that maternal exposure to Sulpiride can alter reproductive function in female offspring rats.\n\nBack to top",
          "content_length": 15111,
          "status": "success"
        },
        "003 | Other | Experimental study": {
          "document_id": "35f00af4-2b55-4b3d-aa10-181ef359b198_d18b246e-13d7-423f-a045-5da4c757759e",
          "markdown_content": "#### Toxicity to reproduction\n\nJump to\n\nHide empty fields\n\n### Administrative data\n\nConfidentiality\n\n[Not publishable]\n\nJustification\n\n[Not publishable]\n\nUse restricted to selected regulatory programmes\n\n[Not publishable]\n\nEndpoint\n\nfertility, other\n\nmale offspring reproductive development\n\nType of information\n\nexperimental study\n\nAdequacy of study\n\nother information\n\nRobust study summary\n\n[Not publishable]\n\nUsed for classification\n\n[Not publishable]\n\nUsed for SDS\n\n[Not publishable]\n\nStudy period: start date\n\n[Empty]\n\nEnd date\n\n[Empty]\n\nRemark\n\n[Empty]\n\nReliability\n\n4 (not assignable)\n\nRationale for reliability incl. deficiencies\n\nabstract\n\nData waiving\n\n[Empty]\n\nJustification for data waiving\n\n[Empty]\n\nJustification for type of information\n\n[Empty]\n\n### Attached justification\n\n### Cross-reference\n\n### Data source\n\nReference\n\n* [Lactational exposure to sulpiride: assessment of maternal care and reproductive and behavioral parameters of male rat pups.](23353ef6-e9f7-460d-bf49-e72491ded2e6_d18b246e-13d7-423f-a045-5da4c757759e)\n\nData access\n\n[Not publishable]\n\nData protection claimed\n\n[Not publishable]\n\n### Materials and methods\n\n### Test guideline\n\n### #1 - Test guideline\n\nQualifier\n\nno guideline followed\n\nGuideline\n\n[Empty]\n\nVersion / remarks\n\n[Empty]\n\nDeviations\n\n[Empty]\n\nPrinciples of method if other than guideline\n\nThe aim of the study was to evaluate if maternal exposure to sulpiride during lactation could disrupt maternal care and/or male offspring reproductive development.\n\nGLP compliance\n\nnot specified\n\nLimit test\n\nno\n\nJustification for study design\n\n[Empty]\n\n### Test material\n\nTest material information\n\n[Test material information](58f5f39d-02e9-43fd-bfb1-bb2cde8000ff_d18b246e-13d7-423f-a045-5da4c757759e)\n\nAdditional test material information\n\n[Empty]\n\nSpecific details on test material used for the study\n\nSulpiride and sulpiride HCl are expected to be similar for this endpoint.\n\nSpecific details on test material used for the study (confidential)\n\n[Not publishable]\n\n### Test animals\n\nSpecies\n\nrat\n\nStrain\n\nWistar\n\nDetails on species / strain selection\n\n[Empty]\n\nSex\n\nfemale\n\nDetails on test animals or test system and environmental conditions\n\n[Empty]\n\n### Administration / exposure\n\nRoute of administration\n\noral: gavage\n\nType of inhalation exposure (if applicable)\n\n[Empty]\n\nMass median aerodynamic diameter (MMAD)\n\n[Empty]\n\nGeometric standard deviation (GSD)\n\n[Empty]\n\nRemarks on MMAD\n\n[Empty]\n\nVehicle\n\nwater\n\nDetails on exposure\n\n[Empty]\n\nDetails on mating procedure\n\n[Empty]\n\nAnalytical verification of doses or concentrations\n\n[Empty]\n\nDetails on analytical verification of doses or concentrations\n\n[Empty]\n\nDuration of treatment / exposure\n\nThe dams were treated during lactation.\n\nFrequency of treatment\n\nDaily\n\nDetails on study schedule\n\n[Empty]\n\n### Doses / concentrations\n\n### #1 - Doses / concentrations\n\nDose / conc.\n\n2.5 \nmg/kg bw/day (nominal)\n\nRemarks\n\n[Empty]\n\n### #2 - Doses / concentrations\n\nDose / conc.\n\n25 \nmg/kg bw/day (nominal)\n\nRemarks\n\n[Empty]\n\nNo. of animals per sex per dose\n\n20 dams/dose level\n\nControl animals\n\n* yes, concurrent vehicle\n\n  water\n\nDetails on study design\n\n[Empty]\n\nPositive control\n\n[Empty]\n\nHigh dose level used\n\n[Empty]\n\nJustification for deviation from the high dose level\n\n[Not publishable]\n\n### Examinations\n\nParental animals: Observations and examinations\n\nMaternal behavior was analyzed on lactational days 5 and 10.\n\nOestrous cyclicity (parental animals)\n\n[Empty]\n\nSperm parameters (parental animals)\n\n[Empty]\n\nLitter observations\n\nReproductive and behavioral parameters were analyzed at different time points.\n\nPostmortem examinations (parental animals)\n\n[Empty]\n\nPostmortem examinations (offspring)\n\n[Empty]\n\nStatistics\n\n[Empty]\n\nReproductive indices\n\n[Empty]\n\nOffspring viability indices\n\n[Empty]\n\n### Model and software\n\nModel name and version\n\n[Empty]\n\nSoftware name and version\n\n[Empty]\n\nRemarks\n\n[Not publishable]\n\n### Any other information on materials and methods incl. tables\n\n[Not publishable]\n\n### Results and discussion\n\n### Results: P0 (first parental generation)\n\n### General toxicity (P0)\n\nClinical signs\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nDermal irritation (if dermal study)\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nMortality\n\n[Empty]\n\nDescription (incidence)\n\n[Empty]\n\nBody weight and weight changes\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nFood consumption and compound intake (if feeding study)\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nFood efficiency\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nWater consumption and compound intake (if drinking water study)\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nOphthalmological findings\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nHaematological findings\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nClinical biochemistry findings\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nEndocrine findings\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nUrinalysis findings\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nBehaviour (functional findings)\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nImmunological findings\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Not publishable]\n\nOrgan weight findings including organ / body weight ratios\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Not publishable]\n\nGross pathological findings\n\n[Not publishable]\n\nDescription (incidence and severity)\n\n[Not publishable]\n\nNeuropathological findings\n\n[Not publishable]\n\nDescription (incidence and severity)\n\n[Empty]\n\nHistopathological findings: non-neoplastic\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nHistopathological findings: neoplastic\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nOther effects\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\n### Reproductive function / performance (P0)\n\nReproductive function: oestrous cycle\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nReproductive function: sperm measures\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nReproductive performance\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\n### Details on results (P0)\n\nBody weight, food intake and general activity in the open-field (data not shown) of dams during lactation were unaffected by sulpiride treatment. Sulpiride treatment did not impair maternal care.\n\n### Effect levels (P0)\n\n### Target system / organ toxicity (P0)\n\n### Results: P1 (second parental generation)\n\n### General toxicity (P1)\n\nClinical signs\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nDermal irritation (if dermal study)\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nMortality\n\n[Empty]\n\nDescription (incidence)\n\n[Empty]\n\nBody weight and weight changes\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nFood consumption and compound intake (if feeding study)\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nFood efficiency\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nWater consumption and compound intake (if drinking water study)\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nOphthalmological findings\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nHaematological findings\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nClinical biochemistry findings\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nEndocrine findings\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nUrinalysis findings\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nBehaviour (functional findings)\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nImmunological findings\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nOrgan weight findings including organ / body weight ratios\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nGross pathological findings\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nNeuropathological findings\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nHistopathological findings: non-neoplastic\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nHistopathological findings: neoplastic\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nOther effects\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nDetails on results\n\n[Empty]\n\n### Reproductive function / performance (P1)\n\nReproductive function: oestrous cycle\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nReproductive function: sperm measures\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nReproductive performance\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\n### Details on results (P1)\n\nAt postnatal day 90, a reduction in testis weight, volume of seminiferous tubule and histopathological alterations such as an increased percentage of abnormal seminiferous tubules were observed.\n\n### Effect levels (P1)\n\n### Target system / organ toxicity (P1)\n\n### Results: F1 generation\n\n### General toxicity (F1)\n\nClinical signs\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nDermal irritation (if dermal study)\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nMortality / viability\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nBody weight and weight changes\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nFood consumption and compound intake (if feeding study)\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nFood efficiency\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nWater consumption and compound intake (if drinking water study)\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nOphthalmological findings\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nHaematological findings\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nClinical biochemistry findings\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nUrinalysis findings\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nSexual maturation\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nAnogenital distance (AGD)\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nNipple retention in male pups\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nOrgan weight findings including organ / body weight ratios\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nGross pathological findings\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nHistopathological findings\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nOther effects\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\n### Developmental neurotoxicity (F1)\n\nBehaviour (functional findings)\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\n### Developmental immunotoxicity (F1)\n\nDevelopmental immunotoxicity\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\n### Details on results (F1)\n\n[Empty]\n\n### Effect levels (F1)\n\n### Target system / organ toxicity (F1)\n\n### Results: F2 generation\n\n### General toxicity (F2)\n\nClinical signs\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nDermal irritation (if dermal study)\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nMortality / viability\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nBody weight and weight changes\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nFood consumption and compound intake (if feeding study)\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nFood efficiency\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nWater consumption and compound intake (if drinking water study)\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nOphthalmological findings\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nHaematological findings\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nClinical biochemistry findings\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nUrinalysis findings\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nSexual maturation\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nAnogenital distance (AGD)\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nNipple retention in male pups\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nOrgan weight findings including organ / body weight ratios\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nGross pathological findings\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nHistopathological findings\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nOther effects\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\n### Developmental neurotoxicity (F2)\n\nBehaviour (functional findings)\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\n### Developmental immunotoxicity (F2)\n\nDevelopmental immunotoxicity\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\n### Details on results (F2)\n\n[Empty]\n\n### Effect levels (F2)\n\n### Target system / organ toxicity (F2)\n\n### Overall reproductive toxicity\n\n### Additional information about applicability domain and reliability of (Q)SAR predictions\n\nFit with the applicability domain\n\n[Empty]\n\nJustification for the fit with the applicability domain\n\n[Empty]\n\nFit with the space defined by the training set of the model\n\n[Empty]\n\nMechanistic and metabolic considerations\n\n[Empty]\n\n### Similar substances with experimental data\n\nPerformance of the model for similar substances\n\n[Empty]\n\nConclusions on applicability domain and reliability\n\n[Empty]\n\nUncertainty\n\n[Empty]\n\n### Any other information on results incl. tables\n\n[Empty]\n\n### Overall remarks, attachments\n\nOverall remarks\n\n[Not publishable]\n\n### Attachments\n\n### Applicant's summary and conclusion\n\nConclusions\n\nStudy results show that maternal exposure to sulpiride during lactation may impact the reproductive development of male rats and the testes seem to be the main target organ at adulthood.\n\nExecutive summary\n\nThe dams were treated daily (gavage) with Sulpiride (SUL) 2.5mg/kg or 25mg/kg during lactation. Maternal behavior was analyzed on lactational days 5 and 10. In offspring, reproductive and behavioral parameters were analyzed at different time points. SUL treatment did not impair maternal care, but caused testicular damage in male offspring. At postnatal day 90, a reduction in testis weight, volume of seminiferous tubule and histopathological alterations such as an increased percentage of abnormal seminiferous tubules were observed. Data shows that maternal exposure to SUL during lactation may impact the reproductive development of male rats and the testes seem to be the main target organ at adulthood.\n\nBack to top",
          "content_length": 14585,
          "status": "success"
        }
      },
      "7.8.2 Developmental toxicity / teratogenicity": {
        "001 | Other | Experimental study": {
          "document_id": "9f582250-ded2-470c-b6d0-4c39ca0e6d0f_d18b246e-13d7-423f-a045-5da4c757759e",
          "markdown_content": "#### Developmental toxicity / teratogenicity\n\nJump to\n\nHide empty fields\n\n### Administrative data\n\nConfidentiality\n\n[Not publishable]\n\nJustification\n\n[Not publishable]\n\nUse restricted to selected regulatory programmes\n\n[Not publishable]\n\nEndpoint\n\ndevelopmental toxicity\n\nType of information\n\nexperimental study\n\nAdequacy of study\n\nother information\n\nRobust study summary\n\n[Not publishable]\n\nUsed for classification\n\n[Not publishable]\n\nUsed for SDS\n\n[Not publishable]\n\nStudy period: start date\n\n[Empty]\n\nEnd date\n\n[Empty]\n\nRemark\n\n[Empty]\n\nReliability\n\n4 (not assignable)\n\nRationale for reliability incl. deficiencies\n\nsecondary literature\n\nData waiving\n\n[Empty]\n\nJustification for data waiving\n\n[Empty]\n\nJustification for type of information\n\n[Empty]\n\n### Attached justification\n\n### Cross-reference\n\n### Data source\n\nReference\n\n* [Pharmacotoxicological aspects of levosulpiride.](0bba3384-7bf4-4c6d-983d-78a29e387ee6_d18b246e-13d7-423f-a045-5da4c757759e)\n\nData access\n\n[Not publishable]\n\nData protection claimed\n\n[Not publishable]\n\n### Materials and methods\n\n### Test guideline\n\n### #1 - Test guideline\n\nQualifier\n\n[Empty]\n\nGuideline\n\nother:\nnot specified\n\nVersion / remarks\n\n[Empty]\n\nDeviations\n\n[Empty]\n\nPrinciples of method if other than guideline\n\n[Empty]\n\nGLP compliance\n\nnot specified\n\nLimit test\n\n[Empty]\n\n### Test material\n\nTest material information\n\n[Test material information](4e39367f-bcf9-4a5f-bd70-64ddd6fbf79e_d18b246e-13d7-423f-a045-5da4c757759e)\n\nAdditional test material information\n\n[Empty]\n\nSpecific details on test material used for the study\n\n[Empty]\n\nSpecific details on test material used for the study (confidential)\n\n[Not publishable]\n\n### Test animals\n\nSpecies\n\nrat\n\nStrain\n\nnot specified\n\nDetails on test animals or test system and environmental conditions\n\n[Empty]\n\n### Administration / exposure\n\nRoute of administration\n\n[Empty]\n\nType of inhalation exposure (if applicable)\n\n[Empty]\n\nVehicle\n\n[Empty]\n\nMass median aerodynamic diameter (MMAD)\n\n[Empty]\n\nGeometric standard deviation (GSD)\n\n[Empty]\n\nRemarks on MMAD\n\n[Empty]\n\nDetails on exposure\n\n[Empty]\n\nAnalytical verification of doses or concentrations\n\n[Empty]\n\nDetails on analytical verification of doses or concentrations\n\n[Empty]\n\nDetails on mating procedure\n\n[Empty]\n\nDuration of treatment / exposure\n\n[Empty]\n\nFrequency of treatment\n\n[Empty]\n\nDuration of test\n\n[Empty]\n\n### Doses / concentrations\n\nNo. of animals per sex per dose\n\n[Empty]\n\nControl animals\n\n[Empty]\n\nDetails on study design\n\n[Empty]\n\nHigh dose level used\n\n[Empty]\n\nJustification for deviation from the high dose level\n\n[Not publishable]\n\n### Examinations\n\nMaternal examinations\n\n[Empty]\n\nOvaries and uterine content\n\n[Empty]\n\nBlood sampling\n\n[Empty]\n\nFetal examinations\n\n[Empty]\n\nStatistics\n\n[Empty]\n\nIndices\n\n[Empty]\n\nHistorical control data\n\n[Empty]\n\n### Model and software\n\nModel name and version\n\n[Empty]\n\nSoftware name and version\n\n[Empty]\n\nRemarks\n\n[Not publishable]\n\n### Any other information on materials and methods incl. tables\n\n[Not publishable]\n\n### Results and discussion\n\n### Results: maternal animals\n\n### General toxicity (maternal animals)\n\nClinical signs\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nDermal irritation (if dermal study)\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nMortality\n\n[Empty]\n\nDescription (incidence)\n\n[Empty]\n\nBody weight and weight changes\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nFood consumption and compound intake (if feeding study)\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nFood efficiency\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nWater consumption and compound intake (if drinking water study)\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nOphthalmological findings\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nHaematological findings\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nClinical biochemistry findings\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nEndocrine findings\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nUrinalysis findings\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nBehaviour (functional findings)\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nImmunological findings\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nOrgan weight findings including organ / body weight ratios\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nGross pathological findings\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nNeuropathological findings\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nHistopathological findings: non-neoplastic\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nHistopathological findings: neoplastic\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nOther effects\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nDetails on results\n\n[Empty]\n\n### Maternal developmental toxicity\n\nNumber of abortions\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nPre- and post-implantation loss\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nTotal litter losses by resorption\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nEarly or late resorptions\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nDead fetuses\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nChanges in pregnancy duration\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nChanges in number of pregnant\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nOther effects\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nDetails on maternal toxic effects\n\n[Empty]\n\n### Effect levels (maternal animals)\n\n### Maternal abnormalities\n\n### Results (fetuses)\n\nFetal body weight changes\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nReduction in number of live offspring\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nChanges in sex ratio\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nChanges in litter size and weights\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nAnogenital distance of all rodent fetuses\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nChanges in postnatal survival\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nExternal malformations\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nSkeletal malformations\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nVisceral malformations\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nOther effects\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nDetails on embryotoxic / teratogenic effects\n\n[Empty]\n\n### Effect levels (fetuses)\n\n### Fetal abnormalities\n\n### Overall developmental toxicity\n\n### Additional information about applicability domain and reliability of (Q)SAR predictions\n\nFit with the applicability domain\n\n[Empty]\n\nJustification for the fit with the applicability domain\n\n[Empty]\n\nFit with the space defined by the training set of the model\n\n[Empty]\n\nMechanistic and metabolic considerations\n\n[Empty]\n\n### Similar substances with experimental data\n\nPerformance of the model for similar substances\n\n[Empty]\n\nConclusions on applicability domain and reliability\n\n[Empty]\n\nUncertainty\n\n[Empty]\n\n### Any other information on results incl. tables\n\nThe oral administration of levosulpiride in rats at 75, 150 or 300 mg/kg/day is without direct effect on fertility, reproduction or organogenesis; more specifically, the administration of levosulpiride before coupling and 13 days after coupling showed that fertility in rats was unchanged, neither time periods nor sequence of gestation modified, newborn vitality was unaffected, no apparent damage to suckling occurred, and either preimplant or post-implant loss remained unchanged. Moreover, in the second generation coming from the zero generation treated with levosulpiride the newborn vitality overlapped with controls. The oral administration of levosulpiride at 10-25 mg/kg/day in rats and 25-50 mg/kg/day in rabbits during organogenesis caused no statistically significant change in weight gain by pregnant animals, in the number of foetal implants, in the number of dead or undeveloped foetuses, and in the weight of foetal offspring from animals treated compared to controls. In addition, some malformations were observed in treated rats and rabbits as well as in controls. Therefore, there is no substantial difference between control groups and treated animals. Teratogenic process in the two tested animal species can be excluded. Levosulpiride administered at dose of 75, 150 or 300 mg/kg/day by oral route in the final period of gestation and during the 21 days of suckling in rats neither changes fertility or gestation indices, nor modify newborn vitality indices. However, all treated groups have suckling indices somewhat lower than controls. The finding does not mean that there is decreased milk production following treatment. On the contrary, there is an increase in production that leads to better nutrition when there are many young and appearance of breast disease (congestion, inflammation) or when the young are few. These findings may be explained by the fact that levosulpiride under the right endocrine conditions and particularly at the end of pregnancy, induces an increase in milk production.\n\n### Overall remarks, attachments\n\nOverall remarks\n\n[Not publishable]\n\n### Attachments\n\n### Applicant's summary and conclusion\n\nConclusions\n\nStudy results show that levosulpiride does not cause any adverse effect to development.\n\nExecutive summary\n\nThe oral administration of levosulpiride in rats at 75, 150 or 300 mg/kg/day is without direct effect on fertility, reproduction or organogenesis; more specifically, the administration of levosulpiride before coupling and 13 days after coupling showed that fertility in rats was unchanged, neither time periods nor sequence of gestation modified, newborn vitality was unaffected, no apparent damage to suckling occurred, and either preimplant or post-implant loss remained unchanged. Moreover, in the second generation coming from the zero generation treated with levosulpiride the newborn vitality overlapped with controls. The oral administration of levosulpiride at 10-25 mg/kg/day in rats and 25-50 mg/kg/day in rabbits during organogenesis caused no statistically significant change in weight gain by pregnant animals, in the number of foetal implants, in the number of dead or undeveloped foetuses, and in the weight of foetal offspring from animals treated compared to controls. In addition, some malformations were observed in treated rats and rabbits as well as in controls. Therefore, there is no substantial difference between control groups and treated animals. Teratogenic process in the two tested animal species can be excluded. Levosulpiride administered at dose of 75, 150 or 300 mg/kg/day by oral route in the final period of gestation and during the 21 days of suckling in rats neither changes fertility or gestation indices, nor modify newborn vitality indices. However, all treated groups have suckling indices somewhat lower than controls. The finding does not mean that there is decreased milk production following treatment. On the contrary, there is an increase in production that leads to better nutrition when there are many young and appearance of breast disease (congestion, inflammation) or when the young are few. These findings may be explained by the fact that levosulpiride under the right endocrine conditions and particularly at the end of pregnancy, induces an increase in milk production.\n\nBack to top",
          "content_length": 11575,
          "status": "success"
        },
        "002 | Disregarded | (Q)SAR": {
          "document_id": "42d0b6a8-f6cc-4daa-a2f2-a9dd3c1adf25_d18b246e-13d7-423f-a045-5da4c757759e",
          "markdown_content": "#### Developmental toxicity / teratogenicity\n\nJump to\n\nHide empty fields\n\n### Administrative data\n\nConfidentiality\n\n[Not publishable]\n\nJustification\n\n[Not publishable]\n\nUse restricted to selected regulatory programmes\n\n[Not publishable]\n\nEndpoint\n\ndevelopmental toxicity\n\nType of information\n\n(Q)SAR\n\nAdequacy of study\n\ndisregarded due to major methodological deficiencies\n\nRobust study summary\n\n[Not publishable]\n\nUsed for classification\n\n[Not publishable]\n\nUsed for SDS\n\n[Not publishable]\n\nStudy period: start date\n\n[Empty]\n\nEnd date\n\n[Empty]\n\nRemark\n\n[Empty]\n\nReliability\n\n3 (not reliable)\n\nRationale for reliability incl. deficiencies\n\nresults derived from a valid (Q)SAR model, but not (completely) falling into its applicability domain, and documentation / justification is limited\n\nData waiving\n\n[Empty]\n\nJustification for data waiving\n\n[Empty]\n\nJustification for type of information\n\n[Empty]\n\n### Attached justification\n\n### Cross-reference\n\n### Data source\n\nReference\n\n* [Developmental Toxicity model (CAESAR) 2.1.7](fd7dbb84-a55c-401e-bb65-421997ebfbe2_d18b246e-13d7-423f-a045-5da4c757759e)\n\nData access\n\n[Not publishable]\n\nData protection claimed\n\n[Not publishable]\n\n### Materials and methods\n\n### Test guideline\n\n### #1 - Test guideline\n\nQualifier\n\nequivalent or similar to guideline\n\nGuideline\n\nother:\nECHA guidance on information requirements and chemical safety assessment Chapter R.6: QSARs and grouping of chemicals.\n\nVersion / remarks\n\n[Empty]\n\nDeviations\n\n[Empty]\n\nPrinciples of method if other than guideline\n\n[Empty]\n\nGLP compliance\n\n[Empty]\n\nLimit test\n\n[Empty]\n\n### Test material\n\nTest material information\n\n[Test material information](58f5f39d-02e9-43fd-bfb1-bb2cde8000ff_d18b246e-13d7-423f-a045-5da4c757759e)\n\nAdditional test material information\n\n[Empty]\n\nSpecific details on test material used for the study\n\nThis endpoint has been predicted by a QSAR model for sulpiride (instead of sulpiride HCl) as salts are not included in the applicability domain of QSAR models. Sulpiride and sulpiride HCl are expected to be similar for this endpoint.\n\nSpecific details on test material used for the study (confidential)\n\n[Not publishable]\n\n### Test animals\n\nSpecies\n\n[Empty]\n\nStrain\n\n[Empty]\n\nDetails on test animals or test system and environmental conditions\n\n[Empty]\n\n### Administration / exposure\n\nRoute of administration\n\n[Empty]\n\nType of inhalation exposure (if applicable)\n\n[Empty]\n\nVehicle\n\n[Empty]\n\nMass median aerodynamic diameter (MMAD)\n\n[Empty]\n\nGeometric standard deviation (GSD)\n\n[Empty]\n\nRemarks on MMAD\n\n[Empty]\n\nDetails on exposure\n\n[Empty]\n\nAnalytical verification of doses or concentrations\n\n[Empty]\n\nDetails on analytical verification of doses or concentrations\n\n[Empty]\n\nDetails on mating procedure\n\n[Empty]\n\nDuration of treatment / exposure\n\n[Empty]\n\nFrequency of treatment\n\n[Empty]\n\nDuration of test\n\n[Empty]\n\n### Doses / concentrations\n\nNo. of animals per sex per dose\n\n[Empty]\n\nControl animals\n\n[Empty]\n\nDetails on study design\n\n[Empty]\n\nHigh dose level used\n\n[Empty]\n\nJustification for deviation from the high dose level\n\n[Not publishable]\n\n### Examinations\n\nMaternal examinations\n\n[Empty]\n\nOvaries and uterine content\n\n[Empty]\n\nBlood sampling\n\n[Empty]\n\nFetal examinations\n\n[Empty]\n\nStatistics\n\nThe applicability domain of predictions is assessed using an Applicability Domain Index (ADI) that has values from 0 (worst case) to 1 (best case). The ADI is calculated by grouping several other indices, each one taking into account a particular issue of the applicability domain. Most of the indices are based on the calculation of the most similar compounds found in the training and test set of the model, calculated by a similarity index that consider molecule's fingerprint and structural aspects (count of atoms, rings and relevant fragments).\nFor each index, including the final ADI, three intervals for its values are defined, such that the first interval corresponds to a positive evaluation, the second one corresponds to a suspicious evaluation and the last one corresponds to a negative evaluation.\nList of indices:\n- Similar molecules with known experimental value.\n- Accuracy of prediction for similar molecules.\n- Concordance for similar molecules.\n- Atom Centered Fragments similarity check.\n- Model descriptors range check.\n- Global AD Index.\n\nIndices\n\n[Empty]\n\nHistorical control data\n\n[Empty]\n\n### Model and software\n\nModel name and version\n\n[Empty]\n\nSoftware name and version\n\n[Empty]\n\nRemarks\n\n[Not publishable]\n\n### Any other information on materials and methods incl. tables\n\n[Not publishable]\n\n### Results and discussion\n\n### Results: maternal animals\n\n### General toxicity (maternal animals)\n\nClinical signs\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nDermal irritation (if dermal study)\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nMortality\n\n[Empty]\n\nDescription (incidence)\n\n[Empty]\n\nBody weight and weight changes\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nFood consumption and compound intake (if feeding study)\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nFood efficiency\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nWater consumption and compound intake (if drinking water study)\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nOphthalmological findings\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nHaematological findings\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nClinical biochemistry findings\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nEndocrine findings\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nUrinalysis findings\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nBehaviour (functional findings)\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nImmunological findings\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nOrgan weight findings including organ / body weight ratios\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nGross pathological findings\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nNeuropathological findings\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nHistopathological findings: non-neoplastic\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nHistopathological findings: neoplastic\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nOther effects\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nDetails on results\n\n[Empty]\n\n### Maternal developmental toxicity\n\nNumber of abortions\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nPre- and post-implantation loss\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nTotal litter losses by resorption\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nEarly or late resorptions\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nDead fetuses\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nChanges in pregnancy duration\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nChanges in number of pregnant\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nOther effects\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nDetails on maternal toxic effects\n\n[Empty]\n\n### Effect levels (maternal animals)\n\n### Maternal abnormalities\n\n### Results (fetuses)\n\nFetal body weight changes\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nReduction in number of live offspring\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nChanges in sex ratio\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nChanges in litter size and weights\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nAnogenital distance of all rodent fetuses\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nChanges in postnatal survival\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nExternal malformations\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nSkeletal malformations\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nVisceral malformations\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nOther effects\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nDetails on embryotoxic / teratogenic effects\n\nToxic to development.\n\n### Effect levels (fetuses)\n\n### Fetal abnormalities\n\n### Overall developmental toxicity\n\n### Additional information about applicability domain and reliability of (Q)SAR predictions\n\nFit with the applicability domain\n\n[Empty]\n\nJustification for the fit with the applicability domain\n\n[Empty]\n\nFit with the space defined by the training set of the model\n\n[Empty]\n\nMechanistic and metabolic considerations\n\n[Empty]\n\n### Similar substances with experimental data\n\nPerformance of the model for similar substances\n\n[Empty]\n\nConclusions on applicability domain and reliability\n\n[Empty]\n\nUncertainty\n\n[Empty]\n\n### Any other information on results incl. tables\n\nThe result appears non-reliable as the predicted compound is outside the applicability domain of the model.\n\n### Overall remarks, attachments\n\nOverall remarks\n\n[Not publishable]\n\n### Attachments\n\n#1\n\n[Not publishable]\n\n#2\n\n[Not publishable]\n\n### Applicant's summary and conclusion\n\nConclusions\n\nThe substance is predicted to be toxic to development.\n\nExecutive summary\n\n[Empty]\n\nBack to top",
          "content_length": 9211,
          "status": "success"
        },
        "003 | Disregarded | (Q)SAR": {
          "document_id": "403a676e-a2e8-4a57-8e48-9af396653e4e_d18b246e-13d7-423f-a045-5da4c757759e",
          "markdown_content": "#### Developmental toxicity / teratogenicity\n\nJump to\n\nHide empty fields\n\n### Administrative data\n\nConfidentiality\n\n[Not publishable]\n\nJustification\n\n[Not publishable]\n\nUse restricted to selected regulatory programmes\n\n[Not publishable]\n\nEndpoint\n\ndevelopmental toxicity\n\nType of information\n\n(Q)SAR\n\nAdequacy of study\n\ndisregarded due to major methodological deficiencies\n\nRobust study summary\n\n[Not publishable]\n\nUsed for classification\n\n[Not publishable]\n\nUsed for SDS\n\n[Not publishable]\n\nStudy period: start date\n\n[Empty]\n\nEnd date\n\n[Empty]\n\nRemark\n\n[Empty]\n\nReliability\n\n3 (not reliable)\n\nRationale for reliability incl. deficiencies\n\nresults derived from a valid (Q)SAR model, but not (completely) falling into its applicability domain, and documentation / justification is limited\n\nData waiving\n\n[Empty]\n\nJustification for data waiving\n\n[Empty]\n\nJustification for type of information\n\n[Empty]\n\n### Attached justification\n\n### Cross-reference\n\n### Data source\n\nReference\n\n* [Developmental/Reproductive Toxicity library (PG) 1.0.0](73030ff2-601e-4584-8031-10a11f7f5ee9_d18b246e-13d7-423f-a045-5da4c757759e)\n\nData access\n\n[Not publishable]\n\nData protection claimed\n\n[Not publishable]\n\n### Materials and methods\n\n### Test guideline\n\n### #1 - Test guideline\n\nQualifier\n\nequivalent or similar to guideline\n\nGuideline\n\nother:\nECHA guidance on information requirements and chemical safety assessment Chapter R.6: QSARs and grouping of chemicals.\n\nVersion / remarks\n\n[Empty]\n\nDeviations\n\n[Empty]\n\nPrinciples of method if other than guideline\n\n[Empty]\n\nGLP compliance\n\n[Empty]\n\nLimit test\n\n[Empty]\n\n### Test material\n\nTest material information\n\n[Test material information](58f5f39d-02e9-43fd-bfb1-bb2cde8000ff_d18b246e-13d7-423f-a045-5da4c757759e)\n\nAdditional test material information\n\n[Empty]\n\nSpecific details on test material used for the study\n\nThis endpoint has been predicted by a QSAR model for sulpiride (instead of sulpiride HCl) as salts are not included in the applicability domain of QSAR models. Sulpiride and sulpiride HCl are expected to be similar for this endpoint.\n\nSpecific details on test material used for the study (confidential)\n\n[Not publishable]\n\n### Test animals\n\nSpecies\n\n[Empty]\n\nStrain\n\n[Empty]\n\nDetails on test animals or test system and environmental conditions\n\n[Empty]\n\n### Administration / exposure\n\nRoute of administration\n\n[Empty]\n\nType of inhalation exposure (if applicable)\n\n[Empty]\n\nVehicle\n\n[Empty]\n\nMass median aerodynamic diameter (MMAD)\n\n[Empty]\n\nGeometric standard deviation (GSD)\n\n[Empty]\n\nRemarks on MMAD\n\n[Empty]\n\nDetails on exposure\n\n[Empty]\n\nAnalytical verification of doses or concentrations\n\n[Empty]\n\nDetails on analytical verification of doses or concentrations\n\n[Empty]\n\nDetails on mating procedure\n\n[Empty]\n\nDuration of treatment / exposure\n\n[Empty]\n\nFrequency of treatment\n\n[Empty]\n\nDuration of test\n\n[Empty]\n\n### Doses / concentrations\n\nNo. of animals per sex per dose\n\n[Empty]\n\nControl animals\n\n[Empty]\n\nDetails on study design\n\n[Empty]\n\nHigh dose level used\n\n[Empty]\n\nJustification for deviation from the high dose level\n\n[Not publishable]\n\n### Examinations\n\nMaternal examinations\n\n[Empty]\n\nOvaries and uterine content\n\n[Empty]\n\nBlood sampling\n\n[Empty]\n\nFetal examinations\n\n[Empty]\n\nStatistics\n\nThe applicability domain of predictions is assessed using an Applicability Domain Index (ADI) that has values from 0 (worst case) to 1 (best case). The ADI is calculated by grouping several other indices, each one taking into account a particular issue of the applicability domain. Most of the indices are based on the calculation of the most similar compounds found in the training and test set of the model, calculated by a similarity index that consider molecule's fingerprint and structural aspects (count of atoms, rings and relevant fragments).\nFor each index, including the final ADI, three intervals for its values are defined, such that the first interval corresponds to a positive evaluation, the second one corresponds to a suspicious evaluation and the last one corresponds to a negative evaluation.\nList of indices:\n- Similar molecules with known experimental value.\n- Accuracy of prediction for similar molecules.\n- Concordance for similar molecules.\n- Atom Centered Fragments similarity check.\n- Global AD Index.\n\nIndices\n\n[Empty]\n\nHistorical control data\n\n[Empty]\n\n### Model and software\n\nModel name and version\n\n[Empty]\n\nSoftware name and version\n\n[Empty]\n\nRemarks\n\n[Not publishable]\n\n### Any other information on materials and methods incl. tables\n\n[Not publishable]\n\n### Results and discussion\n\n### Results: maternal animals\n\n### General toxicity (maternal animals)\n\nClinical signs\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nDermal irritation (if dermal study)\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nMortality\n\n[Empty]\n\nDescription (incidence)\n\n[Empty]\n\nBody weight and weight changes\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nFood consumption and compound intake (if feeding study)\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nFood efficiency\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nWater consumption and compound intake (if drinking water study)\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nOphthalmological findings\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nHaematological findings\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nClinical biochemistry findings\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nEndocrine findings\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nUrinalysis findings\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nBehaviour (functional findings)\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nImmunological findings\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nOrgan weight findings including organ / body weight ratios\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nGross pathological findings\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nNeuropathological findings\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nHistopathological findings: non-neoplastic\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nHistopathological findings: neoplastic\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nOther effects\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nDetails on results\n\n[Empty]\n\n### Maternal developmental toxicity\n\nNumber of abortions\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nPre- and post-implantation loss\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nTotal litter losses by resorption\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nEarly or late resorptions\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nDead fetuses\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nChanges in pregnancy duration\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nChanges in number of pregnant\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nOther effects\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nDetails on maternal toxic effects\n\n[Empty]\n\n### Effect levels (maternal animals)\n\n### Maternal abnormalities\n\n### Results (fetuses)\n\nFetal body weight changes\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nReduction in number of live offspring\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nChanges in sex ratio\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nChanges in litter size and weights\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nAnogenital distance of all rodent fetuses\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nChanges in postnatal survival\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nExternal malformations\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nSkeletal malformations\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nVisceral malformations\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nOther effects\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nDetails on embryotoxic / teratogenic effects\n\nNon-toxic to development/reproduction.\n\n### Effect levels (fetuses)\n\n### Fetal abnormalities\n\n### Overall developmental toxicity\n\n### Additional information about applicability domain and reliability of (Q)SAR predictions\n\nFit with the applicability domain\n\n[Empty]\n\nJustification for the fit with the applicability domain\n\n[Empty]\n\nFit with the space defined by the training set of the model\n\n[Empty]\n\nMechanistic and metabolic considerations\n\n[Empty]\n\n### Similar substances with experimental data\n\nPerformance of the model for similar substances\n\n[Empty]\n\nConclusions on applicability domain and reliability\n\n[Empty]\n\nUncertainty\n\n[Empty]\n\n### Any other information on results incl. tables\n\nThe result appears non-reliable as the predicted compound is outside the applicability domain of the model.\n\n### Overall remarks, attachments\n\nOverall remarks\n\n[Not publishable]\n\n### Attachments\n\n#1\n\n[Not publishable]\n\n#2\n\n[Not publishable]\n\n### Applicant's summary and conclusion\n\nConclusions\n\nThe substance is predicted not to be toxic to development/reproduction.\n\nExecutive summary\n\n[Empty]\n\nBack to top",
          "content_length": 9223,
          "status": "success"
        }
      },
      "7.8.3 Toxicity to reproduction: other studies": {},
      "S-01 | Summary": {
        "document_id": "e4f9c72d-1a1c-4aa9-a4ce-b6ea241c1b46_d18b246e-13d7-423f-a045-5da4c757759e",
        "markdown_content": "#### Toxicity to reproduction\n\nJump to\n\nHide empty fields\n\n### Administrative data\n\nConfidentiality\n\n[Empty]\n\nJustification\n\n[Empty]\n\nUse restricted to selected regulatory programmes\n\n[Empty]\n\n### Description of key information\n\nLevosulpiride does not cause any adverse effect to reproduction. Other studies suggest that sulpiride can alter reproductive function in female offspring rats and may impact the reproductive development of male rats: the testes seem to be the main target organ at adulthood.\n\n### Key value for chemical safety assessment\n\nToxic effect type\n\n[Empty]\n\n### Effects on fertility\n\n### Effect on fertility: via oral route\n\nLink to relevant study record(s)\n\n* [002 | Other | Experimental study](86aebf25-4247-41d8-89fd-652d3ac6ea81_d18b246e-13d7-423f-a045-5da4c757759e)\n* [003 | Other | Experimental study](35f00af4-2b55-4b3d-aa10-181ef359b198_d18b246e-13d7-423f-a045-5da4c757759e)\n* [001 | Other | Experimental study](b86001bf-a7d4-42f6-9451-7c8a508e4e7c_d18b246e-13d7-423f-a045-5da4c757759e)\n\nEndpoint conclusion\n\n[Empty]\n\nDose descriptor\n\n[Empty]\n\nEffect level\n\n[Empty]\n\nStudy duration\n\n[Empty]\n\nExperimental exposure time per week\n\nhours/week\n\nSpecies\n\n[Empty]\n\n### Effect on fertility: via dermal route\n\nLink to relevant study record(s)\n\n[Empty]\n\nEndpoint conclusion\n\nno information available\n\nDose descriptor\n\n[Empty]\n\nEffect level\n\n[Empty]\n\nStudy duration\n\n[Empty]\n\nExperimental exposure time per week\n\nhours/week\n\nSpecies\n\n[Empty]\n\n### Effect on fertility: via inhalation route\n\nLink to relevant study record(s)\n\n[Empty]\n\nEndpoint conclusion\n\nno information available\n\nDose descriptor\n\n[Empty]\n\nEffect level\n\n[Empty]\n\nStudy duration\n\n[Empty]\n\nExperimental exposure time per week\n\nhours/week\n\nSpecies\n\n[Empty]\n\n### Effects on developmental toxicity\n\n### Effect on developmental toxicity: via oral route\n\nLink to relevant study record(s)\n\n* [001 | Other | Experimental study](9f582250-ded2-470c-b6d0-4c39ca0e6d0f_d18b246e-13d7-423f-a045-5da4c757759e)\n\nEndpoint conclusion\n\n[Empty]\n\nDose descriptor\n\n[Empty]\n\nEffect level\n\n[Empty]\n\nStudy duration\n\n[Empty]\n\nExperimental exposure time per week\n\nhours/week\n\nSpecies\n\n[Empty]\n\n### Effect on developmental toxicity: via dermal route\n\nLink to relevant study record(s)\n\n[Empty]\n\nEndpoint conclusion\n\nno information available\n\nDose descriptor\n\n[Empty]\n\nEffect level\n\n[Empty]\n\nStudy duration\n\n[Empty]\n\nExperimental exposure time per week\n\nhours/week\n\nSpecies\n\n[Empty]\n\n### Effect on developmental toxicity: via inhalation route\n\nLink to relevant study record(s)\n\n[Empty]\n\nEndpoint conclusion\n\nno information available\n\nDose descriptor\n\n[Empty]\n\nEffect level\n\n[Empty]\n\nStudy duration\n\n[Empty]\n\nExperimental exposure time per week\n\nhours/week\n\nSpecies\n\n[Empty]\n\n### Toxicity to reproduction: other studies\n\nLink to relevant study record(s)\n\n[Empty]\n\n### Mode of Action Analysis / Human Relevance Framework\n\n[Empty]\n\n### Justification for classification or non-classification\n\nOverall, data available are deemed to be inconclusive for classification.\n\n### Additional information\n\n[Empty]\n\n### Attached background material\n\nBack to top",
        "content_length": 3100,
        "status": "success"
      }
    },
    "7.9 Specific investigations": {
      "7.9.1 Neurotoxicity": {},
      "7.9.2 Immunotoxicity": {},
      "7.9.3 Endocrine disruption": {
        "7.9.3.1 Endocrine disrupter screening â in vitro": {},
        "7.9.3.2 Endocrine disrupter mammalian screening â in vivo (level 3)": {}
      },
      "7.9.4 Specific investigations: other studies": {},
      "7.9.5 Phototoxicity in vitro": {}
    },
    "7.10 Exposure related observations in humans": {
      "7.10.1 Health surveillance data": {},
      "7.10.2 Epidemiological data": {},
      "7.10.3 Direct observations: clinical cases, poisoning incidents and other": {},
      "7.10.4 Sensitisation data (humans)": {},
      "7.10.5 Exposure related observations in humans: other data": {
        "001 | Weight of evidence | Experimental study": {
          "document_id": "2100eae0-ca98-4d15-8907-c036e8a6418c_d18b246e-13d7-423f-a045-5da4c757759e",
          "markdown_content": "#### Exposure related observations in humans: other data\n\nJump to\n\nHide empty fields\n\n### Administrative data\n\nConfidentiality\n\n[Not publishable]\n\nJustification\n\n[Not publishable]\n\nUse restricted to selected regulatory programmes\n\n[Not publishable]\n\nEndpoint\n\nexposure-related observations in humans: other data\n\npharmacokinetics\n\nType of information\n\nexperimental study\n\nAdequacy of study\n\nweight of evidence\n\nRobust study summary\n\n[Not publishable]\n\nUsed for classification\n\n[Not publishable]\n\nUsed for SDS\n\n[Not publishable]\n\nStudy period: start date\n\n[Empty]\n\nEnd date\n\n[Empty]\n\nRemark\n\n[Empty]\n\nReliability\n\n4 (not assignable)\n\nRationale for reliability incl. deficiencies\n\nabstract\n\nData waiving\n\n[Empty]\n\nJustification for data waiving\n\n[Empty]\n\nJustification for type of information\n\n[Empty]\n\n### Attached justification\n\n### Cross-reference\n\n### Data source\n\nReference\n\n* [Absolute bioavailability, rate of absorption, and dose proportionality of sulpiride in humans.](f1135a1d-f026-4a28-939b-7aa86b5d81ed_d18b246e-13d7-423f-a045-5da4c757759e)\n\nData access\n\n[Not publishable]\n\nData protection claimed\n\n[Not publishable]\n\n### Materials and methods\n\nType of study / information\n\n[Empty]\n\nEndpoint addressed\n\n* basic toxicokinetics\n\n### Test guideline\n\n### #1 - Test guideline\n\nQualifier\n\nno guideline followed\n\nGuideline\n\n[Empty]\n\nVersion / remarks\n\n[Empty]\n\nDeviations\n\n[Empty]\n\nPrinciples of method if other than guideline\n\n[Empty]\n\nGLP compliance\n\nnot specified\n\n### Test material\n\nTest material information\n\n[Test material information](58f5f39d-02e9-43fd-bfb1-bb2cde8000ff_d18b246e-13d7-423f-a045-5da4c757759e)\n\nAdditional test material information\n\n[Empty]\n\nSpecific details on test material used for the study\n\nSulpiride and sulpiride HCl are expected to be similar for this endpoint.\n\nSpecific details on test material used for the study (confidential)\n\n[Not publishable]\n\n### Method\n\nEthical approval\n\nnot specified\n\nDetails on study design\n\n[Empty]\n\nExposure assessment\n\nmeasured\n\nDetails on exposure\n\n12 healthy subjects received an oral solution of 200 mg drug and an intravenous (IV) and intramuscular (IM) dose of 100 mg drug, in 6 healthy subjects who received an oral capsule of 200, 300, and 400 mg drug, and an IV injection of 100 mg drug, and in 8 healthy male subjects who received an oral capsule and IM dose of 200 mg drug.\n\n### Model and software\n\nModel name and version\n\n[Empty]\n\nSoftware name and version\n\n[Empty]\n\nRemarks\n\n[Not publishable]\n\n### Any other information on materials and methods incl. tables\n\n[Not publishable]\n\n### Results and discussion\n\nResults\n\nDrug disposition was best described by a 2-compartment model, with absorption appearing to occur by 2 sequential zero-order processes. The fraction of dose absorbed after oral administration was about 30%, based on plasma and urine data. After the 200 mg dose, mean elimination half-life was 7 h and mean residence time was 8.4 h. For each subject total clearance, corrected for the fraction absorbed, and renal clearance were similar. The dose proportionality study demonstrated linear disposition kinetics.\n\n### Additional information about applicability domain and reliability of (Q)SAR predictions\n\nFit with the applicability domain\n\n[Empty]\n\nJustification for the fit with the applicability domain\n\n[Empty]\n\nFit with the space defined by the training set of the model\n\n[Empty]\n\nMechanistic and metabolic considerations\n\n[Empty]\n\n### Similar substances with experimental data\n\nPerformance of the model for similar substances\n\n[Empty]\n\nConclusions on applicability domain and reliability\n\n[Empty]\n\nUncertainty\n\n[Empty]\n\n### Any other information on results incl. tables\n\n[Empty]\n\n### Overall remarks, attachments\n\nOverall remarks\n\n[Not publishable]\n\n### Attachments\n\n### Applicant's summary and conclusion\n\nConclusions\n\nThe dose absorbed after oral administration was about 30%. After the 200 mg dose, mean elimination half-life was 7 h and mean residence time was 8.4 h.\n\nExecutive summary\n\n12 Healthy subjects received an oral solution of 200 mg drug and an intravenous (IV) and intramuscular (IM) dose of 100 mg drug, in 6 healthy subjects who received an oral capsule of 200, 300, and 400 mg drug, and an IV injection of 100 mg drug, and in 8 healthy male subjects who received an oral capsule and IM dose of 200 mg drug.\n\nDrug disposition was best described by a 2-compartment model, with absorption appearing to occur by 2 sequential zero-order processes. The fraction of dose absorbed after oral administration was about 30%, based on plasma and urine data. After the 200 mg dose, mean elimination half-life was 7 h and mean residence time was 8.4 h. For each subject total clearance, corrected for the fraction absorbed, and renal clearance were similar. The dose proportionality study demonstrated linear disposition kinetics.\n\nBack to top",
          "content_length": 4845,
          "status": "success"
        },
        "002 | Weight of evidence | Experimental study": {
          "document_id": "6b410327-938c-40ae-ac01-4a5f4ffe0595_d18b246e-13d7-423f-a045-5da4c757759e",
          "markdown_content": "#### Exposure related observations in humans: other data\n\nJump to\n\nHide empty fields\n\n### Administrative data\n\nConfidentiality\n\n[Not publishable]\n\nJustification\n\n[Not publishable]\n\nUse restricted to selected regulatory programmes\n\n[Not publishable]\n\nEndpoint\n\nexposure-related observations in humans: other data\n\npharmacokinetics\n\nType of information\n\nexperimental study\n\nAdequacy of study\n\nweight of evidence\n\nRobust study summary\n\n[Not publishable]\n\nUsed for classification\n\n[Not publishable]\n\nUsed for SDS\n\n[Not publishable]\n\nStudy period: start date\n\n[Empty]\n\nEnd date\n\n[Empty]\n\nRemark\n\n[Empty]\n\nReliability\n\n4 (not assignable)\n\nRationale for reliability incl. deficiencies\n\nabstract\n\nData waiving\n\n[Empty]\n\nJustification for data waiving\n\n[Empty]\n\nJustification for type of information\n\n[Empty]\n\n### Attached justification\n\n### Cross-reference\n\n### Data source\n\nReference\n\n* [Pharmacokinetics of sulpiride in humans after intravenous and intramuscular administrations](3c8076a2-89cd-4b32-b4c2-6503439dc233_d18b246e-13d7-423f-a045-5da4c757759e)\n\nData access\n\n[Not publishable]\n\nData protection claimed\n\n[Not publishable]\n\n### Materials and methods\n\nType of study / information\n\n[Empty]\n\nEndpoint addressed\n\n* basic toxicokinetics\n\n### Test guideline\n\n### #1 - Test guideline\n\nQualifier\n\nno guideline followed\n\nGuideline\n\n[Empty]\n\nVersion / remarks\n\n[Empty]\n\nDeviations\n\n[Empty]\n\nPrinciples of method if other than guideline\n\n[Empty]\n\nGLP compliance\n\nnot specified\n\n### Test material\n\nTest material information\n\n[Test material information](58f5f39d-02e9-43fd-bfb1-bb2cde8000ff_d18b246e-13d7-423f-a045-5da4c757759e)\n\nAdditional test material information\n\n[Empty]\n\nSpecific details on test material used for the study\n\nSulpiride and sulpiride HCl are expected to be similar for this endpoint.\n\nSpecific details on test material used for the study (confidential)\n\n[Not publishable]\n\n### Method\n\nEthical approval\n\nnot specified\n\nDetails on study design\n\n[Empty]\n\nExposure assessment\n\nmeasured\n\nDetails on exposure\n\n15 healthy subjects (ages 19-30 yr) received 100 mg of the drug by intravenous (IV) and intramuscular (IM) injection.\n\n### Model and software\n\nModel name and version\n\n[Empty]\n\nSoftware name and version\n\n[Empty]\n\nRemarks\n\n[Not publishable]\n\n### Any other information on materials and methods incl. tables\n\n[Not publishable]\n\n### Results and discussion\n\nResults\n\nData were consistent with a 2-compartment, open-body model. After IV administration, the mean apparent elimination half-life of the drug was 6.47 h and mean steady state volume of distribution was 0.94 l/kg. Renal clearance was very close to total clearance. In urine, the mean recovery of unchanged drug was 90% of the dose and the excretion rate versus time showed an elimination half-life similar to that in plasma. Sulpiride partition coefficient between red blood cells (RBC) and plasma did not significantly change as a function of time and concentration. Pharmacokinetic parameters determined from plasma and RBC data were similar.\n\n### Additional information about applicability domain and reliability of (Q)SAR predictions\n\nFit with the applicability domain\n\n[Empty]\n\nJustification for the fit with the applicability domain\n\n[Empty]\n\nFit with the space defined by the training set of the model\n\n[Empty]\n\nMechanistic and metabolic considerations\n\n[Empty]\n\n### Similar substances with experimental data\n\nPerformance of the model for similar substances\n\n[Empty]\n\nConclusions on applicability domain and reliability\n\n[Empty]\n\nUncertainty\n\n[Empty]\n\n### Any other information on results incl. tables\n\n[Empty]\n\n### Overall remarks, attachments\n\nOverall remarks\n\n[Not publishable]\n\n### Attachments\n\n### Applicant's summary and conclusion\n\nConclusions\n\nThe mean apparent elimination half-life of the drug was 6.47 h and mean steady state volume of distribution was 0.94 l/kg. Renal clearance was very close to total clearance. In urine, the mean recovery of unchanged drug was 90% of the dose and the excretion rate versus time showed an elimination half-life similar to that in plasma.\n\nExecutive summary\n\n15 Healthy subjects (ages 19-30 yr) received 100 mg of the drug by intravenous (IV) and intramuscular (IM) injection.\n\nData were consistent with a 2-compartment, open-body model. After IV administration, the mean apparent elimination half-life of the drug was 6.47 h and mean steady state volume of distribution was 0.94 l/kg. Renal clearance was very close to total clearance. In urine, the mean recovery of unchanged drug was 90% of the dose and the excretion rate versus time showed an elimination half-life similar to that in plasma. Sulpiride partition coefficient between red blood cells (RBC) and plasma did not significantly change as a function of time and concentration. Pharmacokinetic parameters determined from plasma and RBC data were similar.\n\nBack to top",
          "content_length": 4852,
          "status": "success"
        },
        "003 | Weight of evidence | Other result type": {
          "document_id": "e20d8d68-9e64-4903-8538-59e702ca1388_d18b246e-13d7-423f-a045-5da4c757759e",
          "markdown_content": "#### Exposure related observations in humans: other data\n\nJump to\n\nHide empty fields\n\n### Administrative data\n\nConfidentiality\n\n[Not publishable]\n\nJustification\n\n[Not publishable]\n\nUse restricted to selected regulatory programmes\n\n[Not publishable]\n\nEndpoint\n\nexposure-related observations in humans: other data\n\nEffects in breastfed infants.\n\nType of information\n\nother:\nData collection.\n\nAdequacy of study\n\nweight of evidence\n\nRobust study summary\n\n[Not publishable]\n\nUsed for classification\n\n[Not publishable]\n\nUsed for SDS\n\n[Not publishable]\n\nStudy period: start date\n\n[Empty]\n\nEnd date\n\n[Empty]\n\nRemark\n\n[Empty]\n\nReliability\n\n4 (not assignable)\n\nRationale for reliability incl. deficiencies\n\nsecondary literature\n\nData waiving\n\n[Empty]\n\nJustification for data waiving\n\n[Empty]\n\nJustification for type of information\n\n[Empty]\n\n### Attached justification\n\n### Cross-reference\n\n### Data source\n\nReference\n\n* [LACTMED: SULPIRIDE. CASRN: 15676-16-1](e5c768fd-2e73-490a-87b8-e4690ab66358_d18b246e-13d7-423f-a045-5da4c757759e)\n\nData access\n\n[Not publishable]\n\nData protection claimed\n\n[Not publishable]\n\n### Materials and methods\n\nType of study / information\n\n[Empty]\n\nEndpoint addressed\n\n* developmental toxicity / teratogenicity\n\n### Test guideline\n\n### #1 - Test guideline\n\nQualifier\n\nno guideline followed\n\nGuideline\n\n[Empty]\n\nVersion / remarks\n\n[Empty]\n\nDeviations\n\n[Empty]\n\nPrinciples of method if other than guideline\n\n[Empty]\n\nGLP compliance\n\nnot specified\n\n### Test material\n\nTest material information\n\n[Test material information](58f5f39d-02e9-43fd-bfb1-bb2cde8000ff_d18b246e-13d7-423f-a045-5da4c757759e)\n\nAdditional test material information\n\n[Empty]\n\nSpecific details on test material used for the study\n\nSulpiride and sulpiride HCl are expected to be similar for this endpoint.\n\nSpecific details on test material used for the study (confidential)\n\n[Not publishable]\n\n### Method\n\nEthical approval\n\nnot specified\n\nDetails on study design\n\n[Empty]\n\nExposure assessment\n\nnot specified\n\nDetails on exposure\n\n[Empty]\n\n### Model and software\n\nModel name and version\n\n[Empty]\n\nSoftware name and version\n\n[Empty]\n\nRemarks\n\n[Not publishable]\n\n### Any other information on materials and methods incl. tables\n\n[Not publishable]\n\n### Results and discussion\n\nResults\n\nIn a study of 14 women given sulpiride 50 mg 3 times daily for 4 weeks, no side effects were reported in their breastfed infants.\n\nIn a study of 24 nursing mothers who received sulpiride 50 mg 3 times daily for 2 weeks, no side effects were reported in their breastfed infants.\n\nIn a study comparing sulpiride to placebo for enhancement of milk production, infant weight gain was greater in the infants of treated women up to day 15, but there was no difference in weight gain between the groups thereafter.\n\n### Additional information about applicability domain and reliability of (Q)SAR predictions\n\nFit with the applicability domain\n\n[Empty]\n\nJustification for the fit with the applicability domain\n\n[Empty]\n\nFit with the space defined by the training set of the model\n\n[Empty]\n\nMechanistic and metabolic considerations\n\n[Empty]\n\n### Similar substances with experimental data\n\nPerformance of the model for similar substances\n\n[Empty]\n\nConclusions on applicability domain and reliability\n\n[Empty]\n\nUncertainty\n\n[Empty]\n\n### Any other information on results incl. tables\n\n[Empty]\n\n### Overall remarks, attachments\n\nOverall remarks\n\n[Not publishable]\n\n### Attachments\n\n### Applicant's summary and conclusion\n\nConclusions\n\nSulpiride does not appear to cause adverse effects in breastfed infants.\n\nExecutive summary\n\n[Empty]\n\nBack to top",
          "content_length": 3600,
          "status": "success"
        },
        "004 | Weight of evidence | Experimental study": {
          "document_id": "40217054-78ce-48cb-b2b9-37b7ef598823_d18b246e-13d7-423f-a045-5da4c757759e",
          "markdown_content": "#### Exposure related observations in humans: other data\n\nJump to\n\nHide empty fields\n\n### Administrative data\n\nConfidentiality\n\n[Not publishable]\n\nJustification\n\n[Not publishable]\n\nUse restricted to selected regulatory programmes\n\n[Not publishable]\n\nEndpoint\n\nexposure-related observations in humans: other data\n\npharmacology\n\nType of information\n\nexperimental study\n\nAdequacy of study\n\nweight of evidence\n\nRobust study summary\n\n[Not publishable]\n\nUsed for classification\n\n[Not publishable]\n\nUsed for SDS\n\n[Not publishable]\n\nStudy period: start date\n\n[Empty]\n\nEnd date\n\n[Empty]\n\nRemark\n\n[Empty]\n\nReliability\n\n4 (not assignable)\n\nRationale for reliability incl. deficiencies\n\nabstract\n\nData waiving\n\n[Empty]\n\nJustification for data waiving\n\n[Empty]\n\nJustification for type of information\n\n[Empty]\n\n### Attached justification\n\n### Cross-reference\n\n### Data source\n\nReference\n\n* [Clinico-pharmacological studies of sulpiride.](17deb15d-e2c5-44ec-8dd5-f80575480bfd_d18b246e-13d7-423f-a045-5da4c757759e)\n\nData access\n\n[Not publishable]\n\nData protection claimed\n\n[Not publishable]\n\n### Materials and methods\n\nType of study / information\n\n[Empty]\n\nEndpoint addressed\n\n* other:\n  pharmacology\n\n### Test guideline\n\n### #1 - Test guideline\n\nQualifier\n\nno guideline followed\n\nGuideline\n\n[Empty]\n\nVersion / remarks\n\n[Empty]\n\nDeviations\n\n[Empty]\n\nPrinciples of method if other than guideline\n\n[Empty]\n\nGLP compliance\n\nnot specified\n\n### Test material\n\nTest material information\n\n[Test material information](58f5f39d-02e9-43fd-bfb1-bb2cde8000ff_d18b246e-13d7-423f-a045-5da4c757759e)\n\nAdditional test material information\n\n[Empty]\n\nSpecific details on test material used for the study\n\nSulpiride and sulpiride HCl are expected to be similar for this endpoint.\n\nSpecific details on test material used for the study (confidential)\n\n[Not publishable]\n\n### Method\n\nEthical approval\n\nnot specified\n\nDetails on study design\n\n[Empty]\n\nExposure assessment\n\nmeasured\n\nDetails on exposure\n\nSulpiride was evaluated in 23 hospitalized patients (20 schizophrenics and 2 depressed). The drug was given by IM injection 3 or 4 times a day. Dosage consisted of 0.6-1.2 g/day in acute schizophrenia and 1.2-1.6 g in the chronic state. It was adjusted according to the symptomatic status by a daily oral dose, 1.2-2.4 g, 3 times/day in acute and chronic states. Patients with depression received 300 to 600 mg of the drug by way of either the parenteral or the oral route.\n\n### Model and software\n\nModel name and version\n\n[Empty]\n\nSoftware name and version\n\n[Empty]\n\nRemarks\n\n[Not publishable]\n\n### Any other information on materials and methods incl. tables\n\n[Not publishable]\n\n### Results and discussion\n\nResults\n\nThe drug elicited a satisfactory response (excellent or good) in 87% of all cases. In acute schizophrenia with delusional or confused state, hallucinations, delusions, motor excitement, anxiety and irritation were rapidly improved. In the more chronic state, the drug's action was outstanding, and the effect was manifested in a shorter period (within 4 to 6 days) than that of other remedies. A dose as massive as 1.2-1.6 g may be advisable to ensure prompt symptomatic response without serious side effects. Adverse reactions included tremor of lips (2) or fingers (one) and salivation (2). These symptoms were all mild, none of these cases required concurrent use of antiparkinsonism drugs. Routine laboratory tests did not reveal any pathological toxic effect during or after therapy.\n\n### Additional information about applicability domain and reliability of (Q)SAR predictions\n\nFit with the applicability domain\n\n[Empty]\n\nJustification for the fit with the applicability domain\n\n[Empty]\n\nFit with the space defined by the training set of the model\n\n[Empty]\n\nMechanistic and metabolic considerations\n\n[Empty]\n\n### Similar substances with experimental data\n\nPerformance of the model for similar substances\n\n[Empty]\n\nConclusions on applicability domain and reliability\n\n[Empty]\n\nUncertainty\n\n[Empty]\n\n### Any other information on results incl. tables\n\n[Empty]\n\n### Overall remarks, attachments\n\nOverall remarks\n\n[Not publishable]\n\n### Attachments\n\n### Applicant's summary and conclusion\n\nConclusions\n\nAdverse reactions included tremor of lips or fingers and salivation. These symptoms were all mild. No pathological toxic effects were observed during (or after) therapy.\n\nExecutive summary\n\nSulpiride was evaluated in 23 hospitalized patients (20 schizophrenics and 2 depressed). The drug was given by IM injection 3 or 4 times a day. Dosage consisted of 0.6-1.2 g/day in acute schizophrenia and 1.2-1.6 g in the chronic state. It was adjusted according to the symptomatic status by a daily oral dose, 1.2-2.4 g, 3 times/day in acute and chronic states. Patients with depression received 300 to 600 mg of the drug by way of either the parenteral or the oral route.\n\nThe drug elicited a satisfactory response (excellent or good) in 87% of all cases. In acute schizophrenia with delusional or confused state, hallucinations, delusions, motor excitement, anxiety and irritation were rapidly improved. In the more chronic state, the drug's action was outstanding, and the effect was manifested in a shorter period (within 4 to 6 days) than that of other remedies. A dose as massive as 1.2-1.6 g may be advisable to ensure prompt symptomatic response without serious side effects. Adverse reactions included tremor of lips (2) or fingers (one) and salivation (2). These symptoms were all mild, none of these cases required concurrent use of antiparkinsonism drugs. Routine laboratory tests did not reveal any pathological toxic effect during or after therapy.\n\nBack to top",
          "content_length": 5651,
          "status": "success"
        }
      },
      "S-01 | Summary": {
        "document_id": "c5101cbb-f9a8-4423-b3d1-b6c0fdd6d906_d18b246e-13d7-423f-a045-5da4c757759e",
        "markdown_content": "#### Exposure related observations in humans\n\nJump to\n\nHide empty fields\n\n### Administrative data\n\nConfidentiality\n\n[Empty]\n\nJustification\n\n[Empty]\n\nUse restricted to selected regulatory programmes\n\n[Empty]\n\n### Link to relevant study record(s)\n\nLink to relevant study record(s)\n\n[Empty]\n\n### Description of key information\n\nSeveral adverse effects have been observed after Diacerin administration. However, the severity and frequency of those effects do not support the classification as STOT RE in accordance with Regulation (EC) 1272/2008.\n\n### Additional information\n\n[Empty]\n\n### Attached background material\n\nBack to top",
        "content_length": 626,
        "status": "success"
      }
    },
    "7.11 Toxic effects on livestock and pets": {},
    "7.12 Additional toxicological information": {}
  }
}